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Abstract
Dry powder inhaler (DPI) formulations are commonly based on a mixture of 
coarse carrier, typically lactose, and micronised drug. The de-aggregation and 
dispersion properties of respirable particles, as well as the stability of the 
formulation, are associated with a delicate balance of the cohesive and adhesive 
interaction forces within the powder blend. This study describes the development 
of a novel atomic force microscopy (AFM) based technique to assess the 
dominant particulate interactions governing behaviour of such systems, and the 
optimisation and control of these interaction forces by the selective introduction 
of force control agents (FCAs) together with a mixing procedure capable of 
producing effective nano-layer coating within DPI formulations.
The atomic force microscope (AFM) colloid probe technique was used to 
measure the adhesive and cohesive force characteristics of dry powder systems 
containing an active component (budesonide, salbutamol sulphate) and the alpha- 
lactose monohydrate excipient. To minimise variations in contact area between 
colloid probes and substrates, nanometre smooth crystal surfaces of the drugs and
the excipient were prepared. A cohesive-adhesive balance (CAB) graphs was 
developed to allow direct comparison of the interaction forces occurring in 
model carrier-based formulations.
Aerodynamic particle analyses together with in vitro characterisation of model 
DPI formulations revealed a paradoxical relationship between particle cohesive 
strength and de-agglomeration efficiencies of drug only formulations, where an 
increase in cohesive strength led to a higher fine particle fraction. A possible 
explanation for the variation in the fluidisation and aerosolisation properties 
between low and high cohesive particles was modelled on the relationship 
between cohesion, metastable agglomerate size and the resulting aerodynamic 
drag force acting on the fluidised agglomerates. The addition of a fine particle 
lactose carrier influenced the drug deposition patterns in different ways 
depending on the relative cohesive and adhesive force balances within the 
formulation.
In order to improve dry powder formulation delivery characteristics, the 
influence of force control agents (FCAs) on the properties and performances of 
model DPI formulations was investigated. Three FCAs were chosen for their low 
surface energetic properties: leucine, lecithin and magnesium stearate. The 
cohesive and adhesive dependencies were controlled by conditioning either the 
drug or the carrier with an FCA before mixing in order to create selective 
modifications of the inter-particulate interactions within the dry powder 
formulation. This was achieved by first using a high energetic process 
(mechanofusion) following a low energetic process (Turbula). Radical 
modifications in the behaviour of the formulation performances, anticipated by 
CAB-graph analyses, were subsequently observed.
This work emphasised that the CAB analysis method can be utilised for pre­
formulation studies in the design of new formulation systems for dry powder
inhalers. The work also confirmed the potential value of the use of force control 
agents together with the Mechanofusion process in the preparation of DPI 
formulations.
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The majority o f drug formulations are delivered to the body in a solid dosage form. A 
variety o f routes are used to transport the solid drug particulates for systemic delivery, 
including oral, rectal, intra-venous, intra-muscular and sub-cutaneous suspension 
injections [1]. However, with the exception o f local treatment o f airway diseases, the 
respiratory tract has, until now, been largely overlooked as a potential portal entry o f 
therapeutic agents for systemic delivery. The lung offers several key advantages over 
other established routes. These advantages include rapid absorption o f therapeutic 
agents via the alveoli and respiratory bronchioles and rapid distribution o f the drug to 
active sites, whilst reducing unwanted side effects encountered with first pass 
metabolism via the liver and unwanted reactions within the gastric system [2, 3].
The major function o f a lung is the exchange o f large volumes o f gaseous material 
between the atmosphere and blood capillaries. This process occurs in the peripheral 
regions o f the lungs. To maximize the degree o f gaseous exchange, these regions 
exhibit an impressive surface area o f about 100m2 in humans [2]. As a result, they 
potentially offer a target o f choice for delivery o f drugs for various pathologies. A 
diagrammatic picture o f human lungs and related descriptions is shown in Figure 1.1 













Figure 1-1: Description o f the lungs
The internal structure o f the lung consists o f a series o f branching airways starting 
from the trachea and dividing into two smaller bifurcations for 24 generations, 
finishing with the alveolar sacs [2]. Thus, for systemic delivery, inhaled particles have to 
circumvent a tortuous path to reach the peripheral regions o f the lung , while 
constantly being subjected to various deposition mechanisms, which are influenced by 
the physico-chemical properties o f the aerosol particles and related physiological 
factors. The major mechanism responsible for deposition in the upper airways is 
inertial impaction [4]; while in the conducting airways, gravitational sedimentation 
dominates due to the decreased velocity and larger relaxation times for the aerosol 
particles in the lower bronchi and bronchioles. O ther modes o f deposition include 
diffusion, interception and electrostatic precipitation [5].
Minimisation o f impaction and sedimentation in the respiratory tract is achievable for 
particles o f low aerodynamic diameter. For systemic delivery, aerosol particles 
exhibiting an average diameter in the range o f 0.5 to 5 Jim are generally regarded as 
suitable to reach the deeper airways [4, 6]. Nevertheless, the majority o f pharmaceutical
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powder particles are not spherical and show rather irregular shapes. In order to address 
these variations and to characterise the key feature which affects transport and 
deposition in the lung, aerosol particles are defined in terms o f their aerodynamic 
diameter. The mass median aerodynamic diameter (MMAD) is defined as the diameter 
o f a sphere with unit density (lg /cm 3) that has the same terminal settling velocity as 
the aerosol particle [4].
Delivery o f therapeutic agents to the lung is mainly achieved via three different types 
o f devices: nebuliser, pressure metered dose inhaler (pMDI), and dry powder inhaler 
(DPI) [7]. In the first two cases, the active drug is aerosolised as either a solution or a 
solid suspension. Drug delivery by a nebuliser is achieved by supplying the active 
ingredient in the form o f aerosolised droplets over a considerable duration. The 
subsequent aerosol is generally passed through a face mask and delivered to the lung 
by the patient natural tidal breathing.
In the case o f a pM DI device, the formulation is contained within a pressurised liquid 
propellant. Currendy, hydro-fluoroalkane (HFA) is the propellant o f choice after the 
signing o f the Montreal protocol in 1986, where the environmental issue o f ozone 
depletion resulted in the banning o f the use o f chloro-fluorocarbon (CFC) propellants. 
Although cheap to manufacture, the major disadvantages o f pMDIs include the 
administration o f low drug doses (generally limited to lmg), the relatively high velocity 
o f the delivered droplets resulting in considerable drug loss in the oropharynx upon 
impaction and the requirement o f synchronisation between discharge activation and 
patient inhalation [8, 9].
In comparison, all current passive DPIs work on the principle o f generating a turbulent 
airflow to disperse a powder formulation by optimising the energy supplied by the 
patient inhalation. The fluidisation, de-aggregation and dispersion o f a dry powder 
formulation are achieved via the patient’s inspiratory action. In contrast to other drug 
delivery platforms, the characteristic properties o f the dry powder formulation are 
critically important to the effective performance o f a D PI system [7, 10]. Thus, the 
development o f a dry powder formulation is highly specialised and a complex
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operation. A formulation is typically required to go through several iterative and 
optimisation steps before a product specification can be achieved.
However, despite technological improvements in inhalation systems and developments 
in formulation science over recent years, there are still difficulties in delivering the 
optimum therapeutic dose to specific target regions o f the respiratory tracts. As the 
mechanisms involved in particle-particle interactions are still not fully understood, 
more detailed investigations are necessary in order to comprehend and control these 
mechanistic processes. Additionally, the complex fluid dynamic environment within 
the device upon actuation and formulation behaviour in that environment need to be 
more clearly understood.
1.2. Particle Interaction Fundamentals
Particle-particle interactions are due to long-range interactions not including covalent 
bonds. Covalent forces bring two atoms together to form a molecule, having an energy 
o f formation usually comprised between 300 and OOOkJ.mol1 (i.e. D c_c=346kJ.mor1, 
D c=c=835kJ.mol1). Particle interactions, however, are due to much weaker physical 
bonding, having energies o f formation inferior to 40kJ.m or\ These forces, although 
inferior to covalent bonds, have a significant influence over relatively large distances.
Interactive forces responsible for the interaction between particles can be broadly 
differentiated into two groups: adhesion or cohesion, depending on the nature o f the 
two interacting materials. Particle adhesion is the result o f forces existing between 
particles o f different chemical nature. Cohesion is referred to interaction between 
particles o f the same material.
1.2.1. Forces Contributing to Particle Interaction
Long-range forces can establish an interaction between two particles before they 
come into contact, the degree o f interaction is critically dependant on the separation 
distance [11]. Particle interactions in pharmaceutical systems are a result o f a 
combination o f different interactive forces; namely the van der Waals forces, 
electrostatic (Coulombic) forces and capillary forces. The contribution o f each o f these
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forces will be dependent on various factors including: physical properties o f the 
material, the degree o f processing, and environmental conditions. For example, if 
particles get charged during handling as a result o f contact or triboelectrification, 
electrostatic forces will arise and may dominate inter-particulate adhesions [12]. 
Similarly, if the material is kept at high relative humidity, the condensation o f water 
vapour between the contiguous bodies may lead to the dissipation o f the electrostatic 
charges due to increased conductance. However, the presence o f the physisorbed water 
may induce capillary interactions with the formation o f stable meniscus bridge between 
the two surfaces [13]. A more detailed overview o f each o f these physical forces is 
described below.
Nevertheless, such interactions are dominant only for very small particles, as gravity 
tends to overcome these physical forces with increasing particle mass (si2e). Particle 
adhesion occurs when the interaction forces applying between a particle and a surface 
exceed the separation forces exerted on the particle. Adhesive (or cohesive) forces 
become significant enough to overcome gravitational forces when the particles size o f 
the material is reduced to less than 10pm [14]. As a result, gravitational forces play a 
negligible role in the behaviour o f respirable particles.
I.2.I.I. Lifshitz-van der Waals Forces
Van der Waals forces, which occur between all solid particles, are extremely 
strong at short range and decline rapidly with increasing separation distance. These 
electro-dynamic interactions consist o f three main types of forces [15]:
• Keesom-orientation forces (permanent moment interactions)
I f  two molecules have a dipolar moment, they will orientate themselves so that the 
negative pole o f one molecule is directed toward the positive pole o f the other.
• Debye-induction forces (permanent moment/induced moment interactions)
A molecule which has a permanent dipole can induce an electrical dipole in an 
apolar molecule only if the latter is polarizable.
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• Dispersion forces (instantaneous moment/ induced moment interactions)
Commonly known as London-van der Waals interactions, these forces provide the 
main contribution o f the interactions between macroscopic bodies. These forces 
arise due to the random movement o f electrons within an electron cloud with 
respect to the nuclear proton, inducing the formation o f a temporary dipole. In 
turn, these instantaneous moments generate an electrical field, which induce a 
dipole to the nearby neutral molecules by polarizing them. According to London 
theory, the energy o f interaction between two molecules can be described by the 
following expression:
u =  - 1  . 3^
(4 7t£Q) 4 d
where U is the potential energy (J), (X is the polarisability (C2.m2.J4), £0 is the 
dielectric permittivity (8.854.1 O'12 C2.m’1 J ’1), \)0 is the characteristic frequency (s’1), 
h is the Planck’s constant (6.626.1034 J.s) and d is the distance separating the two 
objects (m).
However, it must be noted that the interaction energy does not become infinite when 
the separating distance tends to zero, as the formula would suggest. This manifestation 
o f a very short-range repulsive energy is due to the impenetrability o f the electronic 
clouds [16]. The value o f this energy is proportional to d12, thus overcoming any 
attractive interaction at very short separation distance.
In 1937, Hamaker based his theory on the assumption that the interaction between a 
couple o f atoms are not influenced by the neighbouring ones. By integrating on the 
whole pairs of the microscopic objects, Hamaker was able to calculate the interaction 
energy between macroscopic bodies [17].
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The Hamaker constant, A.-, is commonly used to estimate the dispersion interaction at 
shot distance between two microscopic bodies o f the same material and is expressed 
below.
[1-2]
where is the number o f atoms per unit volume and /?„is the London constant related
3h v  CC2
to atom interaction, i.e., /?. = ——-—ry obtained from Equation [1.1].
4 (4 ^ 0 )
According to Berthelot’s principle, the interaction constant between two particles of 
different materials is equal to the geometric mean o f the interaction constant o f the 
individual materials [18]. The combining rules describing the different types of 
interaction between two bodies are expressed below:
• between two materials 1 and 2 in vacuo\
^12 = VAl^22 [1-3]
•  between two particles o f a material 1 immerged in a medium 3:
- A  31 — V A  — 33 |4  -4]
• between two materials 1 and 2 immerged in a medium 3:
A  32 =  ( V A l  — V A 3 W A 2 — V  A 3 )  '5]
By using Hamaker’s pair-wise summation, the free energy o f interaction between 
particles can be assessed. In turn, interaction forces can be calculated by differentiating 
the energy with respect to distance:
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Sphere-sphere (equivalent sized particles):
R1 D R2 [R6]
i—  < ........►-------------------- -► 6 D R , + R 2
Sphere-plan surface (small-large particles):
R1 D  ^ TT _ A R
*  *" '  M ~ 6D2 1 1
where A is the Hamaker constant, related to the Lifshitz-Van der Waals constant co
by:
A  = — ha) [1.8]
4/r
As shown in the formulae, the separation distance D  is a critical parameter. The latter 
parameter being at the square power in the denominator, the forces will considerably 
reduce as the separation distance increases. Hence, the Lifshitz-Van der Waals forces 
can be influenced by the presence o f large asperities that would maintain a greater 
separation distance between the cores o f two interacting bodies
1.2.1.1.1. Lifshitz D ispersive Interactions
In contrast to Hamaker’s approach, Lifshitz calculated the interaction energy 
considering quantum  mechanic and electromagnetic field fluctuations in a continuous 
media, thereby treating the problem from a purely macroscopic framework [19].
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Israelachvili demonstrated the applicability o f the Lifshitz approach to estimate the 
Hamaker constant and corresponding surface tension o f different liquids using the 
following equation [20]:
where y ^  is the apolar component o f the surface tension o f material (i). LW refers to 
the Lifshitz-van der Waals contribution to the total surface tension.
Good, Girifalco and Fowkes determined that the interfacial tension, y^ , between 
two materials 1 and 2 can be expressed as a function o f their respective intrinsic 
surface energy and is given in the following equation [21, 22]:
r ^ = [ W ~ W )  ii-io]
The change in Gibbs free energy, A G if '  is concomitant with the interfacial surface 
energy o f the interacting materials. The relationship was established by Dupre and is 
illustrated in the equation below:
AGjT = t f , - r f ' - r f Jr [1.11]
Substituting Eq. [1.10] into Eq. [1.11] yields:
[1-12]
It can be discerned from Eq. [1.9] that as the free energy o f interaction is stricdy 
negative, the interaction between two condensed phases in vacuo will always be 
attractive.
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From Eq. [1.12], various scenarios can be envisaged in determining particle 
interactions between similar or different materials, in vacuo or immersed in a third 
media:
• free energy o f cohesion o f material 1 in vacuo\
A G f f  = - 2 y f  [1.13]
•  free energy o f cohesion o f material 1 immersed in a medium 3:
A G - = - 2 t f f  [1.14]
• free energy between material 1 and 2 immersed in a medium 3:
A G£ = y £ - r F  [1-151
The Lifshitz-van der Waals interactions can be closely approximated by measuring the 
dispersive surface free energy properties o f the relevant materials. These characteristics 
can be determined by a variety o f different techniques. One o f the most accurate 
methods for determining surface free energy is contact angle measurement [22-25]. 
This method is based on measuring the angle o f repose o f a droplet o f liquid with 
known surface tension on a solid surface. O ther methods, such as inverse gas 
chromatography and capillary intrusion technique are increasingly becoming popular in 
studying the characteristic energies o f pharmaceutical powders [26-30].
I.2.I.I.2. Polar or Lewis Acid-Base Interactions
For many years, intermolecular forces were assessed in dense gases, where the
measurement o f dispersion forces (London), the dipole-dipole interactions (Keesom)
and dipole-induced dipole interactions (Debye) were sufficient to elucidate most o f the 
intermolecular interactions between pair o f atoms or molecules. These considerations
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were subsequently extended to macroscopic bodies for the measurements o f 
interactions between solids and liquids.
However, significant advances in interfacial tension measurements via thermodynamic 
techniques have revealed a deviation from such an approach. It is now widely accepted 
that polar interactions are o f significant importance in the determination of interaction 
forces, especially when occurring in a polar media [31, 32]. Fowkes proposed that the 
surface tension of a material i can be divided into subclass components, namely the 
non-polar Lifshitz-van der Waals (LW) contribution and the polar Lewis acid-base 
(AB) contribution [21]:
y, = y f  + y ?  [1.16]
Since AG.. = —2yi , the total free Gibbs energy can be written as:
AG = AG LW + A G ab [1.17]
where AG LW and AG '43 are the free energy changes due to Lifshitz-van der Waals 
interactions and acid-base interactions, respectively.
Fowkes further investigated the importance o f acid-base interactions by determining 
the work o f adhesion (WSL) between polymer surfaces and liquids o f various acidities as 
a function o f acidity o f the polymer [32]. H e showed that the polar contribution to the 
total work o f adhesion is strictly dependent upon the acidity (basicity) o f the polymer 
o f interest. Polar interactions arise from the interaction between electron-acceptor 
(acid o f Lewis) and electron-donor (base o f Lewis) sites in molecules. The polar 
contribution o f the surface energy o f a material can be expressed as:
where and are the electron-acceptor and electron-donor surface tension 
parameters, respectively.
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Based on Fowkes’ approach, Van Oss et al showed that the interaction between two 
polar materials 1 and 2 is essentially asymmetrical; i.e. the electron-acceptor site o f one 
material interacts with the electron-donor site o f the other and vice versa [33]. The acid- 
base Gibbs free energy between two materials i and j  can therefore be expressed as:
AG f  = - 2 -  f i t f )  [1.19]
Adapting the Dupre equation [1.11] to acid-base parameters, and substituting Eq. 
[1.18] and [1.19], the acid-base surface tension can subsequently be written as:
r ? =2 (VT - - VT) t1 -2°]
I.2.I.I.3. Interaction Predictions by Combining the Interfacial Energy 
Contributions
Using the Dupre equation in the form of:
^ ^ 1 3 2  y  12 7 l3  7:23 [1.21]
to describe the interaction between material 1 and 2 in a media 3 and combining the 
apolar contribution (Equ. [1.10]) with the polar contribution (Equ. [1.20]) yields:
AG132 -  2
{ J t t - J r r l W - W )
+VT(Vif + ^ - 4 r i ) [1.22]
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Similarly, the interaction between molecules o f substance 1 immersed in a media 3 can 
be expressed as:
[ l23]
The resulting interaction between material 1 and 2 in vacuo therefore is:
AG,2 = - 2  [ - J r F W  + V t f j ?  + [1-24]
Interestingly, Eq. [1.24] states that AG12 is always negative and cannot be nought since 
the van der Waals contribution o f all materials has a finite value. Hence, the interaction 
between two substances in vacuo is always attractive. This is o f particular interest when 
considering a material hydrophobicity, as water is always attracted to the most 
hydrophobic material. Polytetrafluoroethylene (Teflon), for example, is one o f the 
most hydrophobic material known although exhibiting an interfacial surface free 
energy o f 40mJ.m~2.
I.2.I.2. Electrostatic Forces
Electrostatic charges develop as a result o f contact and separation o f two 
different surfaces. According to theory, contact and friction electrifications are two 
different phenomena. However, they are both usually described as triboelectrification. 
The major processing o f pharmaceutical powders, such as micronisation, high shear 
mixing or spray drying may induce triboelectrification o f particulate surfaces [34]. As 
all these processes involve very violent collisions between particles, high electrical 
charges can arise on the surfaces o f processed particles. The generation o f electrostatic 
forces onto solid surfaces occurs for various reasons. The simplest case occurs when 
two charged particles come into contact. The electrostatic force can be either attractive 
or repulsive, depending on the respective charges on the surfaces o f the particles.
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The resulting electrostatic force can be described by Coulomb’s law:
P-25I4XE0d
where q, and q2 are the respective electrical charges,80 is the permittivity and d the 
separation distance.
W hen an uncharged particle encounters a charged particle, either positively or 
negatively charged, electrons will transfer between the particles. Thus, if a particle of 
charge q approaches an uncharged particle o f radius r, the first particle will induce what 
is called an image charge on the second particle. The interaction force due to the 




W hen the uncharged particle is a flat surface (r—><»), the previous equation becomes:
F  = -----    [1.27]
1 t>7T£Qd
Finally, the contact between two uncharged particles can result in the induction of 
electrostatic charges. Charge transfer between the two surfaces can be explained in 
terms o f difference in work function o f the materials. The work function is defined as 
the minimum energy required to emit one electron from a particle surface to infinity. 
As two solids are separated from a distance d, the material with the lower work 
function will transfer electrons to the material with the higher work function until 
equilibrium is reached. The resulting force is given by:
F, = ^ o r ^ P ~  [1-28]
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Electrostatic forces are o f considerable importance when considering pharmaceutical 
powders [34]. Generally, pharmaceutical excipients have a low conductivity, behaving 
as insulators, precluding effective surface charges to dissipate into the particle core. 
Thus, electrostatic interactions are considered to be significant during the initial 
attraction and adhesion between particles, while the van der Waals forces are 
responsible for maintaining the ordered unit, once the electrostatic charges have 
dissipated. Staniforth and Rees demonstrated that the stability o f ordered mixes 
depended upon the electrostatic charges developed on the materials during mixing [35]. 
It is even considered that the presence o f electrostatic forces may be beneficial for 
ordered mixing and minimising the segregation tendency o f the blends [36].
I.2.I.3. Capillary Forces
As opposed to van der Waals forces and electrostatic forces, capillary forces arise 
when particles come into intimate contact. Capillary interactions are highly dependant 
on the partial water vapour pressure o f the surrounding atmosphere and the physico­
chemical properties o f the materials, in particular its hydrophilic/hydrophobic nature 
[37]. U pon raising the relative humidity, the condensation o f water vapour onto the 
surface o f solids generally increases. With sufficient condensation, the formation o f a 
liquid bridge between two contacting surfaces may be induced, resulting in significant 
interaction energy [38]. A diagrammatic representation o f capillary interaction between 
a particle and a surface is shown in Figure 1.2.
This capillary condensation only occurs at high relative humidity [39]. W hen a 
meniscus is formed between a sphere and a larger flat surface, the corresponding 
capillary force (to be added to the already existing interaction forces) is described by 
[40]:
P, =  2 /Z7 i / ( c O S  a +  COS P) r j  2 9 j
where OC is the contact angle o f the liquid with the surface, (3 is the contact angle o f the 




Figure 1-2: Capillary interaction between a particle and a surface
1.2.2. Factors Influencing Adhesions
Given the number o f discrete mechanisms in particle interactions, it can be 
expected that a large amount o f factors will influence interaction forces. Surface 
roughness may alter the separation distance between two particles and thus the overall 
interaction forces. Particle size, shape and rugosity may modify the surface energy and 
thus the cohesiveness (or adhesiveness) o f interacting particles. Staniforth reported 
that an increase in the surface area to mass ratio resulted in maximum adhesion [41]. 
This can be achieved by two methods, namely size reduction or through the 
production o f macroporous particles [42]. Environmental parameters must be taken 
into account as well, such as relative humidity affecting the hygroscopicity or the 
charge o f a material. The main factors influencing particles adhesion are described in 
greater detail below.
I.2.2.I. Particle Size
It has been shown previously that particle size has a great effect on interaction 
forces [43]. For example, Lifshitz-van der Waals forces are directly proportional to the
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radius o f the particle. Capillary forces and electrostatic forces are, in some cases, also 
dependent upon particle radius. It is reasonable then to assume that the bigger the 
particle, the greater the overall interaction forces. However, external forces such as 
gravitational or centrifugal forces are acting as separation forces on the particles. Since 
gravitational or centrifugal forces are a direct function o f the cubic radius o f the 
particle, there is a critical radius when separation forces overcome adhesion forces [44]. 
However, as gravitational forces decrease more rapidly with decreasing particle size in 
comparison to the Lifshitz-van der Waals, capillary and electrostatic forces at a critical 
particle size the influence o f the gravitational force is insignificant. As a result very fine 
material tend to form cohesive agglomerates [10] or adhere to solid surfaces [45].
I.2.2.2. Particle Shape and Roughness
O ne o f the most important parameters affecting inter-particulate forces is the 
macroscopic and microscopic geometry o f particles, which defines the true contact 
area between particles. While a perfect sphere sitting on top o f a perfectly flat surface 
will have a very small contact, a cubic object on top of the same surface will have a 
contact area equal to the square o f its side. Meanwhile, regular microscopic (even 
nanoscopic) protrusions or asperities on particle surfaces would dramatically decrease 
the effective contact area o f contiguous surfaces, resulting in a concomitant reduction 
in particle interactions.
In the case o f a carrier-based dry powder inhalation formulation, the dispersion and 
de-aggregation o f drug particles adhering to surface with nanometre asperities will be 
more readily removed from the carrier than those attached to smoother surfaces [46]. 
O n the other hand, if  the size o f the asperities matches the drug particle size, a 
phenom enon o f entrapment or mechanical interlocking may occur, leading to a 
significant increase in particle-particle adhesion. Greater energy would hence be 
required to dislodge the particles [47]. The direct measurement o f surface roughness is 
difficult to quantify and several parameters, such as rugosity and root mean square 
deviation o f surface protrusions have been utilised [48]. In all surface roughness 
measurements, surfaces are normalized by defining the centre line, representing the 
general profile direction of the sampling length, as illustrated in Figure 1.3.
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Figure 1-3: Schematic representation o f roughness parameter determination
The rugosity Ra is the arithmetic mean average distance value o f all points 
(Figure 1.3) o f the profile from the centre line:
R.-ZUIn /=i [1.30]
where y{ is the distance between the point and the centre line, n is the number o f 
points o f the profile. This value is the average height from the centre line.
The root mean square deviation o f the surface roughness characterises the variability 
o f the profile from the centre line:
H P [1.31]




The surface energy o f a solid (ys) is defined as the free energy change during the 
increase o f the surface area by one unit in vacuo. By definition this value is always 
positive. The excess energy is due to force imbalances rising at the surface o f the 
material. As molecules at the surface o f a solid are not as free to move as in a liquid, 
the surface energy is not evenly distributed over the surface. For example, surface 
energies will differ depending on the region o f the solid, whether it is at an edge or a 
planar surface. Adsorption of contaminants on a surface generally reduces adhesive 
forces. In general, solids with a high surface energy exhibit a high adsorbing power, 
leading to stronger inter-surface forces.
Direcdy related to surface energy, the work o f adhesion (Wad) plays a crucial role in 
solid-solid contact. The work o f adhesion is defined as the free energy change required 
to separate unit areas o f two surfaces from contact to infinity under vacuum, and can 
be written as:
ir ,f  = -A G „ [1.32]
As a result, differences between work o f adhesion and work o f cohesion between 
drug-excipient and drug-drug, respectively, are o f critical importance in pharmaceutical 
formulations, and will direcdy influence mixing homogeneity as well as particle 
segregation and preferential agglomeration [23].
1.2.2.4. Relative Humidity
As previously, discussed, the presence o f adsorbed water onto pharmaceutical dry 
powders may have a significant influence on the resulting adhesion forces. The 
magnitude o f its effect is dependent upon environmental conditions (i.e. relative 
humidity) and the nature of the material, (hydrophilic/hydrophobic, hygroscopic) [49].
Despite the ubiquitous attraction between water and a surface in vacuo, a material 
actually presents hydrophobic properties when its adhesive surface free energy with the
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water is actually lower than the cohesive energy o f adsorbed water molecules 
(78.2mJ.m2) [31]. For example, although water is attracted to the surfaces o f low 
surface free energy polymers, the cohesive energy of the water molecules prevents the 
spreading o f the water on the polymer surface.
A diagrammatic representation o f the behaviour o f hydrophobic and hydrophilic 
surfaces with a water droplet is shown in Figure 1.4. The hydrophobic/hydrophilic 
properties o f a surface are measured by the contact angle (0) o f the liquid with the 
substrate surface. The higher the value o f contact angle the more hydrophobic the 
material.
Hygroscopicity is defined as the capacity o f a material to absorb water. However, the 
two concepts o f hydrophilic and hygroscopic are very different. For example, while 
salbutamol sulphate is a highly hydrophilic material and readily water soluble, its mass 
uptake under high relative humidity is very low, suggesting a non-hygroscopic material 
[50]. These properties would have a direct affect on particle interaction forces [51]. If  
the material is very hygroscopic, (i.e. disodium cromoglycate), adsorbed water tends to 







Figure 1-4: Diagrammatic representation o f a material water affinity
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The increased adsorption of water on a particle surface may also increase the 
conductivity o f the particle surface, which may lead to the dissipation o f any 
electrostatic charges that may have build-up on the particle surface during frictional 
contact, reducing electrostatic induced forces [13]. Electrostatic forces would therefore 
be more significant at low relative humidity since surface charge dissipation would be 
limited [53].
Numerous studies have investigated the influence o f relative humidity on the adhesive 
forces between particles [13, 51, 53-57]. Results have indicated that particle adhesion 
increased as a function of relative humidity, which would contribute to macroscopic 
repercussions over the general formulation performances. Several investigations related 
significant deterioration in the stability, de-aggregation and dispersion properties o f dry 
powder formulations to exposure to elevated relative humidity [58-63].
1.3. Particle Physical State
Every powder or solid ingredient used in pharmaceutical industries is initially 
crystallised from solution. To meet the required functionality, crystals are commonly 
subjected to different processes (i.e. micronisation, spray-drying, mechanofusion). 
Hence, the knowledge o f crystal behaviour, surface and physical properties is o f critical 
importance in order to understand the implications o f crystallisation have over particle 
interactions.
1.3.1. The Crystalline State
Crystals are nucleated and grown from supersaturated solutions. A saturated 
solution is a thermodynamic equilibrium between the solid phase and the liquid phase 
at a specified temperature. This requirement for a supersaturated solution is critical for 
nucleation and crystal growth. Ostwald defined different areas (labile, metastable) 
around the solubility curve in which spontaneous nucleation would or would not occur
[64].
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Nucleation can occur spontaneously in a homogenous solution or induced artificially 
by a heterogeneous method. These processes are called primary homogeneous 
nucleation and primary heterogeneous nucleation, respectively. Young and Berkeley 
have shown that agitation, mechanical shock, friction extreme pressures and 
temperature cooling can increase the degree o f nucleation [65, 66].
A supersaturated solution may nucleate at a lower supersaturation, when crystals o f the 
solute are already present, or intentionally added. These crystals, more commonly 
described as seeds, act as nucleation centres for crystal growth. Such a process is 
referred as secondary nucleation [67].
1.3.2. Crystal Habit
Crystal habit, also known as crystal morphology, refers to the external appearance 
o f a crystal. A complete description o f the morphology o f a crystal requires the 
characterisation o f each crystal face present, their relative dominance, specific angles 
between the faces, relative areas and shape factors. These are used to describe the 
macroscopic geometry o f a crystal. However, knowing the internal structure o f a 
crystal unit cell is not sufficient to model the external habit o f the resulting crystals 
formed. External habit is not only controlled by its internal structure, but by the 
conditions in which the crystal has been grown. The rate o f growth, the solvent used, 
and the impurities present in the solution may have a critical influence on the crystal 
habit [68, 69].
1.3.3. Polymorphism
Polymorphism is the term used to describe the phenomenon o f a chemical species 
having more than one crystal structure. When a material crystallises into different 
polymorphs, the chemical nature o f the species remains identical, however due to the 
alteration in the crystal unit cell, physical properties such as density, melting point, 
solubility and hygroscopicity may differ [70]. This phenomenon raises a delicate issue. 
During the crystallisation o f a material, inhibiting polymorphism may be particularly 
crucial. This can sometimes be achieved by optimising and controlling the
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crystallisation conditions (e.g. solution temperature, solvents) as well as storage 
conditions (e.g. temperature and relative humidity), in preventing the formation o f 
undesired polymorphs. For example, cimetidine, a specific competitive histamine H 2- 
receptor antagonist, has seven known polymorphs [71]. Two o f them are o f particular 
interest to the pharmaceutical industry, with one being used in tabletting (form A) and 
the other in suspensions (form B). While form A can be re-crystallised from non- 
aqueous solvents at room temperature, form B requires slow cooling from a hot 
aqueous solution. Lactose is known to have two anomeric forms, namely a  and |3. 
Both are simultaneously present in aqueous solution with a CX/J3 ratio close to 40/60 
but only the (X-lactose monohydrate crystallises spontaneously below 93.5°C [72, 73].
1.3.4. The Amorphous State
An amorphous state is characterised by the absence o f three-dimensional long- 
range order which exists in a crystalline material. Rapid cooling, fast evaporation or 
precipitation may result in the formation o f amorphous solids in a glassy or rubbery 
state. Amorphous areas on solids particles may also be produced from mechanical 
treatments. The differences in physical properties between crystalline and amorphous 
material have been shown to have a profound affect on the stability and performance 
o f dry powder formulations [74, 75]. Molecules within an amorphous region are 
arranged randomly, and exhibit a higher surface energy than the respective crystalline 
material. This results in a higher solubility and lower melting point. Moreover, 
amorphous materials have different plastic properties than the crystalline material, 
usually softer and subject to deformation. The degree o f molecular mobility within a 
particular amorphous material will be dependent on a number o f factors, including 
temperature and solvent vapour pressure. The vapour pressure is defined as the 
pressure at which a liquid and a gas phase are in equilibrium. For example, sorption o f 
a solvent into an amorphous region would increase molecular mobility, thus, lowering 
the glass transition temperature (Tg) [76]. If  the partial pressure o f the solvent is high 
enough to lower the Tg below the experimental temperature the region may re- 
crystallise and expel the solvent [77]. It is important, however, to note that such a 
system is a thermodynamic process and not a kinetic process. It will not reach a true 
equilibrium until the system re-crystallises, but the process may take considerable time.
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In most pharmaceutical applications, dosage forms must exhibit a specific functionality 
that requires a high-energy processing, such as milling or micronisation. This inevitably 
leads to the formation o f molecular defects and dislocation and the creation o f 
amorphous areas within the crystalline material. In general, such amorphous materials 
are thermodynamically unstable and will undergo re-crystallisation if the right 
conditions and the kinetics is favourable [78]. The presence o f amorphous regions will 
directly affect the stability o f a formulation, as the surface energetics will become 
unpredictable, leading to batch-to-batch variations in the stability and aerosolisation 
properties o f the powder blend [79].
1.4. DPI Formulation Development
Dry powder inhalation (DPI) formulations offer many advantages over other routes o f 
drug delivery for inhalation. In comparison with conventional pressurised metered 
dose inhalers (pMDIs), the volatile propellants, such as CFC or HFA, are not required 
thereby avoiding potential detrimental affect on the environment. Secondly, for passive 
D PI devices, the powder is delivered automatically when the patient inhales, thereby 
avoiding coordination problems usually encountered with propellant driven systems. In 
addition, DPIs offer the possibility o f delivering high drug doses.
As mentioned previously, the active drug must exhibit a specific particle size (<5pm) 
to reach the conducting airways and peripheral regions o f the lung. This leads to a well- 
known paradox, that respirable sized particles tend to be highly cohesive, which causes 
entrainment problems due to their poor flowability [10]. In addition, strong cohesion 
forces hinder the handling o f the powder during the manufacturing process (pouring, 
filling). These constraints play a critical role in the processing and design o f powder 
formulations and inhalation devices, respectively.
To overcome the highly cohesive nature o f respirable powders, the drug is commonly 
co-processed (blended) with larger carrier particles o f an inert excipient to aid 
flowability and drug re-dispersion. However, the carrier-based formulation approach is 
severely limited by the restrictive availability o f excipient materials. The only approved 
excipients hitherto are lactose and glucose [80].
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By blending a micronised drug with a carrier, sufficient adhesive bonds between the 
two ingredients may be generated to form an interactive mixture. Thus, the balance o f 
inter-particulate forces within the interactive mixture is critically important. The drug 
particles need to be attracted to the carrier during mixing to aid blend homogeneity, 
device filling and formulation stability during storage and handling. Yet the active 
ingredient must be easily detached from the carrier upon activation to form a fine 
particle cloud.
Numerous techniques have been applied to modify particulate interactions in dry 
powder formulations. The majority have targeted the use of carrier and the control o f 
its physical properties or the use o f a ternary agent, such as fine lactose. Other 
methods involve the manufacture o f more uniform respirable particles by particle 
engineering technology such as spray drying or supercritical fluid precipitation.
1.4.1. Particle Engineering Techniques
In order for drug particles to be o f a desired ultra-fine particle size for respiratory 
tract delivery, the active material must undergo high energy processing. The most 
common technique for obtaining the optimum particle size range for inhalation is 
mechanical micronisation. This process involves the use o f high shear forces, which 
results in the continuous fracturing o f large particles into the desired particle size 
range. One drawback o f this processing is the lack o f control in the size or shape 
homogeneity [81]. Moreover, particles produced by mechanical micronisation tend to 
exhibit increased surface rugosity, residual electrostatic charges and significant levels o f 
crystalline disorder [82-84]. These modifications will typically be present on the surface 
o f the processed material [85]. Furthermore, micronised powders generally exhibit a 
high surface free energy [86]. Under favourable conditions o f temperature and /o r 
humidity, these amorphous regions may undergo a re-crystallisation process, possibly 
inducing solid crystal bonding and subsequent aggregation. Moreover, Feeley et al. 
showed that the micronisation o f crystalline particles resulted in a significant increase 
in their surface free energy [81, 87]. Since both van der Waals and capillary forces are 
functions o f this latter parameter, dramatic alterations in the stability and performances 
o f drug particles during storage and handling may be expected upon micronisation.
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O ther methods such as spray drying or supercritical fluids have been developed as an 
alternative means of generating particles suitable for inhalation. Spray drying involves 
solubilization o f the active ingredient in a suitable solvent, and spraying the solution 
into a heated air stream [75, 88]. The resulting particles are often spherical and hollow 
due to the rapid drying process o f the aerosolised droplets [89, 90]. However, the rapid 
solidification o f the particles generally leads to an amorphous structure [88, 91]. It has 
been reported that in vitro studies o f spherical spray-dried cromoglycate particles gave a 
higher fine particle fraction than for the crystalline micronised material [92]. It was 
suggested that the hollowed structure o f the spray-dried particles significantly reduced 
their overall density, allowing larger particles to exhibit the required aerodynamic size 
range for inhalation. However, the stability issues related to amorphous materials have 
precluded their wider use in dry powder formulations. Due to the metastable nature of 
these amorphous particles, the use o f spray-drying is currently limited to producing 
particles with stable glass properties, such as proteins or peptides.
A more recent development in obtaining crystalline particles within a well-defined 
particle size involves the use o f supercritical fluids, typically carbon dioxide [93, 94]. By 
increasing pressure and temperature to a critical point, there is no distinction between 
the gaseous and liquid phase. This offers a media with interesting properties for re­
crystallisation purposes. The active drug is first dissolved in a solvent and then injected 
with a supercritical fluid in a high pressure chamber. As the supercritical fluid 
evaporates, the rapid increase in supersaturation within the droplets eventually induces 
precipitation. More recently, the SEDS-process (Solution Enhanced Dispersion by 
Supercritical fluids) was introduced [94]. This technique involves a continuous flow of 
a solution o f drug co-introduced into a particle formation vessel with a supercritical 
fluid. The mixing and dispersion o f the drug solution leads to rapid supersaturation, 
subsequent nucleation and particle formation. The resulting particles are usually highly 
crystalline, thereby exhibiting lower surface free energies and increased stability in 
comparison to micronised products [87, 95]. Studies performed with inverse gas 
chromatography (IGC) indicated that while the dispersive surface free energy of 
micronised salbutamol sulphate was 58.6mJ.m~2, SEDS-produced salbutamol sulphate 
exhibited a surface free energy o f 38.5mJ.m'2. However, particles produced by SEDS 
techniques typically exhibit smooth and planar crystal faces, resulting in a significant
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increase in the contact area of contiguous surfaces. Despite the reduction in interfacial 
surface free energy, the particle adhesion may therefore generally be increased and 
reduce particle flowability [95, 96].
1.4.2. The U se o f Coarse Carrier Particles
Carriers are mainly utilised as a bulking agent to improve the flowability o f the 
active ingredient. It must be chemically and physically stable, and not chemically 
interact with the active material [41]. A large number o f solid materials have been 
investigated as possible candidates, although lactose and lactose derivates are the m ost 
commonly employed, mainly because o f their history as a safe excipient [3, 97-99].
Lactose carrier particles are mosdy prepared by crystallisation, and can be obtained in a 
wide variety o f shapes and sizes [72, 100-102]. A specific structure o f lactose, OC-lactose 
monohydrate, is preferred among others and is shown in Figure 1.5. This type o f 
crystal particles exhibit excellent flowing properties and its particular “tomahawk” 
shape provides a significant area for drug-excipient interaction.
Investigations on the influence o f the carrier size over formulation performance 
revealed that drug emission tended to increase with particle size o f the carrier whilst 
fine particle fraction, fine particle dose and drug dispersibility appeared to increase 
with decreasing particle size o f the carrier particles [103, 104]. Bell et al have shown 
that optimal flowability and aerosolisation properties are obtained within a 63-90|Um 
particle size range [105].
As mentioned previously, carrier morphology such as shape and roughness can play an 
important role in determining the particulate interaction between the drug and the 
carrier, thereby influencing powder properties such as flowability, mixing uniformity 
and de-aggregation [106, 107]. Variations in rugosity may be obtained by specific re­
crystallisation techniques. Zeng et al showed that the re-crystallisation o f lactose from 
Carbopol gel or supersaturation at high temperatures (40°C) in the presence o f 
glycerine induced the formation o f smoother and more regular crystals [102, 108]. 
More recently, a novel technique o f controlled surface etching was developed on the
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partial but controlled surface re-dissolution o f lactose crystals by subtle changes o f 
temperatures around the supersaturation curve [109]. An illustration o f engineered 
smooth lactose is shown in Figure 1.6.
Figure 1-5: Representative scanning electron micrograph o f a coarse lactose particle
lOtyjnn
Figure 1-6: Representative scanning electron micrograph o f a smooth lactose particle
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Lactose crystals o f various shapes and roughness have been shown to significandy 
influence the in vitro deposition profiles o f salbutamol sulphate particles 
[100, 110, 111]. Kawashima et al. showed that lactose particles with higher surface 
roughness resulted in a reduction in the respirable fraction due to strong adhesion 
between drug and carrier [107]. Similar conclusions were recendy reached by Chan et al 
who immobilised fine particles on lactose carrier by precision coating and assessed its 
effect on the performance o f dry powder formulations [112].
1.4.3. Addition o f Fine Excipient Particles
One o f the most successful advances in optimising drug delivery performance of 
dry powder formulations is the addition o f  small amounts o f fine excipient particles. 
Such systems are usually referred to as ternary formulations. Extensive work on the use 
of fines in dry powder formulations and their influence on delivery performances has 
been published in the scientific literature [99, 111, 113-116]. W ithout exception, the 
addition o f fine particles o f lactose was found to increase the fine particle fraction of 
the drug. A number o f these studies investigated the influence o f the concentration of 
fines within dry powder formulations. The inclusion o f 1.5% to 10% o f ternary agent 
resulted in a general increase in fine particle dose [114].
Various theories on the possible mechanisms by which additional fine excipient 
particles may enhance carrier-based formulations have been reported [117-120]. It is 
generally believed that particles of the ternary agent occupy higher energetic sites on 
the surface o f the coarse carrier. As a consequence, only the lower energetic sites 
remain available for the drug to adhere to the carrier. The resulting reduced adhesion 
forces would thereby facilitate the more efficient drug detachment upon patient 
actuation. This theory was supported by several studies investigating the effect of the 
order in which the coarse carrier, fine excipient and drug particles were mixed. Zeng et 
al. found that formulations produced by first blending the coarse carrier and fine 
excipient yielded greater fine particle fractions than formulations produced by first 
blending the coarse carrier and the drug [111, 113].
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Conversely, work by Lucas et al revealed that for certain active ingredients the order of 
blending had no apparent affect on the performances of a ternary formulation. It was 
suggested that during the blending process, fine excipient and drug particles were 
redistributed over the coarse carrier surface to form satellite aggregates or fine particle 
multiplets [121]. These agglomerates could exhibit the desirable effect o f being more 
readily detached from the large coarse carrier than individual particles, and subjected to 
higher drag forces and kinetic energies upon de-agglomeration and dispersion [114].
1.4.4. Force Control Agent (FCA)
The primary role o f these low surface free energy materials is to change the surface 
chemistry of the guest particles and decrease their intrinsic cohesion. In the early 
eighties, Staniforth et al reported that the addition o f magnesium stearate in a lactose 
and salicylic acid blend decreased drug-carrier interactions [122]. Previous studies 
suggested that the ternary agent preferentially adheres to the high-energy active sites o f 
the carrier, “stripping” the active ingredient from the lactose surfaces, leading to a 
passivation o f the carrier surfaces [123].
The use o f force control agents as a possible means o f increasing the aerosolisation 
efficiencies o f dry powder inhaler formulations is more recent and mostly industrially 
driven. As a result, most o f the relevant information regarding FCAs can be obtained 
via patent literature, while very little is available in the scientific literature [46, 114, 124, 
125]. The initial concept o f modifying the adhesive interactions in a carrier-based D PI 
formulation with an additive was invented by Staniforth and filed in 1996 (patent 
W 09623485). A force control agent preferably exhibits an anti-adherent and /o r anti­
friction aptitude, thereby increasing the flow properties o f pharmaceutical 
compositions. These FCAs include conventional lubricants used in powder 
compression technology, and include amino acid such as leucine, phospholipids such 
as lecithin or fatty acids like magnesium stearate (MgST) [126]. The processing o f 
FCAs has since been enhanced by various methodologies including the co-processing 
of fine lactose with the additive (patent W OOl78695) or the specific coating o f host 
particles by high energetic mixing processes (patent WO09703639). Claims indicate
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that the quantity o f force control agent shouldn’t exceed 40% (w/w) o f the total 
powder mixture, with a preferred interval comprised between 0.25 to 5%.
1.5. Aim of the Study
In order to manufacture a suitable inhalation formulation with an effective and 
reproducible dose delivery, the physico-chemical properties o f the drug must be stable 
and predictable. However, many mechanical processes used in the pharmaceutical 
industry to produce an inhalation formulation often lead to the generation of particles 
with haphazard physico-chemical properties. This may inevitably lead to substantial 
variations in particle interactions and undesired repercussions on powder mixing, 
stability and drug delivery performance.
It has been previously discussed that the general properties o f a dry powder inhaler 
formulation (stability, handling, and fluidisation) are associated with a delicate balance 
between the cohesive and adhesive interaction forces within the powder blend. As a 
result, these forces and the factors which affect them will directly influence the overall 
characteristics and performance o f the formulation. Thus, optimisation o f the 
formulation performance requires an efficient control o f these particulate interactions. 
A more fundamental knowledge o f particle interactions is therefore necessary to 
effectively understand the mechanistic processes which control and modify dry powder 
inhaler formulations.
In this study, the initial work was dedicated to the development o f a novel AFM-based 
technique and analysis procedure to quantify the relative cohesive and adhesive 
interactions within model dry powder formulations. This subsequent analysis 
procedure was then used to investigate the specific role o f the cohesive and adhesive 
force balances on the de-agglomeration efficiencies and deposition characteristics o f 
drug only and model drug-lactose formulations in predicting blending, segregation and 
dispersion properties o f active pharmaceutical ingredients in dry powder systems. The 
knowledge gained from these analyses was subsequently used to try and optimise dry 
powder formulation performances by specifically introducing a force control agent into 
a dry powder formulation to selectively target the desired interaction to be controlled.
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The in-vitro deposition profiles o f model drug-lactose and drug only formulations 
were investigated to establish a possible correlation between the cohesive and adhesive 
nature o f the modified formulations with aerosol delivery performance.
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Figure 2-1: Chemical structure o f budesonide
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•  Salbutamol sulphate
Supplier: Becpharm Ltd, Harlow, UK; Batch N°: 940077 
Group: Bronchodilators, J32-agonists
Figure 2- 2: Chemical structure of salbutamol
Sorbalac 400 (oc-Lactose monohydrate)









Figure 2- 3: Chemical structure o f Ot-Lactose monohydrate
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L-Leucine
Supplier: Ajimoto Co., Tokyo, JAPAN; Batch N°: 601FK72 
Group: Amino-acids
NH
Figure 2- 4: Chemical structure of L-leucine
• Lecithin
Supplier: lip o id  GmbH, Ludwigshafen, Germany;
Batch N°: 25661113-1/14 
Group: Phospholipids
CH3(CH2)14C (0 )0 -C H 2 
CH3(CH2)uC (0 )0 -C H  
(CH3)3NCH2CH20 P (0 )0 -C H 2
o—
Figure 2- 5: Chemical structure o f lecithin
•  Magnesium stearate
Supplier: Avocado, Heysham, UK; Batch N°: H1028A 
Group: Fatty acids
/ °  o ° ~
CH3(CH2),£ \  _ M g+ ^  CH3(CH2)16
o o
Figure 2- 6: Chemical structure o f magnesium stearate
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2.1.2. Liquids
Denomination Supplier Address Batch number
Methanol Fisher Chemicals Loughborough, UK N /A
Ethanol Fisher Chemicals Loughborough, UK N /A
Acetonitrile Fisher Chemicals Loughborough, UK N /A
Diodomethane Acros Organics Geel, Belgium 169835
Ethylene Glycol Aldrich Gillingham, UK N /A
Acetic acid glacial 100% BDH Poole, UK N /A
Water (reverse osmosis) MilliQ, Millipore Molsheim, France N /A
2.2. Particle Size Analysis
Various techniques are available to determine the size range o f powder samples. These 
include sieve analysis, time-of-flight determination, sedimentation, low angle laser light 
scattering (LALLS) or impaction based techniques. The techniques chosen for this 
study were namely low angle laser light scattering, time-of-flight technique and
impaction analysis using two different impingers. It is important to stress that the
former method determines the actual geometrical particle size, whereas the others 
elucidate the aerodynamic particle diameter. Nevertheless, the two parameters can 
easily be related via a simple equation [1]. It has been shown that lung sedimentation 
behaviour is closely related to the aerodynamic diameter [1], ensuing the wide use o f 
impinger techniques to characterise formulation and inhaler device performances. 
These are described in greater detail in section 2.5.
2.2.1. Light Scattering Analysis
The LALLS technique is based on the diffraction o f a monochromatic, collimated 
light by a particle or group of particles. The diffracted light caused by the powder 
dispersion traversing the laser forms a scattering pattern, which is specific to an
individual particle size. The latter parameter is then calculated by Fourier
transformation, using Fraunhofer diffraction theory, which allows correlation between
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particle size and diffraction pattern. In the case o f micron-sized particles, the Mie 
theory is applied to elucidate the scattering patterns, as the optical properties o f the 
material to be analysed have to be considered [2].
In essence, the scattering pattern is obtained by integration over the whole range of 
single scatters caused by each particle present in the sample. Particle size distributions 
are then calculated by matching experimental and theoretical diffractograms [3].
Analyses were performed using a Mastersizer X  (Malvern Instruments Ltd, Malvern, 
UK) with a 300mm lens. Prior to analysis, powders were dispersed in a mixture of 
lecithin (0.1% w/w) and cyclohexane before being sonicated for 5 minutes to facilitate 
dispersion. Samples were then stirred with the dispersant in a large volume cell inside 
the Mastersizer, using a magnetic stirrer in order to obtain an obscuration level o f 20- 
30%. All samples were prepared and analysed in triplicate.
2.2.2. Tim e-of-Flight Analysis
Aerodynamic Time-of-Flight (TOF) o f airborne particles can be measured by 
detecting their velocity between two laser beams. Essentially, a powder sample is 
dispersed in air, creating an aerosol beam which is accelerated by the drag forces 
generated in the air stream. As particles pass through two laser beams in the measuring 
region spaced at a pre-set distance, the time required for individual particles to pass 
between the beams is detected and converted by two photomultiplier tubes into 
particle size.
Analyses were performed using an Aerosizer® (Amherst Process Instruments, Hadley, 
USA). The amount o f shear forces applied to the powder sample is adjusted by 
monitoring the pressure drop across the annular gap between the disperser pin and the 
pin bowl. Therefore, subsequent shear forces are expressed as the corresponding 
pressure drop, varying from 0 to 5psi. After each measurement, the sample cup and the 
disperser unit were thoroughly cleaned.
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2.3. Particle Shape Analysis
General morphology o f the pharmaceutical ingredients was investigated by both 
scanning electron microscopy (SEM) for particle shape study and atomic force 
microscope (AFM) for surface topography analysis.
2.3.1. Scanning Electron Microscopy (SEM)
A scanning electron microscope creates a high resolution image o f a sample in vacuo 
by the use o f a collimated beam of electrons instead o f light waves. An electron gun 
emits a beam o f focused electrons which is scanned back and forth over a conductive 
sample. As the electron continuously sweeps across the specimen at high speed, 
secondary electrons are knocked loose from its surface due to the local irradiation. The 
signal produced by the secondary electrons emitted from the specimen is detected and 
interpreted to form the final image.
Representative powder samples were mounted on aluminium stubs using carbon 
coated adhesive tabs. A thin film o f gold was vaporised onto the sample surface using 
a sputter coater (Model S150B, Edwards High Vacuum, Sussex, UK). Specimens were 
examined using a JEO L 6310 SEM (Japanese Electron optics Ltd, Tokyo, Japan).
2.3.2. Atomic Force M icroscopy (AFM)
The atomic force microscope is a very accurate apparatus allowing the discernment 
o f solid surfaces at the nanometre scale. However, as this surface topography analysis 
is only one o f the AFM techniques used in this study, a fully detailed section is 
therefore dedicated to the description o f the apparatus in section 2.7.
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2.4. True Density
True density analyses were determined by helium pycnometry (Accupyc 1330 Gas 
Pycnometer, Micromeritics, Norcross, USA). Measurements were performed by 
determining the pressure change o f helium of a calibrated sealed volume containing a 
powder sample o f known mass and unknown volume [4].
Samples were first dried in opened pans at 40°C for 24 hours to remove any adsorbed 
water. Temperature was kept constant at 25°C throughout experiments. Each sample 
density was measured ten times for reproducibility.
True density measurements for salbutamol sulphate, budesonide and lactose were 
determined as 1.248 g.cm'3 (± O.OOlg.cm'3), 1.473 g.cm'3 (± O.OOlg.cm'3) and 1.532 
g.cm'3 (± O.OOlg.cm'3), respectively.
2.5. Formulation Performance Analysis
The most important physico-chemical parameter influencing the deposition o f aerosols 
in the lung is particle size. However, aerodynamic diameter is often preferred to 
geometric diameter when considering the behaviour o f fluidised particles. Hitherto, 
inertial impaction is the most commonly used methodology to determine the 
aerodynamic particle size o f aerosols.
Two different apparatus were employed in this study. An impinger (impaction on 
liquid) or impactor (impaction on a solid surface) usually consists o f a series o f stages 
o f different cut-off diameters mounted as a cascade. The desired particle cut-off size of 
an impinger is relative to the airflow velocity passing through the apparatus.
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2.5.1. Twin-Stage Impinger (TSI)
The twin-stage liquid impinger (TSI) apparatus was the first device operating on 
inertial impaction to assess drug delivery to be adopted by the British Pharmacopoeia
[5]. A representative TSI apparatus (Copley Scientific Ltd, Nottingham, UK) is shown 
in Figure 2.7. The TSI apparatus was operated at bOL.min'1 (± 2L.min_1), 
corresponding to a cut-off diameter o f 6.4|j.m between the first and second stage. Flow 
rate was calibrated using a flowmeter (SCR2, Glass precision, Eng. Ltd., UK).
95
01.85  ± 0.125
Figure 2- 7: Schematic representation o f a Twin-stage liquid impinger, reproduced 
from British Pharmacopoeia, 2001, Volume II.
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2.5.2. N ext Generation Impactor (NGI)
The amount of time requited in the testing of pharmaceutical inhalers by existing 
cascade impactors has encouraged the development of a novel impactor, specifically 
designed for pharmaceutical aerosols. This resulted in the creation of the next 
generation impactor (NGI), which was launched in 2000 (Figure 2.8). It is a high 
performance particle-classifying cascade impactor for testing pressurised metered dose 
or dry powder devices.
The N G I is composed o f seven stages plus a Micro-Orifice Collector (MOC). The 
effective cut-off diameters at 60L.min1 are as follows:
• Stage 1: >8.06pm
• Stage 2: 4.46 — 8.06pm
• Stage 3 2.82 - 4.46pm
• Stage 4 1.66 — 2.82pm
• Stage 5 0.94 — 1.66pm
• Stage 6 0.55 — 0.94pm
• Stage 7 0.34 -  0.34pm
• Stage 8 (MOC) <0.34pm
The air flow passes through the impactor in a saw-tooth pattern. Particle separation 
and sizing is achieved by successively increasing the velocity o f the air stream as it 
passes through each stage by forcing it through a series o f nozzles containing 
progressively reducing jet sizes. Drug particles are collected on plates, which can be 
individually removed from the N G I core to collect the drug particles. Advantageously, 
no liquid is necessary for the in vitro testing. After each experiment, each stage plate can 
be readily removed and quickly rinsed with an adequate solvent for analytical analyses.
2. Material and Methods 56
t i i w i m f  i — -t mmmmm+ 0
Figure 2- 8: Next Generation Im pactor (Open View showing nozzles & collection 
cups), reproduced from Copley web site.
2.6. D ru g  A nalysis
2.6.1. Solubility A nalysis
D rug solubility analyses were measured by gravimetric technique. This m ethod was 
chosen over methods like UV/VIS-spectroscopy, fluorescence spectroscopy or high 
performance liquid chromatography (HPLC) in order to avoid any solvent effect on 
the quantifying method. Solubility studies o f budesonide and salbutamol sulphate in 
different conditions were conducted in order to determine the required conditions for 
satisfying re-crystallisation.
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2.6.1.1. Solubility of Budesonide as a Function of 
Temperature
Saturated solutions o f budesonide in ethanol and in methanol were shaken for 
12 hours at different temperatures from 25 to 40°C (G76, Gyrotory water bath shaker, 
New Brunswick Scientific, Edison, USA) in sealed volumetric flasks. The saturated 
solutions were filtered and dried at 40°C before calculating solubility by mass. The 
solubility curves are expressed graphically in Figure 2.9. It can be noticed that the two 
curves followed the same trend, the solubility in methanol being slightly higher than in 
ethanol. However, the difference o f solubility between 25 and 40°C was just about 1- 
1.5% (w/w) in both cases. It would therefore appear that temperature did not have a 
great effect on drug solubilization.
•■•••• Solubility in ethanol
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Figure 2- 9: Solubility o f budesonide as a function o f temperature
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2.6.I.2. Solubility of Budesonide as a Function of 
Solvent/Anti-Solvent Ratio
Solubility o f budesonide in mixtures o f organic solvent and water was 
determined by saturating the drug in ethanol/water mixtures or m ethanol/water 
mixtures. The solubility curves for budesonide in mixtures o f ethanol/water and 
m ethanol/water are expressed graphically in Figure 2.10. Budesonide, like most 
corticosteroids, is practically insoluble in water. As expected, the solubility decreased 
with increase o f water percentage in the mixtures. However, the solubility of 
budesonide in ethanol/water mixtures seemed to reach a maximum at a 20:80 
w ater/ethanol ratio. Similar trends have been observed with other materials in 
ethanol/water mixtures, but the phenomenon is still not well understood. Interestingly, 
the maximum of solubility was obtained with ethanol as the organic solvent. Moreover, 
the solubility dropped from 5.3% (w/w) at a 20:80 water/ethanol ratio to virtually 
naught at a 80:20 water/ethanol ratio.
5 -
•#■' Ethanol solvent 
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Figure 2- 10: Solubility o f budesonide as a function o f solvent/anti-solvent ratio
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2.6.I.3. Solubility of Salbutamol Sulphate as Function of 
Solvent/Anti-Solvent Ratio
Solubility o f salbutamol sulphate in mixtures of ethanol and water at a constant 
temperature o f 20°C was determined using the conditions described previously. The 
solubility curve is expressed graphically in Figure 2.11. The solubility curve showed 
high solubility o f salbutamol sulphate in water, corroborating its hydrophilic properties 
and affinity with water. However, salbutamol sulphate was virtually insoluble in 
ethanol. The resulting drop o f solubility was quite significant, being around 40%.
Given the excellent solubility patterns o f salbutamol sulphate in ethanol/water 
mixtures, it was decided not to investigate further the change o f solubility of 
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Figure 2-11: Solubility o f salbutamol as a function o f solvent/anti-solvent ratio
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2.6.2. HPLC Analyses
2.6.2.1. Methods
Drug concentrations collected from the various device components and TSI 
sampling stages during in vitro studies were analysed by high performance liquid 
chromatography (HPLC). Succinctly, the HPLC operates by separating the organic 
compounds relative to their affinity for the solid phase in the HPLC column. The 
liquid chromatograph system was equipped with an autosampler (AS-950, Jasco, 
Tokyo, Japan), a pump (PU-980, Jasco, Tokyo, Japan), a column oven (CO-866, Jasco, 
Tokyo, Japan), and a UV/VIS-detector (UV-975, Jasco, Tokyo, Japan). Data were 
analysed by computer (Borwin, JMBS Developments, Grenoble, France). Each value 
was determined by comparing the peak area o f the sample to reference peaks of 
standard solutions o f known concentration. Each sample concentration was 
determined in duplicate.
• Budesonide
A 5pm Hypersil column (Hypersil MOS C8, Jones Chromatography Ltd, UK) was 
used. The HPLC pump was operated at 1.5ml.min1 and the UV detection 
wavelength set at 248nm. The mobile phase consisted o f 60% o f water and 40% of 
acetonitrile (%v/v).
• Salbutamol sulphate
A Sperisorb® 5pm ODS1 column (Waters, Milford, MA, USA) was used for 
salbutamol sulphate. Salbutamol sulphate was analysed using a mobile phase 
consisting o f methanol and water in a 60:40 ratio (%v/v) with 0.1% (%v/v) of 
acetic acid. The HPLC pump was operated at L25m l.m in1 and the UV detection 
wavelength set at 276nm.
2.6.2.2. Preparation of Standards and HPLC Calibration
Standards for each o f the micronised drugs were prepared prior to HPLC 
analysis. Duplicate stock standard solutions were prepared by accurately weighing 
25mg aliquots o f material into two 100ml volumetric flasks. Solutions were sonicated
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for approximately 10 minutes to ensure complete dissolution and left to cool to room 
temperature. Standard solutions were prepared by serial dilution o f the stock solutions 
using calibrated (class A) laboratory pipettes. A series o f working standard with 
concentrations comprised between O.lpg.mT1 and lOpg.ml1 were subsequently 
prepared for each drug substance.
In order to correlate UV-absorbance response to drug concentration, the 
concentration-peak area response for budesonide and salbutamol sulphate in their 
respective mobile phase was investigated through linear regression analysis and is 
shown in Figure 2.12. The coefficient o f determination (R2) o f 1 for both curves 
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Figure 2- 12: Calibration curves for budesonide and salbutamol sulphate.
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2.7. A tom ic  Force M icroscop e
The Atomic Force Microscope was originally an innovative development of the 
Scanning Tunneling microscope (STM) invention [6]. The STM technique relies on 
measuring the “tunnelling current” between a sharp conducting probe and a sample, 
and reconstructing the topography of the sample surface. However, the STM requires a 
conducting tip and sample, which limited quite significantly the broader use of the 
technique. In contrast, the Atomic Force Microscope (AFM) technique, developed by 
Binnig et al. in 1986 provided a means of characterizing the surface morphology of 
non-conducting surfaces to the atomic scale [7].
2.7.1. General D escription  o f the Apparatus
The AFM used throughout the study was a DI Multimode™ AFM with a 
Nanoscope Ilia controller and extender module, (DI Instruments, Cambridge, UK). A 
schematic of the apparatus is given in Figure 2.13. The major components of the AFM 
system are described in great detail below:
Quadrapole 



























Figure 2- 13: Photograph and schematic representation of multimode™ AFM
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• Micro-fabricated cantilever probe (1)
The AFM probe is typically a sharp proximal tip positioned at the free end o f a 
spring-like cantilever. The probe is generally made o f silicon nitride using well 
documented techniques used in the semiconductor industry. The spring constant 
o f the cantilever, which is dependant on its shape and thickness, is application 
dependent.
• Detector (2)
In the case o f the multimode AFM, a laser is positioned at the apex o f the 
cantilever and reflected to a four quadrant photodiode detector. Early detectors 
used an STM probe to determine cantilever deflection [7], However, more recent 
designs have incorporated piezoelectric sensors in the cantilever construct allowing 
direct deflection measurement.
• Piezoelectric scanner (3)
The scanner is a polycrystalline piezo cylinder constructed o f doped zirconium 
titanate. The application o f a high voltage to any one of the 3 axes will induce 
scanner movement. The amount o f applied voltage can be calibrated to scanner 
movement allowing sub-Angstrom (A) control. In the case o f the multimode AFM, 
the sample is mounted on the scanner, which is moved relative to a stationary 
cantilever.
• Feedback Loop Controller (4)
The controller is a sensitive feedback data collection system between the 
photodiode analyser and the movement o f the piezo scanner. It operates by 
attempting to maintain a set parameter (i.e. cantilever deflection, amplitude, e tc ...) 
monitored through the detector (Figure 2.14) by varying the position o f the sample 
relative to the probe via the piezo scanner.
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As deflection o f  cantilever changes, feedback 
system adjusts scanner voltage to maintain set 
point
Scan Direction
Figure 2- 14: Feedback loop controlling tip sample distance.
2.7.2. Surface T opography Analysis
Nanometre surface topography analyses were first operated by contact mode 
[8-11]. This scanning probe method involves the continuous contact between the tip 
and the substrate. When the probe encounters protrusions or surface deformations, 
the bending of the cantilever is identified by the laser deflection on the photodiode 
detector. The signal is then interpreted by a computer to reconstruct the substrate 
surface in a 3D image. A major drawback of this technique is the significant load and 
resulting frictional forces applied to the substrate that may potentially be destructive 
for soft samples [12].
Recent alterations of this AFM technique have allowed an intermittent contact of the 
tip with the sample surface reducing the lateral forces which may disrupt the surface of 
particularly fragile substrates during imaging. This intermittent mode, commonly 
known as Tapping mode, is based on measuring the change in amplitude o f a tip 
oscillating at its resonance frequency, as it comes into contact with the underlying 
substrate surfaces. Variations in the amplitude of the oscillating tip are recorded by 
measuring the deflection of the laser. As the distance between the tip and the sample 
changes, a variation in the amplitude will occur. The feedback loop maintains the 
height of the scanner in order to keep the amplitude of the tip constant. A 
diagrammatic representation of Tapping mode method is shown in Figure 2.15.











Figure 2- 15: Diagrammatic representation o f tapping mode™ method
Although originally developed as a tool for surface topography analysis, numerous 
auxiliary uses o f the AFM techniques have been developed providing a very powerful 
and versatile tool. Lateral friction microscopy, for example, allows measurement of the 
torsion of a tip as it is dragged across a sample surface. These measurements of lateral 
forces encountered along the surface yields a map of high/low friction sites [9, 13, 14].
A novel technique, “phase shift” imaging is an auxiliary method to Tapping mode 
AFM which measures the degree of phase shift in the oscillation of the tip upon 
encountering areas of different physico-mechanical properties [15-17]. As the 
oscillating cantilever tip encounters regions on a surface containing different physical 
properties, such as hardness or elasticity, a shift in phase will occur (lag in oscillation). 
A diagrammatic representation of phase imaging method is shown in Figure 2.16.
The phase lag of the drive of the cantilever-tip assembly oscillation is constantly 
measured. Since it is expected that crystalline regions will have a low surface free 
energy and a high packing density, the phase difference upon interaction with the 
scanning tip is expected to be very small. However, for disordered or amorphous 
regions, a high phase lag is expected due to a high surface free energy (large adhesion) 
and high deformation of the contact.
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Figure 2- 16: Diagrammatic representation of phase imaging method
By measuring the degree of phase shift in unison with topography it becomes possible 
to identify variations in surface structure. Phase imaging has been considered as a 
possible tool for the visualisation o f amorphous/crystalline regions on pharmaceutical 
material surfaces [18].
2.7.3. Solid-Solid Interaction M easurem ents
One of the most significant advances in AFM technology in term of 
pharmaceutical applications is Force Imaging. By affixing a particle on the apex of a 
tipless cantilever, it is possible to quantify the interaction forces between a particle and 
a substrate, at a Pico-Newton scale (10'12N). This technique consists of moving the 
piezo-scanner vertically in a sinusoidal pattern, while the cantilever is kept in a fixed 
position. By plotting the measured deflection as a function of displacement, a complete 
picture of the interactive behaviour between an individual particle and a substrate 
surface can be elucidated upon contact and removal of a particle from a substrate 
surface. Such a plot is known as a force-distance plot or more commonly as a force 
curve. A diagrammatic representation o f an ideal force curve in which a non- 
deformable tip interacts with a hard surface is shown in Figure 2.17.
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Figure 2-17: Schematic representation of a force curve
Initially, although the scanner is moving up in the approach cycle (a), the tip is too far 
away to be influenced by any long-range forces and no deflection is therefore visible. 
At the short range (b), attractive van der Waals forces overcome the resistance of the 
cantilever spring and the tip jumps onto the sample surface. Scanner extension is then 
pursued until a pre-set compressive loading is applied between the particle and the 
substrate surfaces (d). This region is referred to as the region of constant compliance. 
Upon retraction of the tip, the same linear response is observed until the restoring 
force o f the cantilever equals the interaction forces between sample and particle, and 
the maximum of the interaction forces is reached (e). Beyond this critical point, the 
retraction force overcomes the interaction forces and the tip separates abruptly from 
the surface o f the sample (f). The scanner then keeps moving downward and no 
deflection is observable.
When the system is in equilibrium (e), the following equation is applicable:
F  = F  1211retraction adhesion L ' J
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The retraction force can be determined using Hooke’s law:
Fn,ration = [2-2]
where k is the spring constant, z is the extent o f the cantilever deflection, and the 
minus sign expresses the fact that the force is acting against the causes o f its creation. 
It is then possible to determine Fadhesion as z can be calculated by means of laser 
deflection.
2.7.4. M aterials and M eth od s
2.7.4.1. Particle Attachment onto Tipless AFM Cantilevers
Prior to force volume experiments, particles were affixed onto tipless 
cantilevers. The process can be divided into two distinctive steps. First, the apex o f the 
standard V-shaped tipless cantilever (DNP-020, Digital Instruments, CA, USA) was 
coated with a thin layer o f epoxy resin glue (Araldite, Bostik Ltd, Leicester, UK). The 
apex was then gently brought into contact with a particle. In order to achieve such a 
precise task, a high-resolution microscope (Zeiss, Leiptzig, Germany) was used 
throughout the procedure, thus allowing a control o f the cantilever cleanliness as well 
as the particle attachment integrity. The spring constant (k) o f the cantilevers was 
determined by the thermal noise method (k = 0.282 ± 0.039 N /m ) [19-21]
2.7.4.2. Substrate Sample Preparation
Two techniques were developed for the preparation o f sample substrates for 
AFM experiments: the use o f model compacts formed by direct compression and the 
preparation o f crystalline substrates with uniform flat surfaces by controlled re­
crystallisation.
•  Preparation o f  crystal substrates
Large planar surfaces o f the various powder materials were produced by controlled 
crystallisation techniques. The precise method o f crystallisation was dependent on
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the sample solubility profile. Saturated solutions were first prepared and shaken for 
12 hours at 20°C (G76, Gyrotory water bath shaker, New Brunswick Scientific, 
Edison, USA) in sealed volumetric flasks prior to filtration via a 0.22 pm 
membrane filter (Whatman Inc., Clifton, USA).
Powder samples were crystallised by primary nucleation, using an anti-solvent as a 
precipitating agent. A schematic representation of the crystallisation apparatus is 
shown in Figure 2.18. A microscope cover slip (12 mm x 12 mm) was supported 
on a vertical post in a crystallisation dish, which contained the anti-solvent. A 
droplet (~ 1 ml) of the filtered saturated solution was placed on the cover slip via a 
glass pipette. The system was sealed by inverting a suitable glass beaker within a 
crystallisation dish containing the anti-solvent. Upon equilibration of the vapour 
phases of the miscible solvents, nucleation and crystal growth within the solution 
droplet occurred. The glass cover slip was subsequendy removed and fixed onto a 
magnetic stub with glass bond glue (Loctite, UK) for AFM studies.
Figure 2- 18: Schematic representation o f the anti-solvent re-crystallisation step. Where 
A: saturated solution droplet, B. glass slide, C. crystalline dish containing the anti­
solvent, D. Beaker.
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• Preparation of compressed powder substrates
Model surfaces o f the various powders were prepared by high-pressure 
compression (TA H D I Texture analyser, Stable Micro Systems, Surrey, UK). 
Approximately 250mg o f material was weighed into a 10mm stainless steel die and 
compacted during 3min, with a load o f 500kg.
2.1 A 3 .  Control of Relative Humidity
A stream of dry nitrogen gas is divided into two, one o f which humidified at 
100% by bubbling into a botde filled with water, while the other is maintained at 
0%RH. The two streams were then recombined prior to insertion in the AFM head. By 
varying the flow rates o f the wet and dry gases, it was possible to change the humidity 
from 0% up to 100% with a precision o f + 1%.
2.8. Surface Energy Characterisation
2.8.I.I. Principles and Methods
Several methods are available for calculating the dispersive and polar 
contributions to the total surface energy o f a solid [22-25]. However, given the nature 
o f the materials to be analysed, the preferred route was to calculate solid surface energy 
from contact angle measurements, using the sessile drop method [26-29]. This 
technique involves the measurement o f the angle of contact between a liquid droplet 
and the surface o f a solid o f interest, as illustrated in Figure 2.19. The estimate o f the 
contact angle, 0, is made from the tangential vector formed between the solid surface 
and the sessile drop profile. The contact angle is a measure o f the competing 
tendencies o f the liquid to spread over the solid surface or rounds up to minimise its 
contact area. For instance, if  the molecular adhesion between solid and liquid is greater 
than the cohesion between the molecules o f liquid, wetting will occur. In contrast, 
liquids with high surface tension will generate a finite contact angle.
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Figure 2- 19: Diagrammatic representation o f contact angle measurement
by sessile drop technique
Equilibrium o f the surface forces is expressed mathematically by Young’s equation:
Ylv co s^  — Ysv ~ Ysl P-3]
where yLV is the interfacial tension between the liquid and vapour phase, ysv is the 
interfacial tension between the solid and vapour phase and ysl is the interfacial tension 
between the solid and liquid phase.The interfacial energy between two phases may be 
expressed as a function o f their respective dispersive and acid-base contributions, as 
shown in Eq. [1.24] given in Chapter 1. Substituting this equation with Eq. [2.3] yields 
to:
( i + cos e)yL = [ 2 2 2 2  + 2 2 2  ) p-4]
which is known as the Van Oss-Chaudhury-Good thermodynamic approach to 
determine the contributions o f the total surface free energy o f solids [30, 31]. The 
characterisation o f the three components o f  the solid surface tension ( r  , y+s and 
/ s )  from Eq. [2.4] requires therefore the use o f a minimum o f three liquids; one
apolar and two polars. This results in a series o f equations with three unknowns that 
can be mathematically resolved [23].
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Contact angle measurements were performed using a Goniometer (Rame-hart Inc., 
New Jersey, USA). Diiodomethane was used as an apolar liquid whereas ethylene 
glycol and glycol were used as polar liquids. Surface tension contributions o f the 
various laquids are summarised in Table 2.1.
Liquid YL Yllw Ylab YL+ YL
Diiodomethane 50.8 0.0 0.0 0.0 0.0
Ethylene glycol 48.0 29.0 19.0 1.9 47.0
Water 72.8 21.8 51.0 25.5 25.5
Table 2- 1: Surface tension contributions (in mj.m '2) o f liquids used in direct contact
angle measurements.
2.8.I.2. Results
Contact angles measured on tablets o f the various materials used in this study 
are summarised in Table 2.2. Resulting surface energy contributions and Gibbs surface 
free energy o f  cohesion o f these powders are summarised in Table 2.3.
Contact angle (0)




40.00 ±  1.00
8.00 ±  1.00 
17.33 ±  1.53
15.00 ±  1.00
45.67 ±  7.23
14.67 ±  2.52
21.67 ±  1.53 
30.33 ±  2.08




62.33 ±  1.53
69.67 ±  2.51
69.67 ±  2.08
71.33 ±  2.08 
13 ±  2.64
73.33 ±  3.05
63.66 ±  1.53 
20.00 ± 0.5
94.67 ±  2.51
Table 2- 2: Contact angle measurements of powders assessed by sessile drop
techniques
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Sample yLW Y+ T y tO t AGtot
Salbutamol sulphate 43.94 0.01 55.59 45.58 -91.19
Budesonide 50.40 2.77 72.68 78.74 -157.51
Sorbalac 400 48.51 0.05 66.29 52.28 -104.65
leucine 27.23 0.59 40.20 36.87 -73.88
lecithin 23.07 2.29 64.43 47.38 -94.77
Magnesium stearate 23.06 0.15 3.32 24.42 -48.92
Table 2- 3: Powder surface energy contributions and resulting Gibbs surface free
energy o f cohesion (in mj.m '2).
2.9. Statistical analyses
The average and deviation o f populations were expressed as arithmetic mean (37) and 
standard deviation (SD) for normal distributions, median (x50 corresponding to the 50th 
percentile) and geometric standard deviations (GSD) for lognormal distributions.
Arithmetic mean was calculated by:
1 n 
37 = ~ Y Jx i 
n ,=i
[2.5]
The standard deviation o f a pool o f numbers was calculated using:
[2.6]
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Geometric standard deviation was expressed as a function o f the 16th and 84th 
percentile o f the population as follow:
GSD =
r  \Y i
X 84%
\ X 16% J
[2 .8]
Statistical analyses between different populations were carried out by one-way 
ANOVA. A population was regarded as significandy different if the assumption o f 
similarity was rejected with a probability greater than 95%. Comparison o f the means 
was performed by Fisher pair wise comparison.
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Chapter 3 
Quantification of the Interaction Force Balance 
in Dry Powder Formulations
3.1. Introduction
The adhesion between a micron-sized particle and a solid surface is a result o f a 
complex combination o f physical forces. These include the ubiquitous van der Waals 
forces, as well as possible influences from electrostatic and capillary forces [1]. The 
contribution o f each o f these forces to the overall adhesion is dependant on various 
factors, including the physical properties o f the contiguous surfaces as well as 
environmental conditions. However, direct characterisation of the specific influence of 
these individual forces is difficult, as is their dependence on physico-mechanical and 
environmental conditions. Well-established techniques for measuring particle adhesion 
include centrifugal particle detachment, fluid dynamic and vibration methods [2-4]. 
These techniques provide quantitative information concerning the integrated effect of 
physical and environmental variations on particle adhesion. They are, however, 
severely limited when the properties that influence the adhesion o f an individual 
particle and a substrate surface are required. With the advent o f the atomic force 
microscope (AFM) and the development o f the colloid probe technique, quantification 
of the total interaction force between an individual drug particle and a substrate surface 
can be determined [5].
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Measurements o f the pull-off forces between pharmaceutical particles with irregular 
morphologies and varying degree o f surface roughness have previously been reported
[6]. Although the effects o f surface roughness on variations in adhesion forces are 
acknowledged, direct quantification o f true contact area between two contiguous 
surfaces remains difficult [7]. More recently, however, a method for characterising the 
contact area between a micronised particle and a substrate surface has been developed 
[8, 9]. This AFM based approach involves scanning a colloidal drug probe over a grid 
composed o f very sharp asperities. Due to a limitation in the Villarrubia algorithm 
utilised to reconstruct the substrate topography, a reverse surface image o f the tip is 
recorded. Although an estimate o f the area o f contact o f a micron sized particle can 
subsequently be discerned, the approach is limited when considering the surface 
deformation of the interacting materials and the variations between two substrate 
surfaces o f different rugosities.
Model substrate surfaces for AFM colloid probe investigations are commonly prepared 
by high-pressure compaction tableting [8, 10]. It is speculated that the high loading 
pressures required are sufficient to induce local defects and dislocations, and 
potentially significant areas o f amorphous disorder [11, 12]. The presence o f these 
amorphous domains may alter the surface free energy properties of the substrate 
material and subsequently modify the associated mechanical properties and 
thermodynamic work o f cohesion/adhesion upon interaction.
In this study, model drug and carrier particles were crystallised directly from solution 
to obtain well-defined and highly reproducible single crystals with characteristically 
smooth and planar surfaces. Although the contact area between an interacting probe 
and substrate would remain unknown, the uniform texture o f substrate surfaces should 
allow direct comparison o f interactions between a specific colloid probe and an array 
of substrate materials. This AFM based approach may provide a novel means o f 
quantifying the cohesive and adhesive interactions within a dry powder formulation 
and ultimately provide a critical understanding o f the force balance, which directly 
influence the overall characteristics and performance o f a dry powder formulation.
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3.2. M e th o d s
General methods o f each technique or apparatus used in this study are described in 
detail in Chapter 2.
• Crystallisation of material substrates
Saturated solutions o f budesonide in ethanol, salbutamol sulphate in water and 
lactose in water were prepared prior to re-crystalhsation. Samples were shaken for 
12 hours at 20°C (G76, Gyrotory water bath shaker, New Brunswick Scientific, 
Edison, USA) in sealed volumetric flasks prior to filtration via a 0.22 pm 
membrane filter (Whatman Inc., Clifton, USA).
Budesonide, salbutamol sulphate and lactose were crystallised by primary 
nucleation, using an anti-solvent as a precipitating agent. The heterogeneous 
nucleation and growth o f the crystals onto the glass cover slips precluded the need 
for any sample preparation o f the crystals for AFM investigations.
• Microscopic surface topography analysis
All AFM surface topography images were recorded in Tapping Mode operation 
(TM-AFM). Tetrahedral-tipped silicon-etched cantilevers (OTSP, Digital 
Instruments) were utilized for imaging. Surface roughness measurements were 
analyzed over a 2.5jlm x 2.5Jim area. To quantify the variations in the surface 
properties o f the crystal surfaces, the root-mean-squared surface roughness 
measurement (R^ and the mean surface roughness (RJ o f the height deviations o f 
the surface asperities were computed.
• Interaction force measurements
The AFM was housed in an environmental chamber and the ambient conditions 
maintained at a constant temperature o f 25°C (± 0.2°C) and relative humidity of 
35% RH (± 3%). The partial water vapour pressure was controlled via a custom- 
built perfusion unit coupled to a highly sensitive humidity sensor (Rotronic AG, 
CH).
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Individual force curves (n = 4096) were conducted over a 2.5pm x 2.5pm at a scan 
rate of 4Hz and a compressive loading o f lOnN. These parameters were kept 
constant throughout the study. Statistical analysis o f these data was performed by 
Fisher’s pair wise comparison o f one-way ANOVA with 99% confidence limits.
3.3. Results
3.3.1. Morphological Characterisation
The macroscopic morphology o f the budesonide, salbutamol sulphate and lactose 
crystals were first identified by scanning electron microscopy. The Miller indices o f the 
dominant growth faces o f the crystals obtained were identified using a 3D simulation 
program (SHAPE V7.0, Shape Software, Tennessee, USA). The 3D crystal structures 
required the input o f the unit cell lattice parameters and the space group symmetry 
operators. Budesonide crystallises in the orthorhombic crystal system (a = 8.550A, b = 
9.406A and c = 28.401A), space group P212121 [13]. Salbutamol sulphate crystallises in 
the monoclinic crystal system, (a = 28.069A, b = 6.183A, c = 16.914 A and [3 = 
81.19°), space group Cc [14]. Alpha-lactose monohydrate crystallises in the monoclinic 
crystal system (a = 7.982A, b = 21.562A, c = 4.824 A and = 109.57), space group 
P2t [15]. Representative scanning electron micrographs of the dominant growth faces 
of crystallised budesonide, salbutamol sulphate and lactose are shown in Figure 3.1 A, 
3.IB and 3.1 C respectively. Budesonide crystals displayed an elongated dodecahedral
shape in relation to the growth o f the dominant (012) and (012) Miller indices. 
Electron micrographs o f salbutamol sulphate crystals suggested a needle like 
morphology dominated by the (200) face, while the majority o f lactose crystals
exhibited the well-known tomahawk shape, dominated by the (100) and (110) 
crystalline faces. The single crystals exhibited highly smooth surface textures.












Figure 3- 1: Representative SEM images and corresponding 3D morphologies (a) o f 
crystals o f budesonide (A), salbutamol sulphate (B) and CX-lactose monohydrate (C).
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Representative AFM amplitude images o f the dominant single crystal faces of 
budesonide, salbutamol sulphate and (X-lactose monohydrate are shown in Figure 3.2A, 
3.2B and 3.2C, respectively. Topographical AFM images indicated varying degrees of 
nanometre roughness for the model substrate surfaces. These variations were probably 
related to differing growth processes and kinetics during crystallisation.
The surface rugosity Ra (average height from the centre line) and root mean square 
deviation Rq (variability o f the profile from the centre line) o f the three samples are 
shown in Table 3.1.
The data confirmed the extremely smooth surface morphology o f the crystals faces 
observed by SEM, exhibiting surface roughness measurements well below 5nm. It 
should be noted that there was no observable modification in surface morphology over 
large areas (>20 jam2) o f the crystal faces. Thus, the engineered crystal substrates should 
provide highly suitable surfaces for quantitative analysis of the force balance in model 
dry powder formulations.
budesonide salbutamol sulphate a-lactose monohydrate
rugosity (nm) 0.681 2.258 1.837
RMS (nm) 0.872 3.142 2.284
Table 3- 1: Roughness properties o f budesonide, salbutamol sulphate and a-lactose
monohydrate.
3. Quantification o f  the Interaction Fort e balance in Dry Powder Formulations 84
x  0.5#m /div  z. 50 nm/dry0 .5
x  0.5^m /div  
r  50 nm/div
x  0.5 flm/div 
M z: 50 nm/div
Figure 3- 2: Representative AFM amplitude images o f  the surface o f re-crystallised 
budesonide (A), salbutamol sulphate (B) and a-lactose monohydrate (C).
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3.3.2. Interaction Force Measurements
For consistency, the dominant crystal face of each material was chosen and care 
was taken to place the probes in the same region on the substrate for each experiment. 
For all systems, the force distributions could be fitted to a Gaussian distribution, 
related to the uniformity in contact area between probe and multiple contact points on 
the substrate surface. Furthermore, the small standard deviation o f the distributions 
confirmed the suitability of the engineered crystal surfaces in producing highly accurate 
and reproducible data.
The adhesion force o f interaction between a series o f budesonide probes and a-lactose 
monohydrate, salbutamol sulphate and budesonide crystal substrates are shown in 
Figure 3.3A. The adhesive interaction between budesonide and lactose were 
significantly higher than with salbutamol sulphate (P<0.01). However, a significant 
increase and overall dominance o f the cohesive interaction was observed for all 
budesonide probes (P<0.01).
Interacion forces between salbutamol sulphate probes and the dominant crystal faces 
o f  a-lactose monohydrate, salbutamol sulphate and budesonide crystal substrates are 
shown in Figure 3.3B. In contrast to budesonide interactions, the salbutamol sulphate 
probes exhibited extremely weak cohesive properties with respect to the adhesive 
interactions with both Ot-lactose monohydrate and budesonide (P<0.01). The adhesive 
interactions between salbutamol sulphate and lactose were significantly higher than the 
adhesive salbutamol sulphate-budesonide interaction (P<0.01).
Interaction forces between lactose probes and a-lactose monohydrate, salbutamol 
sulphate and budesonide crystal substrates are illustrated in Figure 3.3C. The adhesive 
interaction between a lactose and salbutamol sulphate were significantly greater than 
both the cohesive lactose-lactose and adhesive lactose-budesonide interaction 
(P<0.01). However, the cohesive lactose interactions were significantly greater than the 
adhesive interactions between lactose and budesonide (P<0.01).
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Figure 3- 3: Interaction forces between budesonide (A), salbutamol sulphate (B) and 
lactose (C) probes and a-lactose monohydrate, salbutamol sulphate and budesonide
crystal substrates.
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Since the drug probes were prepared from untreated material, variability in probe 
geometry was expected. This would result in significant variations in contact area 
between each probe and the model substrate surface and concomitandy the adhesion 
force measurements. This variation in contact geometry was highlighted by the 
variations in adhesion force measurements between each probe and a given substrate. 
Nevertheless, a relationship between adhesive and cohesive interactions could be 
obtained by determining the specific variation in interaction between each individual 
probe and model substrate surfaces.
3.4. D iscussion
The balance o f inter-particulate forces within dry powder inhaler formulations is 
critical in the mixing, stability and de-aggregation and dispersion properties o f  active 
pharmaceutical ingredients. However, quantitative measurements o f these fundamental 
interactions and their specific role on blending and aerosolisation behaviour have not 
been fully realised. Such measurements have been limited due to the complex nature of 
the physico-mechanical interactions and, in particular, the major influence o f variations 
in contact area on particle adhesion. Furthermore, efforts to predict the adhesion 
forces using theoretical approaches and surface energy measurements have proven 
unsatisfactory [16, 17]. Theoretical estimates are often several orders o f magnitude 
greater than experimental measurements. The m ost plausible explanation for this 
disparity is that the true contact area between contiguous surfaces is significantly less 
than expected macroscopic dimensions.
In this study, a novel analysis o f the AFM colloid probe technique has been utilised to 
determine the cohesive-adhesive force balances within model dry powder 
formulations. Controlling the nanoscale morphology o f dominant growth faces o f drug 
and excipient crystals substantially reduced the influence o f substrate surface 
roughness on particle adhesion, as described previously [7]. Under controlled 
environmental conditions, force measurements were observed to be highly 
reproducible. However, quantification o f force measurements was precluded, as it 
would require normalisation through the determination o f the probe-substrate contact 
area.
3. Quantification o f the Interaction Force balance in D ry Powder Formulations 88
In the absence o f any significant electrostatic force or upon complete dissipation o f the 
build-up o f electrostatic charges from interacting surfaces, the principal forces 
contributing to particle adhesion are the van der Waals and capillary forces. Various 
theoretical models, derived from the Hertz approximation [18], have been developed 
to determine the van der Waals force o f interaction. The two most commonly used 
models are the Johnson-Kendall-Roberts (JKR) [19] and the Deryaguin-Muller- 
Toporov (DMT) [20] models. The resulting force o f adhesion between two spheres is 
provided in equation [3.1].
[3-1]
where R* is the harmonic mean o f the particle radii (also called contact radius), Wadh is 
the thermodynamic work o f adhesion (mj.m'2), and n is a pre-determined constant 
depending on the selected model (n=3/2  for JKR and n=2 for the DMT).
Capillary forces arise from the dynamic condensation o f water molecules onto particle 
surfaces. If  the amount o f condensed water is sufficient, a meniscus is formed between 
the contact points o f the adjacent surfaces as liquid is drawn by capillary action around 
the contact points, inducing an attractive force. Fisher and Israelachvili [21] proposed a 
method to predict the capillary interaction between two spherical particles that is valid 
for AFM experiments. The subsequent capillary force equation is shown below:
Fc = 4^R*yL cos 6 + 4nR*ySL [3.2]
where yL is the water surface tension, ySL is the solid-liquid interfacial free energy and 0 
is the measured contact angle o f the liquid with the particle surface.
It should be noted that both the thermodynamic work o f adhesion Wad and contact 
angle are direcdy dependant on the surface free energies and the interfacial free energy 
of the interacting surfaces. Furthermore, van der Waals and capillary forces are direcdy 
proportional to particle radii, i.e. contact area. Thus, these two factors are o f critical 
importance in the quantification o f inter-particle forces.
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In order to overcome these limitations, the ratios of adhesive and cohesive balances 
were compared rather than the separation forces. By combining Eq. [3.1] and Eq. [3.2], 
this cohesive-adhesive balance between materials A and B can be expressed as:
F a - a  =  K - a  {x ^ a - a  COS 0 a - a + 4 ” 7 a  —water ) )  ra
F A-B K - B  (” ^ A - B  +  e A_h +  4 X y A_mlrr) )
where FA A and FA B are the cohesive and adhesive forces, respectively. It can be 
concluded from Eq. [3.3] that with constant environmental conditions, the work of 
adhesion and contact angle are only dependant on the material physical characteristics. 
For a colloidal particle interacting with the substrate materials, the only parameters 
which are susceptible to vary are the contact radii R*A_A andR*A_B. Assuming the 
similarity o f the two tailored substrate surface contact radii, the cohesion-adhesion 
ratios for a number o f interacting probes o f a specific material should theoretically 
remain constant. Thus, by plotting the measured force o f cohesion as a function o f the 
force o f adhesion for a number o f probes, the force balance within a model 
formulation could be quantified.
A cohesive-adhesive balance (CAB) graph of a theoretical binary system is illustrated in 
Figure 3.4. The adhesive force measurements for a number o f probes o f the interacting 
materials (FA_B and F ^  are plotted on the X-axis; the related forces o f cohesion (FA A 
and Fb_b) o f the respective probes are plotted on the Y-axis. For equivalent contact 
geometry, the force data o f several probes o f a specific material plotted on a CAB- 
graph should follow a linear fit, resulting from the consistency in the cohesive-adhesive
F  /  F  /
balance ratio ( A~A/ p A B an<^  B/ F b bisecting ^ne corresponds to
equilibrium between forces o f adhesion and forces o f cohesion, which defines two 
distinctive regions. The relative position o f the aligned plots with respect to the 
bisector is a direct indication o f the cohesive-adhesive balance o f the interacting 
material within the binary system. Plots in the lower section indicate a ascendancy of 
adhesive interactions (Fadh >Fcoh). Conversely, plots in the upper section o f the graph 
denote a dominancy o f cohesive properties. Quantitative assessment o f  the 
adhesive/cohesive interactions can be directly measured by the linear regression slopes.
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Figure 3- 4: Description o f a CAB-graph for a theoretical binary system.
From the force measurements in Figure 3.3, a CAB-graph o f a lactose-budesonide 
system is shown in Figure 3.5. A linear regression was performed for each set o f data 
to verify the consistency of contact area uniformity o f probe interaction from one 
substrate to another. A coefficient o f determination (R2) o f 0.9910 and 0.9873 for the 
lactose probes and budesonide probes, respectively, confirmed uniformity in contact 
area between crystals and the relationship between adhesion and cohesion for the 
interactive probes. Furthermore, the two plots indicated that for an equivalent contact 
area, both budesonide and lactose particles experience a greater affinity for cohesive 
interactions. The measurement o f the relative slopes suggested that the budesonide- 
budesonide interactions are 3.84 fold greater than the adhesive budesonide-lactose 
interactions, while lactose-lactose interactions are 2.36 fold greater than the adhesive 
lactose-budesonide interactions. From a formulation perspective, the data suggested 
that this binary system would exhibit poor blend homogeneity unless a significant 
amount of shear energy was introduced to overcome the cohesive bonds. Moreover, 
such a formulation would possibly be subjected to segregation over time due to the 
very strong budesonide cohesive bonds.
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Figure 3- 5: Comparison between forces o f cohesion and force o f adhesion in a binary
lactose/budesonide system.
A CAB-graph generated from the data in Figure 3.3 for a lactose-salbutamol sulphate 
system is shown in Figure 3.6. The linearity o f the data was again validated, with a 
coefficient o f determination o f 0.9938 and 0.8537 for the lactose probes and 
salbutamol sulphate probes, respectively. The relative position o f the data below the 
bisecting line indicated the two materials possess a strong affinity for one another with 
respect to their cohesive interactions (particularly salbutamol sulphate). The 
measurement o f the slopes indicated that the interaction between salbutamol sulphate 
and lactose is 16.88 times and 1.22 times greater than the cohesive salbutamol sulphate 
and lactose interactions, respectively. U pon processing such a powder formulation, the 
system should not require an excessive amount o f energy to generate a homogenous 
blend with good content uniformity.
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Figure 3- 6: Comparison between forces o f cohesion and force o f adhesion in a binary
lactose/salbutam ol sulphate system.
The novel treatment o f the AFM data has provided a potentially useful technique in 
the quantitative determination o f the force balance within binary systems. This process, 
however, may be further expanded to m ore complex formulations, e.g. combination 
product formulations, by cross normalising the data. The resulting cohesive-adhesive 
balance dependencies between salbutamol sulphate, lactose and budesonide are 
summarised in Table 3.2. The cohesive salbutamol sulphate interactions ratio was set 
to 1.00 and all the subsequent CAB ratios were calculated relative to this reference 
ratio. The corresponding matrix provides a complete description o f all the various 
interaction forces within a ternary system. Furthermore, cross normalisation provides a 
novel means o f measuring the hierarchy o f the cohesive forces o f the materials. The 
coefficient o f  proportionality with respect to salbutamol sulphate for lactose and 
budesonide is 14.13 and 31.76, respectively.







Salbutamol sulphate® 1.00 ±  0.08 16.88* ±  0.85 6.59* ±  0.00
Lactose® 16.88* ±  1.06 14.13* ± 1.06 7.00* ±  1.6
Budesonide® 6.59* ± 0.32 7.00* ± 1.6 31.76* ±  1.53
(a): probe; (b): substrate, * p<0.01
Table 3- 2: Cohesive-adhesive balance dependencies between salbutamol sulphate, 
lactose and budesonide interaction combinations.
3.5. Conclusions
The colloid probe AFM technique has been utilised to measure the characteristics o f 
the inter-particulate forces that govern bulk properties of dry powder formulations. 
The tailoring o f well-defined substrate surfaces minimised intra-variations in the 
contact area o f a colloid probe. This enabled direct characterisation o f the adhesive and 
cohesive interactions within a model dry powder inhaler formulation. Together with 
the development o f a novel cohesive-adhesive balance (CAB) analysis procedure, a 
quantitative relationship between measurements o f the relative interactions within dry 
powder inhaler formulations was achievable. In combination with bulk techniques, this 
novel approach may provide a pivotal role in predicting blending, segregation and 
dispersion characteristics o f active pharmaceutical ingredients in dry powder systems.
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Chapter 4 
Influence of the Cohesive-Adhesive Balance on 
DPI Formulation Behaviour
4.1. Introduction
Dry powder inhaler (DPI) formulations are commonly prepared as a binary blend o f a 
coarse carrier, typically Ot-lactose monohydrate, and micronised drug [1]. The 
homogeneity o f the blend and the de-aggregation and dispersion properties o f the 
respirable particles upon activation (driven by the patients inspirational energy) are, on 
a microscopic scale, governed by the resulting cohesive (drug-drug) and adhesive 
(drug-excipient) interaction forces within the formulation. Excessive adhesive forces 
may prevent elutriation of the respirable particles from the carrier surfaces, leading to 
upper airway deposition. Similarly, the presence o f strong cohesive forces may increase 
segregation and agglomerate formation, which could directly affect the fluidisation and 
dispersion characteristics o f the formulation [2, 3]. Numerous studies have investigated 
the in-vitro deposition characteristics o f respirable drug particles from carrier based 
D PI formulations [4-6]. Many o f these studies have indicated that the choice o f inhaler 
device and inspiration flow rate is o f critical importance in the fluidisation and aerosol 
characteristics o f a formulation [7-9]. This suggests that the aerodynamic forces, 
generated within the device, play a crucial role in powder aerosolisation through 
disruption o f the force balances within the formulation.
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The aim o f this study was to investigate the specific role of the cohesive and adhesive 
force balances on the de-agglomeration efficiencies and deposition characteristics of 
drug only (salbutamol sulphate and budesonide) and model drug-lactose formulations 
via the AFM colloid probe technique in conjunction with CAB-graph analysis 
procedure.
4.2. M eth o d s
General methods o f each technique or apparatus used in this study are described in 
detail in Chapter 2.
• Preparation of powder formulations
Drug-lactose blends were prepared by geometrically mixing lg  o f drug and lg  o f 
lactose Sorbalac 400 in lOOmg increments via a Whirlimixer (Fisons Scientific 
Apparatus, UK). The resulting blend was further mixed in a Turbula (Glen Creston 
Ltd, Middlesex, UK) at 46rpm for 30 minutes.
• Particle size analyses
The particle size distribution o f the ‘as supplied’ budesonide, salbutamol sulphate 
and lactose samples were determined by laser light scattering (Mastersizer X, 
Malvern, UK), using a 300mm lens. Samples were dispersed in cyclohexane and 
sonicated for 5 minutes prior to analysis (Ultrasonic Bath FS300b, Decon®, UK).
The aerodynamic diameters o f budesonide, salbutamol sulphate and lactose 
samples were determined using an Aerosizer in conjunction with an Aerodisperser 
(Amherst Process Instruments, Inc., Hadley, MA, USA). Approximately 5mg o f 
powder was introduced into the sample cup o f the Aerodisperser. Experiments 
were carried out at a medium feed rate, with a run time o f 180s at both low shear 
(lpsi ~ 6.895 KPa) and high shear forces (5psi ~  34.474 KPa). This was achieved 
by varying the pressure drop across the annular gap between the disperser pin and 
the pin bowl o f the Aerodisperser.
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• Content uniformity measurements
The content uniformity o f the salbutamol sulphate-lactose and budesonide-lactose 
blends was measured by analysing the quantity o f active in lOmg ± 0.5mg samples 
(n=10). Drug content was analysed by HPLC. Relative standard deviation between 
samples was calculated to assess the homogeneity o f the different blends.
• In  v itro  aerosol deposition studies
To determine the influence o f the aerodynamic drag forces on the fluidisation and 
aerosol characteristics o f the cohesive and adhesive formulations, a low and high 
resistance device were chosen [7]. Various measurements o f the internal resistance 
o f dry powder inhaler devices as a function o f  flow rate have been previously 
studied [7]. A Turbuhaler® (Astra Draco AB, Sweden) was utilised as a high 
resistance device and a Rotahaler® (Glaxo Wellcome, UK) as a low resistance 
device [10-12]. Approximately 1.5mg o f the drug only and carrier formulations was 
accurately weighed into the metering chamber o f the Turbuhaler and 2.5 mg into a 
gelatine capsule to be loaded into the Rotahaler device.
In vitro deposition investigations were performed using a twin-stage liquid impinger 
(TSI) (Copley, UK). The first and second stages were filled with 7ml and 30ml o f 
mobile phase, respectively. The loaded device was connected to the glass throat o f 
the TSI via a moulded mouthpiece. In vitro analysis was performed after each 
actuation o f the device. Each experiment (n=3) was performed at bOL.min1 flow 
rate with a 5 second exposure.
4.3. Results and Discussion
4.3.1. General Physical Characterisation
Representative scanning electron micrographs o f the ‘as supplied’ lactose, 
salbutamol sulphate, and budesonide are shown in Figure 4.1A, 4.1B and 4.1C, 
respectively. Each powder sample exhibited variations in particle size, shape and 
morphology. Electron micrographs suggested that lactose (Sorbalac 400) particles were 
significantly larger than the active ingredients. The use o f smaller lactose particles
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(<10pm) with respect to more conventional carrier sizes (63-90pm) was dictated by the 
need to minimise the potential influence o f larger carrier particles over fluidisation and 
de-aggregation processes o f particle agglomerates. Variations in the degree o f 
agglomeration o f the particles were also evident. The salbutamol sulphate particles 
were assembled as loose agglomerates while the budesonide particles formed highly 
dense agglomerates.
The particle size measurements o f ultrasonically dispersed lactose, salbutamol sulphate 
and budesonide samples measured by laser scattering are shown in Table 4.1. As each 
distribution followed a lognormal fit, the average diameter was thus expressed as the 
50th percentile size (d50). In addition, the dispersion o f the distribution was 
characterised by the 16th and 84th percentiles. Both salbutamol sulphate and budesonide 
exhibited a median diameter below the respirable size o f 5pm [13]. The median particle 
diameter o f  the lactose samples was ca. 10pm, in accordance with the SEM and 
suppliers data.
Diameter Lactose Salbutamol Budesonide
in (pm) sulphate
die 3.00 ±  0.19 2.17 ± 0.03 2.06 ±  0.02
d50 9.29 ±  1.07 4.77 ± 0.13 3.75 ±  0.05
d84 20.26 ±  2.36 11.58 ±  1.09 6.81 ±  0.2
Table 4- 1: Particle size distribution characteristics o f lactose Sorbalac 400, micronised 
salbutamol sulphate and micronised budesonide by laser scattering (mean ± SD, n=5).
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Figure 4- 1: Representative SEM images o f ‘as supplied’ lactose Sorbalac 400 (A), 
salbutamol sulphate (B) and budesonide (C).
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4.3.2. Influence o f Particle Cohesiveness on Powder 
Behaviour
The aerodynamic particle diameters o f micronised lactose, salbutamol sulphate and 
budesonide at low and high shear forces are summarised in Table 4.2. At high shear 
forces, the data exhibited relatively narrow lognormal distributions. The median 
particle diameter o f micronised salbutamol sulphate and budesonide were 2.91pm and 
2.63pm, respectively. As expected, the aerodynamic diameter o f lactose was 
significantly larger at 10.54pm. The reasonable correlation o f these data with 
ultrasonically dispersed laser scattering measurements suggested complete de­
agglomeration o f the powder at high shear forces.
At low shear forces, a significant shift in the particle distribution o f the time o f flight 
data was observed for both lactose and budesonide (Table 4.2). However, only a very 
small shift was observed for micronised salbutamol sulphate. The increase in the 
median aerodynamic diameter and dispersion o f the particle size data for lactose and 
budesonide suggested that the applied low shear force was insufficient to overcome the 
cohesive bonds within the bulk powders. However, the similarity o f the aerodynamic 
diameter measurements o f salbutamol sulphate at low and high shear forces suggested 
salbutamol sulphate particles can be readily de-agglomerated under shear. Similar 
changes to particle size distributions o f powder samples as a function o f shear force 
have been reported previously [14-17].
Diameter Lactose Salbutamol sulphate Budesonide
in (pm) 5 psi 1 psi 5 psi 1 psi 5 psi 1 psi
di5 5.59 ±  0.37 18.35 1 3 .5 3  1.89 10.08 2 .0 4 1 0 .4 0  1.63 1  0.20 20.65 1 2 .3 4
d50 10.54 1  0.70 29.70 1  4.58 2.91 1  0.30 3.58 1  0.88 2.63 1  0.28 35.96 1  3.12
d85 14.47 1  1.29 41.39 16.1 4 .3 2 1 0 .8 6  5.33 1  1.35 3 .9 2 1 0 .4 0  49.18 1 3 .1
Table 4- 2: Particle size distribution characteristics o f lactose Sorbalac 400, micronised 
salbutamol sulphate and micronised budesonide by time o f flight measurements at high 
(5psi) and low (lpsi) shear forces (mean 1  SD, n=5).
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Further information regarding the possible role o f powder cohesiveness on variations 
in aerodynamic size measurements with shear can be obtained from the difference in 
the apparent aerodynamic volume. By assuming that the aerodynamic diameters 
observed for a particular powder at high and low shear are the median particle 
diameter o f the de-agglomerated powder and median diameter o f the agglomerated 
particles, respectively, the agglomerate volume can be expressed as:
^  = n V p.M  + A  [4-!]
Where n is the number o f particles in the agglomerate, and 8V is the interstitial volume 
between particles.
Figure 4.2 shows a corresponding plot o f the apparent aerodynamic volume ratio (on a 
logarithmic scale) versus the corresponding cohesive balance dependencies o f the 
powders. The cohesive dependencies o f the particles were obtained from the 
quantitative colloidal AFM measurements undertaken in Chapter 3. A fit o f the data 
indicated that the degree o f de-agglomeration decreased exponentially as a function o f 
agglomerate cohesive strength. Thus, the efficiency o f de-agglomeration has been 
dramatically affected by the relative internal cohesive strength o f agglomerated 
particulates and shear force applied. This, in turn, may directly influence the aerosol 
characteristics and deposition behaviour o f an agglomerated system.
The in vitro deposition behaviour o f a drug only formulation o f micronised salbutamol 
sulphate delivered via low (Rotahaler®) and high (Turbulaher®) internal resistance DPI 
devices is shown in Figure 4.3A. The emitted dose percentage o f the two devices was 
very high (>80%). This indicated that the pressure drop variations between the two 
devices, at tiOL.min'1, had no significant affect on the fluidisation o f the micronised 
salbutamol sulphate particles. However, significant differences between the devices 
were observed in the amount o f the active material collected in the first and the second 
stages o f the TSI (p<0.05). Dispersion using the Rotahaler was rather poor. Similar 
results were found by other workers [18]. However, the high resistance device 
significantly increased the fine particle fraction by two fold. Nevertheless, a 
considerable amount of drug was recovered for both devices in the first stage of the
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TSI. This large percentage suggested that micronised salbutamol sulphate did not fully 
de-aggregate upon aerosolisation. These results were rather surprising considering the 
relatively low cohesive strength of salbutamol sulphate and the high de-agglomeration 
efficiency o f the particles upon exposure to low shear forces o f the Aerodisperser.
The deposition pattern of a drug only formulation containing micronised budesonide 
from both a Rotahaler® and Turbuhaler® D PI are shown in figure 4.3B. Although a 
small increase in the percentage of emitted dose was observed for the Turbuhaler® 
device, a very high percentage o f the budesonide remained within the devices upon 
activation. More significant, however, was the variation in the aerosol characteristics 
between the two devices. The high resistance device led to a four fold increase in the 
de-agglomeration efficiency o f budesonide with respect to the low resistance inhaler 
device. This significant increase in the de-agglomeration efficiency o f budesonide with 
increasing airflow resistance may relate to a critical energy requirement o f the device in 
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Figure 4- 2: Apparent agglomerate volume versus cohesion ratio dependency of 
salbutamol sulphate, budesonide and lactose (mean ± S.D., n=3).
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Figure 4- 3: In vitro deposition o f salbutamol sulphate (A) and budesonide (B) from a 
Rotahaler® and a Turbuhaler® D PI (mean ± S.D., n=3).
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It should be stressed that the in vitro aerosol behaviour o f salbutamol sulphate and 
budesonide particles was unexpected as the aerosolisation patterns o f salbutamol were 
worse than budesonide. These results highlighted the highly complex nature o f de­
agglomeration and aerosol dispersion mechanisms in the most basic formulations. To 
further understand this apparent paradoxical behaviour, the stability o f agglomerated 
particles entrained in an air flow was modelled relative to the aerodynamic drag force 
generated through the device. Assuming a physical system o f an object (agglomerate) 
in an airborne flow, the drag force generated by the displacement o f air molecules with 
respect to the moving object can be expressed as:
^drag ~  C d  Q P a i r ® a g g V j k v  f t -2 ]O
where Cd is the drag coefficient, which is dependant upon the ratio o f inertial and 
frictional forces o f the agglomerated particles in the airflow, is the density o f the air, 
is the effective diameter o f the agglomerate, and vflow is the airflow velocity. The 
corresponding initial kinetic energy o f the moving object may be expressed as:
E ‘° = —  P ( o /0 )V- [4.31c ' A0*'
where q is the density of the agglomerate. Equations [4.2] and [4.3] indicate that the 
aerodynamic drag force acting on an object and the kinetic energy o f a moving object 
are directly proportional to the square and the cube o f its diameter, respectively. As a 
result, the aerodynamic drag force and kinetic energy differences between a 5 pm and a 
50pm object at a constant settling velocity would be 102 and 103, respectively. This 
relationship would play a significant role in the de-aggregation and dispersion of 
agglomerated particles. Thus, despite the significant increase in the cohesive strength 
o f budesonide particles with respect to salbutamol sulphate, the drag force experienced 
by airborne budesonide aggregates may lead to a higher efficiency in the de­
agglomeration and dispersion o f respirable particles than for smaller agglomerates with 
a lower cohesive strength. Furthermore, the substantial increase in kinetic energy o f the
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larger agglomerates may increase de-aggregation efficiency within the device via 
impaction (assuming an inelastic collision and no subsequent energy loss).
Hence, it is conceivable that during the de-aggregation and dispersion process, a state 
can be reached where the internal binding forces o f the agglomerate and the drag 
forces generated within the device reach an equilibrium (Fcoh = Fdrag). This would 
subsequently lead to the suspension o f the elutriadon process. The characteristic 
properties o f the metastable aggregate would be directly dependant on the airflow 
characteristics via the inhaler device and the cohesive properties o f the particles within 
the agglomerate. A schematic representation o f the possible aerosol dispersion 
mechanisms o f salbutamol sulphate and budesonide agglomerated particles is therefore 
illustrated in Figure 4.4.
Salbutam ol sulphate
B u d e s o n id e
Figure 4- 4: Schematic representation o f the possible de-agglomeration and dispersion 
mechanisms o f weakly cohesive (salbutamol sulphate) and highly cohesive
(budesonide) particles.
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The low cohesive strength o f salbutamol sulphate particles, which readily allows 
aerosolisation and entrainment o f relatively small agglomerates, will quickly attain their 
aerodynamic metastable state, thereby decreasing the degree o f respirable particle 
dispersion. As indicated by in-vitro measurements, this may lead to high emission yet 
poor fine particle delivery performances. In contrast, highly cohesive budesonide 
particles require a significantly higher amount o f energy to fluidise the aggregated 
powder, and may lead to the entrainment o f larger agglomerates. However, these 
agglomerates will exhibit greater inertial properties and experience significantly greater 
aerodynamic drag forces and impact events than smaller agglomerates. This would lead 
to higher dispersion efficiency and yield to a greater percentage o f fine respirable 
particles, as indicated by in-vitro measurements.
4.3.3. Influence o f Drug-Excipient Interactions on  
Formulation Behaviour
Rowe et al. have advanced the efficiency o f wet granulation preparation o f powders 
for oral solid dosage forms by judiciously selecting binding agents on the basis o f their 
spreading coefficient (X12) [19, 20]. The reduced spreading coefficient is defined as the 
ratio between the work of adhesion o f the substrate and the binder and the work o f 
cohesion o f the binder [21]. A similar approach for blending characteristics o f carrier- 
based formulation systems has been applied in this study. The term reduced 
intermixing coefficient (A12), derived from the reduced spreading coefficient, can be 
described by the following relationship:
Ff2 CAB depedency,2
A., = —— = --------- ------[4.4]
F™ CAB depedencyn
A12, a dimensionless parameter, corresponds to the force ratio between adhesive 
interactions (F12) and cohesive interactions (F^) o f two interacting materials.
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For carrier based systems, the reduced intermixing coefficient reflects the affinity o f 
the drug (material 1) to interact with the carrier (material 2). Hence, the position o f A 12 
with respect to unity is a direct indication o f the alacrity (A12>1), or the reluctance 
(A12<1), o f the active particles to form an interactive mixture with the carrier particles. 
The reduced intermixing coefficients between salbutamol sulphate, budesonide and Ot- 
lactose monohydrate were consequently calculated from the quantitative cohesive- 
adhesive balance dependencies obtained from Chapter 3 and are given in table 4.3. A 
clear distinction between salbutamol sulphate and budesonide (materials 1) was 
observable with OC-lactose monohydrate (material 2). The disparity in the reduced 
intermixing coefficients of salbutamol sulphate (A12= 16.88) and budesonide (A12=0.22) 
strongly suggests that agglomerated salbutamol sulphate particles can be easily 
displaced to form an interactive mixture within a carrier based formulation, whereas 
budesonide would require an intensive mixing process to form a metastable carrier 
based formulation.




Salbutamol sulphate® - 16.88 ± 0.91 6.59 ±  0..21
Lactose® 1.19 ±  0.42 - 0.5 ±  0.31
Budesonide® 0.21 ±  0.13 0.22 ±  0.21 -
(a): material 1, (b): material 2
Table 4- 3: Reduced intermixing coefficient o f salbutamol sulphate, budesonide and
lactose (mean ± S.D., n=3).
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To highlight the influence o f the intermixing coefficient on the blending characteristics 
o f salbutamol sulphate and budesonide carrier based formulation, scanning electron 
microscopy and drug content uniformity analyses o f the blends were investigated. 
Representative scanning electron micrographs o f salbutamol sulphate-lactose and 
budesonide-lactose are shown in Figures 4.5A and 4.5B, respectively.
The electron micrographs suggested a uniform distribution o f highly dispersed 
salbutamol sulphate particles over the lactose surface. In contrast, budesonide particles 
appeared to remain agglomerated and unevenly spread over the lactose carrier. 
Predictably, dose content uniformity analysis revealed a relative standard deviation o f 
4.2% for salbutamol sulphate and 28.1% for budesonide. These observations both 
suggested good correlation between the reduced intermixing coefficient and the 
characteristics o f the respective carrier based formulations. In addition to providing 
pertinent information regarding the blending characteristics o f carrier formulations, the 
reduced intermixing coefficient may also provide an insight into the stability and 
aerosol characteristics o f such systems.
The aerosol delivery properties o f salbutamol sulphate and budesonide carrier-based 
formulations from both a Rotahaler® and Turbuhaler® DPI are shown in figures 4.6A 
and 4.6B, respectively. The emission efficiency o f salbutamol sulphate-lactose 
formulations was very similar to the drug only formulation, with no significant 
differences between the two devices. Significant changes in the fine particle delivery 
behaviour were, however, measured between the two systems. The significant decrease 
in stage 1 deposition (p<0.05) for a carrier based formulation led to an increase in 
stage 2 deposition (p<0.05), resulting in a net increase in fine particle fraction delivery. 
The co-processing o f budesonide with OC-lactose monohydrate resulted in a significant 
decrease in stage 1 deposition and an associated improvement in fine particle delivery 
performance via a Rotahaler® device (p<0.05). N o significant variations between drug 
only and carrier based formulations were measured with a high resistance Turbuhaler® 
inhaler.
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Figure 4- 5: Representative micrographs o f blends o f salbutamol sulphate-lactose (A),
and budesonide-lactose (B).
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Figure 4- 6: In vitro deposition o f salbutamol sulphate-lactose (A) and budesonide- 
lactose (B) carrier-based formulation from a Rotahaler® and a Turbuhaler® D PI
(mean ± S.D., n=3).
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A summary table o f the deposition percentages o f the drug only and carrier-based 
formulations are shown in Table 4.4. The high reduced intermixing coefficient between 
salbutamol sulphate and lactose suggested that salbutamol sulphate particles would 
interactively mix with OC-lactose monohydrate. Thus, the de-aggregation and dispersion 
behaviour of the salbutamol sulphate particles should be dominated by the drug- 
excipient interactions. In vitro measurements indicated, however, that the performance 
of the carrier-based formulation remained mediocre. This may be attributed to the 
excessive adhesive forces leading to an incomplete detachment o f the salbutamol 
sulphate from the carrier. This may subsequently lead to a substantial amount o f active 
material deposition in the throat and stage 1. The high emission efficiency o f the 
carrier-based formulation was possibly a result o f the high affinity o f salbutamol to the 
carrier. Meanwhile, the increase in the fine particle performance o f the carrier-based 
formulation may relate to the higher aerodynamic drag force experienced by the 
particulates adhering to the excipient particle surface. This behaviour was corroborated 
by the improvement in drug detachment at higher shear forces when the Turbuhaler 
was used. The measurements further supported the requirement for the formation o f 
stable agglomerate o f critical dimensions to induce a significant aerodynamic drag force 
within the device to disperse the respirable particles. The dimensions and aerodynamic 
properties o f the fine carrier particles may, therefore, have a significant affect on the 
dispersion energy o f the adhering drug particles. The colloidal AFM measurements 
also indicate that modifying the adhesive-cohesive force balance may enhance the 
efficiency of dispersion. For a salbutamol sulphate formulation this may be achieved by 
lowering the interfacial energy o f interaction between drug and excipient, leading to 
adhesive forces which would nonetheless remain stronger than the drug cohesive 
forces.
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Formulation
WRotahaler ® (^Turbuhaler ®
FPF (%) Emission (%) FPF (%) Emission (%)
Salbutamol sulphate 6.2 ±  0.6 84.9 ±  3.4 13.7 ± 0.5 81.9 ±  2.1
Salbutamol + Lactose 12.6 ± 1.2 81.3 ±  3.3 28.4 ±  1.5 84.2 ±  2.7
Budesonide 14.4 ±4.9 57.7 ±  5.0 63.4 ±  3.4 64.8 ±  4.6
Budesonide +  Lactose 26.3 ±  6.2 47.7 ±  1.2 58.9 ±  7.1 66.3 ±  8.0
(a): Rotahaler®, 0.68 kPa pressure drop at 60 L .m in1.
(b): Turbuhaler®, 8.5 kPa pressure drop at 60 L .m in1.
Table 4- 4: Fine particle fraction and emission efficiency o f salbutamol sulphate and 
budesonide carrier-based formulations from a Rotahaler® and Turbuhaler® DPI
(mean ± S.D., n=3).
The reduced intermixing coefficient between budesonide and lactose suggested that 
budesonide particles would not interactively mix with Ot-lactose monohydrate. These 
findings were supported by electron micrographs, content uniformity measurements 
and in vitro profiles o f the drug only and carrier based formulation. The instability of 
budesonide particles in a carrier based formulation was corroborated by the low 
emission efficiency and the reduction in fine particle fraction delivery o f carrier based 
budesonide formulations under high shear. This suggested that an increase in the 
aerodynamic drag coefficient resulted in the rapid separation o f the budesonide 
agglomerates from the lactose surface, introducing a similar dispersion mechanism as 
for the cohesive drug only formulation. It would therefore appear that the drug-drug 
interaction forces are the predominant factor in the delivery characteristics o f highly 
cohesive drug systems. Optimisation o f such dry powder formulations would require 
passivation o f the excessive cohesive bonds through controlled modifications o f the 
interfacial energetics.
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4.4. Conclusions
The influence o f the cohesive and adhesive dependencies o f salbutamol sulphate and 
budesonide particles in model dry powder formulations was investigated. A surprising 
relationship between particle cohesive strength and de-agglomeration efficiencies of 
drug only formulations was observed. A possible explanation for the dramatic variation 
in the fluidisation and aerosolisation properties between low and high cohesive 
particles was modelled on the relationship between cohesion, metastable agglomerate 
size and the resulting aerodynamic mechanisms acting on the fluidised agglomerates 
such as drag forces and impaction/collisions. The addition o f a fine particle lactose 
carrier influenced the drug deposition patterns in different ways depending on the 
relative cohesive and adhesive force balance within the formulation. The use o f the 
colloid AFM technique together with the novel development o f CAB-graph system 
provides a novel pre-formulation tool for predicting the likely behaviour o f a dry 
powder formulation and a possible means o f interpreting the possible de-aggregation 
and dispersion mechanisms o f carrier-based formulations.
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Chapter 5 
The Use of Force Control Agents in Model 
Salbutamol Sulphate DPI Formulations
5.1. Introduction
The co-processing o f carrier particles with low surface free energy materials has been 
reported as a possible means o f increasing the aerosolisation efficiencies o f dry powder 
inhaler formulations [1-3]. The predominant role o f these agents is to modify the 
interfacial properties o f the excipient particles to decrease drug-excipient adhesion. To 
optimise the efficiency o f a carrier based formulation, the force control agent must be 
specifically introduced into the dry powder formulation to selectively target the particle 
interactions to be modified.
In this study, the FCA was mechanically fused via a highly intensive Mechanofusion 
system, with the aim o f achieving a nanometre thick coating o f a guest material with a 
host component in the formulation [4]. This approach for inhalation powders was 
recently developed by Staniforth et al [5]. In contrast to other low energetic mixing or 
even conventional intensive mixing, this dry coating process is designed to provide a 
relatively complete ultra thin coating onto the host particles via the application o f a 
combination o f high shear and compression forces. A schematic representation o f the 
possible effect o f increasing shear on particle coating is shown in Figure 5.1.
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Figure 5- 1: Schematic representation o f mechanofusion particle mixing mechanisms.
Succinctly, a Mechanofusion mixer is composed o f  a large rotor with one or more 
rounded blades revolving in a steel vessel at very high speed (up to 8000rpm). The gap 
size between the rotor blades and the vessel wall as well as the angular velocity7 can be 
adjusted in order to vary the processing energy delivered to the powder blend. As a 
result, the particles experience very high shear forces as they are compressed between 
the inner drum wall and the rotor.
The aim o f this study was to investigate the specific influence o f force control agents 
(leucine, lecithin and magnesium stearate) on the interfacial properties o f a salbutamol 
sulphate-lactose dry powder inhaler formulation. The influence o f the FCAs on the 
cohesive and adhesive force balance was direcdy assessed via an AFM colloid probe 
technique in conjunction with CAB-graph analysis procedure (Chapter 3). By 
quantifying the cohesive-adhesive balances in a dry powder formulation, this technique 
can be direcdy utilised to highlight their specific effect on formulation behaviour and 
delivery characteristics (Chapter 4). The in-vitro deposition profile o f the model 
salbutamol sulphate formulations was investigated to elucidate any correlation between 
the cohesive and adhesive nature o f the modified formulations with their aerosol 
delivery performance.
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5.2. Methods
General methods o f each technique or apparatus used in this study are described in 
detail in Chapter 2.
• Preparation of powder formulations
Powder mixing was achieved in two successive steps involving different energetic 
processes. Pre-blends o f salbutamol sulphate and FCA (5% w /w ) or lactose and 
FCA (5% w/w) were prepared using a Mechanofusion system (Hosokawa-Alpine, 
Augsburg, Germany). Powders to be processed were sealed into the 
Mechanofusion system core. A cold-water circulation provided the regulation of 
the internal vessel temperature using an incorporated water jacket. Samples were 
mixed at 5000rpm for 10 minutes to achieve the required process intensity and 
mechanically fuse the FCA to the host particles.
The formulations were subsequently prepared by geometrically mixing lg  o f pre­
blend and lg  o f either lactose or drug depending on the nature o f the pre-blend in 
lOOmg increments via a Whirlimixer (Fisons Scientific Apparatus, Loughborough, 
UK). The resulting mixture was further mixed in a Turbula (Glen Creston Ltd, 
Middlesex, UK) at 46rpm for 30 minutes.
This blend design was not intended to reflect any commercially available or 
relevant DPI powder formulation. The use o f Sorbalac 400 lactose particles 
(d5O<10pm) with respect to more conventional carrier sizes (63-90pm) was dictated 
by the need to minimise the potential influence o f larger carrier particles over 
fluidisation and de-aggregation processes o f particle agglomerates [6, 7]. This 
formulation was selected solely to suit the objectives o f the study o f the cohesive- 
adhesive balance between drug and lactose components.
• Contact angle measurements
The sessile drop technique was used to determine the surface free energy o f the 
powders. Compact surfaces o f the powder samples were prepared for analysis. 
Contact angle measurements were performed using a Goniometer (Rame-hart Inc.,
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New Jersey, USA). Diiodomethane was used as an apolar liquid while ethylene 
glycol and glycol were used as polar liquids.
• Interaction force measurements
The AFM was housed in an environmental chamber and the ambient conditions 
maintained at a constant temperature o f 25°C (± 0.2°C) and relative humidity of 
35% RH (+ 3%). The partial water vapour pressure was controlled via a custom- 
built perfusion unit coupled with a highly sensitive humidity sensor (Rotronic AG, 
CH). Individual force curves (n = 4096) were conducted over a 2.5|am x 2.5pm at a 
scan rate o f 4Hz and a compressive loading of lOnN. These parameters were kept 
constant throughout the study. Statistical analysis o f these data was performed by 
Fisher’s pair wise comparison o f one-way ANOVA with 99% confidence limits.
• Cohesive-adhesive balance (CAB) graph analysis
The wealth o f information from AFM measurements o f the interparticulate forces 
was analysed using a recendy developed cohesive-adhesive balance procedure. 
Detailed information regarding the CAB graph analysis is described in Chapter 3.
• Content uniformity measurements
The content uniformity o f the salbutamol sulphate-lactose blends was measured by 
analysing the quantity o f active in lOmg ± 0.5mg samples (n=10). Drug content 
was analysed by HPLC. Relative standard deviation between samples was 
calculated to assess the homogeneity of the different blends.
• In  v itro  aerosol deposition studies
Approximately 10 mg o f the carrier formulations was accurately weighed into a 
gelatine capsule to be loaded into a Monohaler® device (Miat SpA, Milan, Italy). In- 
vitro deposition investigations were performed using a next generation impactor 
(NGI) (Copley Scientific, Nottingham, UK) .The loaded device was connected to 
the throat o f the N G I via a moulded mouthpiece. In vitro analysis was performed 
after each actuation o f the device. Each experiment (n=3) was performed at 
bOL.min'1 flow rate with a 5 second exposure. Each N G I plate was rinsed with 
mobile phase and the subsequent solution was collected in a 50ml volumetric flask.
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5.3. Results and Discussion
Previous studies have emphasi2ed the relative strength o f the adhesive salbutamol 
sulphate-lactose adhesive forces with respect to salbutamol sulphate cohesive forces 
(Chapter 3). The initial part o f the present study was to quantify possible variations in 
cohesive and adhesive bonds via the introduction o f a force control agent. This was 
achieved by first conditioning the lactose with various force control agents using a 
Mechanofusion system, prior to mixing with the drug.
The CAB-graph obtained for a salbutamol sulphate-lactose binary system (with the use 
o f compact substrates) is shown in Figure 5.2. The relative position o f the data below 
the bisecting line indicated a stronger affinity between salbutamol sulphate and lactose 
than their cohesive forces. This suggested a predisposition for an interactive blend. 
However, the quantitative measurement o f the relative strength o f the cohesive- 
adhesive ratio indicated that the adhesive salbutamol sulphate-lactose interaction was 
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Figure 5- 2: CAB-graph o f a salbutamol sulphate lactose binary system .
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It should be highlighted that the previous assessments (Chapter 3) performed with 
model crystal substrates revealed a salbutamol sulphate-lactose reduced intermixing 
coefficient o f 16.88 (Chapter 4). This disparity may be explained by the inevitable 
increase in surface roughness by using compressed powder substrates in contrast to 
smooth crystalline substrates. This would be anticipated to have a considerable effect 
on relative contact area and influence both van der Waals forces and capillary forces [8, 
9]. Nevertheless, both studies revealed a consequent adhesively led system, suggesting 
that a significant amount o f energy would be required to overcome the adhesive 
interaction for efficient dispersion o f the drug from a lactose surface. Thus, the 
introduction o f an FCA was intended to advantageously lower the adhesive 
interactions between drug and excipient to facilitate the detachment of the drug 
particles from the carrier upon aerosolisation provided that an adhesive led system was 
maintained.
5.3.1. M odel Formulations with Conditioned Lactose
The CAB-graphs obtained for the interaction o f salbutamol sulphate probes and 
lactose probes where the lactose particles have been conditioned with leucine, lecithin 
and MgST are shown in Figures 5.3, 5.4 and 5.5, respectively. As expected, the addition 
o f FCAs significantly modified the salbutamol-lactose interactions. In all cases, the 
introduction of the ternary agent significantly reduced the adhesive interactions of the 
salbutamol probe with the various modified lactose substrates. However, particle 
adhesion decreased to such an extent that the reduced intermixing coefficient (Fdrug_ 
lactose/ d^mg-drug)> calculated from the gradient o f the CAB plots, was below 1 (Table 5.3). 
This shift moved the CAB system to one synonymous o f a cohesive led system. The 
conditioning o f lactose with MgST resulted in the lowest intermixing coefficient value 
(A12=0.61) while the addition o f leucine and lecithin reduced the intermixing 
coefficient to 0.96 and 0.88, respectively. Thus, the pre-conditioning o f lactose 
particles with leucine, lecithin or MgST transformed a system which was dominated by 
the adhesive drug-lactose forces into a cohesive system. Such lowering o f the 
interactions between drug and excipient via the introduction o f the FCAs may possibly 
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Figure 5- 3: Influence of the mechanofusion of lactose with leucine on the cohesive-
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Figure 5- 4: Influence of the mechanofusion of lactose with lecithin on the cohesive-
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Figure 5- 5: Influence of the mechanofusion of lactose with lecithin on the cohesive-
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Contact angle measurements were performed on compact surfaces o f mechanofused 
lactose with leucine, lecithin and MgST. The resulting contact angles obtained with 
diiodomethane, ethylene glycol and ultra pure water are shown in Table 5.1. Using the 
van Oss-Chaudhury-Good (VCG) thermodynamic approach [10], described in more 
detail in Chapter 2, the surface energy contributions and resulting Gibbs interfacial free 
energy o f cohesion of mechanofused lactose with leucine, lecithin and MgST are 
summarised in Table 5.2.
Contact angle (0)
Sample Diiodomethane Ethylene glycol U.P. water
Sorbalac 400 + Leucine 52.00 ± 1.00 44.33 ±  3.51 14.67 ±  2.52
Sorbalac 400 + Lecithin 60.00 ±  3.61 11.67 ± 0 .5 8  8.67 ±  1.53
Sorbalac 400 + MgST 62.00 ±  1.00 81.00 ± 2 .0 0  87.33 ±  5.86
Table 5- 1: Contact angle measurements o f mechanofused lactose with FCAs.
Sample yLW Y+ r y t O t AGtot
Sorbalac 400 + Leucine 33.15 0.18 85.48 40.42 -82.01
Sorbalac 400 + Lecithin 28.58 1.09 69.67 45.99 -91.98
Sorbalac 400 + MgST 27.42 0.59 12.43 32.79 -76.41
Table 5- 2: Surface energy contributions and resulting Gibbs interfacial free energy of 
interaction o f mechanofused lactose with FCAs (All units are in mj.m '2).
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As anticipated, the inclusion o f FCAs with the lactose greatly decreased the total 
surface free energy o f the coated particles in comparison to the ‘as supplied’ Sorbalac 
400 (Chapter 2). The dispersive contribution (yLVC) decreased from 48.51mJ.m~2 for the 
untreated material to 33.15mJ.m~2 when mechanofused with leucine, 28.58mJ.m 2 when 
mechanofused with lecithin and 27.42mJ.m~2 when mechanofused with MgST. These 
results were very close to the pure FCAs, being 27.23mJ.m~2, 23.07mJ.m~2 and 
23.06mJ.m~2 for leucine, lecithin and MgST, respectively. The resulting total surface 
free energy o f the mechanofused materials, calculated from the van der Waals and 
polar contributions, significantly decreased from 52.28mJ.m~2 for the untreated material 
to 40.42mJ.m~2 when mechanofused with leucine, 45.99mJ.m~2 when mechanofused 
with lecithin and 32.79mJ.m~2 when mechanofused with MgST. The interfacial Gibbs 
free energy o f cohesion of the three mechanofused samples, calculated from VCG 
theory, indicated a significant decrease in particle-particle interaction via the inclusion 
o f leucine, lecithin or MgST. These data were in good accordance with the force ratios 
obtained via CAB graphs analyses. They also supported the premise that the pre­
conditioning o f lactose particles with leucine, lecithin or MgST may possibly lead to an 
unstable formulation, subjected to undesirable segregation.
Representative SEM images o f formulations o f salbutamol sulphate mixed with 
lactose-leucine, lactose-lecithin and lactose-MgST conditioned particles are shown in 
Figures 5.6A, 5.6B and 5.6C, respectively. As anticipated from the intermixing 
coefficient measurements, scanning electron micrographs highlighted a high degree of 
drug segregation via the introduction o f the FCAs. A very limited adhesive interaction 
was apparent between agglomerated salbutamol sulphate particles and conditioned 
lactose-leucine (Figure 5.6A). However, large quantities o f drug particles were present 
as loose agglomerates. This segregation was even more pronounced for lecithin (Figure 
5.6B) and MgST (Figure 5.6C) conditioned lactose particles. Virtually no interaction 
was observed between chug and the conditioned lactose surfaces, which resulted in the 
formation of large drug agglomerates. Interestingly, the mechanofused Sorbalac 400 
lactose particles appeared to be smoother after pre-conditioning with leucine, lecithin 
or magnesium stearate, compared to the ‘as supplied’ Sorbalac (Chapter 4). This 
suggested a smooth continuous coating o f the FCAs over the surface o f the lactose 
particles.
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Figure 5- 6: Representative scanning electron micrographs o f ternary mixtures of 
salbutamol sulphate and lactose pre-conditioned with leucine (A), lecithin (B) and
magnesium stearate (C).
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As anticipated, dose content uniformity measurements revealed an increase in the 
relative standard deviation o f salbutamol sulphate o f each blend (Table 5.3). The RSD 
of 4.2% for micronised salbutamol sulphate mixed with lactose increased to 8.92% 
with the conditioning o f lactose with leucine, 9.31% for lactose-lecithin and 15.51% 
for lactose-MgST. These observations suggested good correlation between the 
reduction o f the intermixing coefficients, which were significantly below 1, and the 
content uniformity measurements o f salbutamol sulphate in the corresponding carrier- 
based formulations.
The de-agglomeration and dispersion behaviour of the salbutamol sulphate particles 
from the model carrier based formulations are shown in Figure 5.7. The emitted dose 
o f the salbutamol sulphate-lactose formulation via the low resistance Monohaler® 
device was quite high (76.57%). However, a significant percentage o f the drug was 
recovered in the throat and the first stage o f the N G I apparatus. These results were in 
accordance with the previous in vitro study conducted with a Rotahaler® and 
Turbuhaler® DPI devices (Chapter 4). This study suggested that the observed 
deposition pattern was due to the limited detachment o f the drug from the carrier 






Mechanofusion, 10 min @ 5200 rpm Turbula, 30 min@ 46 rpm coefficient (A12) (% RSD)
Salbutamol sulphate (non treated) Sorbalac 400 6.25 4.20
Sorbalac 400 + Leucine Salbutamol sulphate 0.96 8.92
Sorbalac 400 + Lecithin Salbutamol sulphate 0.88 9.31
Sorbalac 400 + MgST Salbutamol sulphate 0.61 15.51
Table 5- 3: Mixing sequences o f salbutamol sulphate carrier-based formulations with 
conditioned lactose and reduced intermixing coefficients and content uniformities.
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p<0.05, ** p<0.01, *** p<0.001: significant difference compared to without force control agent by ANOVA one-way.
Figure 5- 7: In-vitro deposition o f salbutamol sulphate carrier-based formulations with 
conditioned lactose (mean ± S.D., n=3).
The mechanical fusion of leucine with lactose resulted in a similar drug emission 
efficiency to the conventional blend. However, the amount o f salbutamol sulphate 
recovered in the first stage o f the N G I significantly increased with respect to the non 
coated lactose blend. The coating o f lactose with either lecithin or MgST slightly 
reduced the device retention o f the active ingredient from 23.43% to 18.73% and 
18.99%, respectively. Although the interactions between drug and coated lactose 
surfaces were significantly decreased, a large amount o f  drug was still recovered on the 
upper stage o f the in vitro apparatus.
These results were consistent with the assessment from the CAB-graphs. The CAB 
analysis indicated that the energy o f interaction between the drug and coated lactose 
would reduce to such an extent that the adhesively led salbutamol sulphate-lactose 
formulation would shift to an unfavourable cohesive system. The aerosolisation
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performances o f the modified lactose carrier-based formulations may not have 
improved since the dramatic shift in the force balance was shown to lead to poor blend 
homogeneity and the potential for significant segregation between drug and carrier 
particles.
5.3.2. M odel Formulations with Conditioned Salbutamol 
Sulphate
The conditioning o f excipient particles with a FCA modified the adhesive 
interaction between drug-carrier and excipient-excipient interactions. In contrast, the 
processing o f the micronised drug particles with the FCA would alter both the 
cohesive (drug-drug) and adhesive (drug-lactose) interactions. To further investigate 
the possibility o f selectively modifying both these interactions within a carrier based 
formulation, the drug was mechanofused with the FCAs.
The CAB-graphs obtained for the interaction between conditioned salbutamol 
sulphate with leucine, lecithin or MgST and lactose are shown in Figures 5.8, 5.9 and 
5.10, respectively. The balance remained adhesive for all three systems, although the 
drug-lactose forces decreased by more than a half o f its original value. The 
conditioning o f salbutamol sulphate with leucine, lecithin and MgST led to an 
intermixing coefficient of 1.89, 2.13 and 1.52, respectively. These mixtures would 
therefore be expected to form homogenous interactive blends with advantageously 
weak drug-lactose interactions.
Concomitantly, the force balance o f lactose interactions transformed from an adhesive 
to a cohesive led system. Nevertheless, it can be speculated that this shift should not 
greatly affect the formulation properties as this change o f behaviour is predominately 
due to a decrease in the adhesive (drug-lactose) forces and not due to an increase of 
























Figure 5- 8: Influence of the mechanofusion of salbutamol sulphate with leucine on
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Figure 5- 9: Influence of the mechanofusion of salbutamol sulphate with lecithin on
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Figure 5- 10: Influence of the mechanofusion of salbutamol sulphate with lecithin on
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As for the mechanofused lactose samples, contact angle measurements were 
performed on compact surfaces of mechanofused salbutamol sulphate with leucine, 
lecithin and MgST. contact angles obtained with diiodomethane, ethylene glycol and 
ultra pure water are shown in Table 5.4. The surface energy contributions and resulting 
interfacial Gibbs free energy o f cohesion o f mechanofused salbutamol sulphate 
particles are expressed in Table 5.5.
Contact angle (0)
Sample Diiodomethane Ethylene glycol U.P. water
Salbutamol + Leucine 30.67 ±  1.53 18.33 ±  0.76 25.83 ±  1.89
Salbutamol + Lecithin 60.00 ±  1.00 12.00 ±  2.00 12.67 ±  2.08
Salbutamol + MgST 55.00 ± 1.00 61.00 ±  2.65 57.67 ±  1.53
Table 5- 4: Contact angle measurements o f mechanofused salbutamol sulphate with
leucine, lecithin and MgST.
Sample yLW Y+ r y t O t AGtot
Salbutamol +  Leucine 39.61 0.15 59.44 45.42 -90.98
Salbutamol + Lecithin 28.57 1.12 67.83 46.03 -92.09
Salbutamol + MgST 31.45 0.28 40.72 37.88 -75.42
Table 5- 5: Surface energy contributions and resulting interfacial Gibbs free energy of 
cohesion o f mechanofused salbutamol sulphate with FCAs (in mj.m '2).
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The introduction o f the FCAs significantly decreased the surface energy contributions 
o f the coated particles in comparison to the ‘as supplied’ micronised drug (Chapter 2). 
The dispersive contributions decreased from 43.94mJ.m 2 for the untreated material to 
39.61mJ.m 2 when mechanofused with leucine, 28.57mJ.m'2 when mechanofused with 
lecithin and 31.45mJ.m’2 when mechanofused with MgST. It is important to note, 
however, that the polar contributions o f the mechanofused samples, although less than 
the micronised drug, remained substantial. As a result, total surface free energy and 
corresponding Gibbs free energy were higher than anticipated from CAB graphs 
analyses. These discrepancies may have arisen from the smaller size o f the drug 
particles and resulting increase in specific surface area with respect to the Sorbalac 400 
particles (Chapter 4). The mechanofusion o f the same amount o f FCA with the drug 
may have therefore resulted in a thinner and more permeable coating. This may have 
contributed to partial adsorption o f the liquids upon contact angle measurements and 
resulted in limited but direct interaction between liquids and drug particles.
Representative scanning electron micrographs o f the lactose particles blended with 
conditioned salbutamol sulphate-leucine, salbutamol sulphate-lecithin, and salbutamol 
sulphate-MgST are shown in Figures 5.11 A, 5.1 IB and 5.11C, respectively. In contrast 
to the ternary mixture o f drug and conditioned lactose shown in Figure 5.6, the 
conditioned drug particles strongly interacted with the lactose particles for all three 
FCAs. This suggested an effective adhesive disposition, in agreement with the CAB 
data analyses.
The corresponding content uniformity measurements o f the ternary mixtures reflected 
an adhesive led system with low relative standard deviations for lactose mixed with 
salbutamol sulphate-leucine (2.92%), salbutamol sulphate-lecithin (3.00%) and 
salbutamol sulphate-MgST (3.62%) conditioned particles (Table 5.6). These 
observations suggested good correlation between the reduced intermixing coefficients 
and the characteristics o f the respective carrier-based formulations. Such formulations 
would be expected to be stable during handling and storage, and may lead to a greater 
de-agglomeration and dispersion efficiency o f the respirable particles.
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Figure 5-11: Representative scanning electron micrographs o f ternary mixtures o f 
lactose and salbutamol sulphate pre-conditioned with leucine (A), lecithin (B) and
magnesium stearate (C).






Mechanofusion, 10 min @ 5200 rpm Turbula, 30 min@ 46 rpm coefficient (A 12) (% RSD)
Salbutamol sulphate (non treated) Sorbalac 400 6.25 4.20
Salbutamol sulphate + Leucine Sorbalac 400 1.89 2.92
Salbutamol sulphate + Lecithin Sorbalac 400 2.13 3.00
Salbutamol sulphate + MgST Sorbalac 400 1.52 3.62
Table 5- 6: Mixing sequences o f salbutamol sulphate carrier-based formulations with 
conditioned drug and reduced intermixing coefficients and content uniformities.
The in-vitro deposition profiles o f formulation o f Sorbalac 400 mixed with micronised 
salbutamol sulphate and Sorbalac 400 mixed with salbutamol sulphate conditioned 
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** p<0.01, *** p<0.001: significant difference compared to without force control agent by ANOVA one-way.
Figure 5- 12: In-vitro deposition o f carrier-based formulations with conditioned 
salbutamol sulphate (mean ± S.D., n=3).
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The mechanofused salbutamol sulphate particles resulted in a significant decrease in 
device retention from 23.42% for the FCA free formulation to 12.51% with leucine, 
14.52% with lecithin and 8.23% with MgST. These results suggested a lubrication 
effect o f the FCA and subsequent reduction in interaction between the powder bed 
and the capsule, while the formulation conserved its metastability as suggested by the 
CAB analyses. More dramatic was the significant decrease o f the percentage o f drug 
deposited in the first stage (cut off diameter ~ 8.06pm) o f the N G I apparatus. Stage 1 
deposition decreased from 22.89% to 6.16% for the conditioning o f salbutamol 
sulphate with leucine, to 9.20% for salbutamol sulphate-lecithin and 7.99% for 
salbutamol sulphate-MgST. This indicated a greater de-agglomeration efficiency o f the 
coated salbutamol sulphate particles in the carrier based formulations, which was 
further highlighted by the increase deposition o f the active ingredient in the lower 
stages o f the in vitro apparatus.
A summary o f the device retention, fine particle fraction (% respirable particle o f  the 
emitted dose) and total fine particle fraction (% respirable particle from total recovered 
dose) o f the salbutamol sulphate carrier-based formulations is shown in Figure 5.13. A 
clear pattern o f formulation performance was observed depending on whether the 
force control agent was fused either with the drug or the lactose. Formulations with 
pre-conditioned drug, in contrast to conditioned lactose, offered the best drug delivery 
performances. It is suggested that the conservation o f an adhesive system for the pre­
conditioned drug particles directly led to the increased de-aggregation performance. 
Meanwhile, the selective decrease o f the drug-lactose interfacial interaction for 
conditioned lactose particles led to a dominant cohesive (drug-drug) system, which 
resulted in poor blend homogeneity and poor fluidisation. The highest %FPF o f the 
emitted dose was obtained for formulations with leucine and lecithin coating 
salbutamol sulphate particles (73.72% and 71.87%, respectively). The low drug 
retention o f salbutamol sulphate-MgST conditioned particles (8.23% device retention) 
contributed to deliver an equivalent total fine particle dose as for leucine and lecithin 
(64.43% for leucine, 61.41% for lecithin and 63.79% for MgST). These data clearly 
indicated that the characteristic properties o f carrier based formulations can be 
controllably enhanced by judicious selection o f the interparticulate interactions to be 
modified by the introduction o f the FCAs.
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p<0.05, ** p<0.01, *** p<0.001: significant difference compared to without force control agent by ANOVA one-way.
Figure 5- 13: Fine particle fraction and emission efficiency o f salbutamol sulphate 
carrier-based formulations (mean ± S.D., n=3).
5.4. C o n c lu sio n s
The influence o f force control agents on the properties and performances o f model 
salbutamol sulphate carrier based formulations was investigated. The cohesive and 
adhesive dependencies were controlled by conditioning either the drug or the carrier 
before mixing in order to create selective modifications o f the inter-particulate 
interactions within the dry powder formulation. The colloid probe AFM technique 
together with the novel cohesive-adhesive balance (CAB) analysis procedure was 
utilised to measure the variations in inter-particulate forces o f the ternary blends. The 
predictive CAB-graph indicated radical modifications in the behaviour o f the 
formulation dependant on whether the FCAs were conditioned with the drug or the 
lactose. The content uniformity measurements and drug deposition patterns o f the
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various ternary mixtures were in good accordance with predictions o f the CAB
assessment o f the colloid probe AFM measurements.
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Chapter 6 
The Use of Force Control Agents in Model 
Budesonide DPI Formulations
6.1. Introduction
Chapter 3 highlighted the increased cohesive properties o f micronised budesonide 
particles with respect to its adhesive interaction with the dominant growth face o f 0C- 
lactose monohydrate particles, as measured by the quantitative CAB-graph analyses of 
AFM data. Further work, which was presented in Chapter 4, investigated the behaviour 
o f a mixture of lactose Sorbalac 400 and budesonide. The formulation exhibited poor 
content uniformity and visual observations by scanning electron microscopy implied a 
highly segregated system. These findings in conjunction with in vitro studies suggested 
a mechanism in which the presence o f large and dense agglomerates o f budesonide 
may significantly increase the deaggregation efficiencies o f the active ingredient. The 
influence o f the carrier would hence be relatively inconsequential as the drug 
agglomerates would readily fluidise upon actuation, resulting in similar aerosolisation 
properties as the drug-only formulation. It was therefore suggested that delivery 
characteristics o f D PI formulations o f highly cohesive drug systems were 
predominantly governed by the drug-drug interaction forces. As the lactose cohesive 
bonds would only play a minor role in the overall formulation behaviour, optimisation 
o f such dry powder formulations would require passivation o f the excessive cohesive 
bonds to create a more interactive drug-lactose system.
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The use of a force control agent (FCA) in conjunction with a mixing procedure 
capable of producing effective nano-layer coating, presented in Chapter 5, have shown 
to strongly affect de-agglomeration and entrainment properties o f model lactose- 
salbutamol sulphate D PI formulations. For that purpose, the Mechanofiision system 
was used to ensure an efficient coating o f the drug to be conditioned with the force 
control agent. The shear forces involved in the Mechanofusion process may provide 
the necessary energy to break up the cohesive drug agglomerates. While the host 
particles (FCAs) interact with the guest particles to create a more homogeneous blend, 
the compression forces may then complete the fusion o f the guest onto the host by 
solid sintering. The conditioning o f budesonide particles with ternary agents in 
lowering the surface energy o f interaction may, therefore, dramatically affect their 
cohesive behaviour. The drug mixture could exhibit a greater affinity to the lactose 
carrier, leading to a more homogenous formulation that may in turn improve the 
stability and aerosolisation properties o f budesonide.
The study was carried out with three force control agents (leucine, lecithin and 
magnesium stearate). Cohesive and adhesive force balances were assessed via the AFM 
colloid probe technique together with CAB-graph analysis. Aerosol drug deposition of 
the budesonide formulations was assessed by in-vitro measurements.
6.2. Methods
General methods of each technique or apparatus used in this study are described in 
detail in Chapter 2.
• Preparation of powder formulations
Powder mixing was achieved in two successive steps involving different energetic 
processes. Pre-blends o f budesonide and FCA (5% w/w) or lactose and FCA (5% 
w /w ) were prepared using a Mechanofusion system. (Hosokawa-Alpine, Augsburg, 
Germany). Powders to be processed were sealed into the Mechanofusion system 
core. A cold-water circulation assured the regulation o f the internal vessel 
temperature using an incorporated water jacket. Samples were mixed at 5000rpm 
for 10 minutes to achieve the required process intensity and mechanically fuse the
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FCA to the host particles. The formulations were subsequently prepared by 
geometrically mixing lg  of pre-blend and lg  o f either lactose or drug depending on 
the nature o f the pre-blend in lOOmg increments via a Whirlimixer (Fisons 
Scientific Apparatus, Loughborough, UK). The resulting mixture was further 
mixed in a Turbula (Glen Creston Ltd, Middlesex, UK) at 46rpm for 30 minutes.
• Contact angle measurements
The sessile drop technique was used on tablets o f the samples to be analysed. 
Analyses were performed using a Goniometer (Rame-hart Inc., New Jersey, USA). 
Diiodomethane was used as an apolar liquid whereas ethylene glycol and glycol 
were used as polar liquids.
• Interaction force measurements
The AFM was housed in an environmental chamber and the ambient conditions 
maintained at a constant temperature o f 25°C (+ 0.2°C) and relative humidity o f 
35% RH (± 3%), The partial water vapour pressure was controlled via a custom- 
built perfusion unit coupled to a highly sensitive humidity sensor (Rotronic AG, 
CH). Individual force curves (n = 4096) were conducted over a 2.5pm x 2.5pm at a 
scan rate o f 4Hz and a compressive loading o f lOnN. These parameters were kept 
constant throughout the study. Statistical analysis o f these data was performed by 
Fisher’s pair wise comparison o f one-way ANOVA with 99% confidence limits.
• Content uniformity measurements
The content uniformity of the conditioned budesonide-lactose blends was 
measured by analysing the quantity o f active in lOmg ± 0.5mg samples. Drug 
content was analysed by HPLC. Relative standard deviation between samples was 
calculated to assess the homogeneity o f the different blends.
• In  v itro  aerosol deposition studies
Approximately 10 mg o f the carrier formulations was accurately weighed into a 
gelatine capsule to be loaded into a Monohaler® device (Miat SpA, Milan, Italy). In- 
vitro deposition investigations were performed using a next generation impactor 
(NGI) (Copley Scientific, Nottingham, UK). The loaded device was connected to
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the throat o f the N G I via a moulded mouthpiece. In-vitro analysis was performed 
after each actuation o f the device. Each experiment (n=3) was performed at 
60L.min~1 flow rate with a 5 second exposure. Each N G I plate was rinsed with the 
mobile phase and the subsequent solution was collected in a 50ml volumetric flask.
6.3. Results and Discussion
A CAB-graph o f a budesonide-lactose binary system (with the use o f compressed 
tablet substrates) is shown in Figure 6.1. As expected, the AFM data indicated strongly 
cohesive budesonide interactions. The resulting reduced intermixing coefficient o f 0.33 
calculated from the slope coefficient o f the budesonide probes strongly suggested the 
probable reluctance o f the drug to form an interactive mixture with the lactose. The 
CAB analysis clearly suggested the need to lower the budesonide-budesonide 
interactions to convert a cohesive drug-drug system into an adhesive drug-carrier 

































Figure 6- 1: CAB-graph o f a budesonide lactose binary system
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6.3.1. Model Formulations with Conditioned  
Budesonide
CAB-graphs obtained for lactose probes and probes o f budesonide conditioned 
with leucine, lecithin and MgST are shown in Figure 6.2, 6.3 and 6.4, respectively. The 
pre-conditioning o f budesonide by mechanofusion with the FCAs significandy reduced 
the budesonide-budesonide interactions, as illustrated by the sharp drop o f circle plot 
groups in the respective figures. The position o f the coated drug probes (O) with 
respect to the bisector when compared to the micronised drug probes ( • )  indicated 
that an adhesive drug system had successfully been achieved.
The corresponding reduced intermixing coefficients (Table 6.3) exhibited values higher 
than 1, ergo indicative o f an adhesive system. Budesonide particles coated with leucine 
exhibited a A12 o f 1.33. The use o f lecithin and magnesium stearate seemed to have the 
additional effect o f concurrently decreasing the adhesive lactose-budesonide 
interactions, contributing to create a weaker adhesively led system. This resulted in the 
higher reduced intermixing coefficients o f 1.43 and 1.96 for budesonide particles 
mechanofused with lecithin and magnesium stearate, respectively. Assuming that the 
coverage of the ternary agents over the drug particles is uniform, it would be expected 
that conditioned budesonide would display an enhanced carrier affinity and exhibit 
better formulation homogeneity.
Concomitantly, the force balance o f lactose interactions transformed from an adhesive 
to a cohesive led system. Nevertheless, it can be speculated that this shift should not 
greatly affect the formulation properties as this change o f behaviour is predominately 
due to a decrease in the adhesive (drug-lactose) forces and not due to an increase of 



























Figure 6- 2: Influence of the coating of budesonide with leucine on the cohesive-
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Figure 6- 3: Influence o f the coating of budesonide with lecithin on the cohesive-
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Figure 6- 4: Influence of the coating of budesonide with magnesium stearate on the
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Contact angle measurements were performed on compact surfaces of 
mechanofusebudesonide with leucine, lecithin and MgST to assess their surface free 
energies. The resulting contact angles obtained with diiodomethane, ethylene glycol 
and ultra pure water are shown in Table 6.1. Using the van Oss-Chaudhury-Good 
(VCG) thermodynamic approach, described in more detail in Chapter 2, the surface 
energy contributions and resulting Gibbs interfacial free energy o f cohesion of 
mechanofused lactose with leucine, lecithin and MgST are summarised in Table 6.2. 
Contact angle measurements o f micronised budesonide particles indicated a dispersive 
surface free energy (yLW) of 50.40mJ.m'2, and a total surface free energy (ytot) of 
78.74mJ.m'2. The interfacial free energy o f the cohesive interaction was calculated as 
157.51mJ.m'2. The inclusion o f FCA clearly reduced the surface energy o f the drug 
particles, thereby decreasing the drug cohesiveness. Although the dispersive 
contributions o f the mechanofused powders remained significant with respect to the 
corresponding pure FCA (Chapter 2), the interfacial Gibbs free energy o f cohesion 
decreased by more than a third for all three samples. This indicated effective force 
modification upon conditioning the drug with leucine, lecithin or MgST.
Contact angle (0)
Sample Diiodomethane Ethylene glycol U.P. water
Budesonide +  Leucine 32 ±  1.00 47.33 ±  1.15 34.67 ±  0.58
Budesonide + Lecithin 46.00 ± 2.65 38.00 ±  2.65 18.67 ±  2.08
Budesonide+MgST 41.00 ±  3.46 55.00 ±  1.73 88.33 ±  2.89
Table 6- 1: Contact angle measurements o f mechanofused budesonide with leucine,
lecithin and MgST.
Sample yLW Y+ Y" y t O t AGtot
Budesonide +  Leucine 41.08 0.22 56.75 48.16 -96.39
Budesonide + Lecithin 36.46 0.07 75.62 40.72 -82.23
Budesonide+ MgST 39.08 0.12 1.81 39.92 -80.01
Table 6- 2: Surface energy contributions and resulting interfacial Gibbs free energy of 
cohesion o f mechanofused budesonide with FCAs (in mj.m-2).
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To assess the influence o f FCAs on the physical properties o f a budesonide-lactose 
blend, the ternary powder samples were characterised by scanning electron 
microscopy. Representative scanning electron micrographs o f formulations o f lactose 
mixed with mechanofused budesonide-leucine, budesonide-lecithin, and budesonide- 
MgST are shown in Figure 6.5A, 6.5B and 6.5C, respectively. Corroborating with the 
CAB predictions, SEM micrographs illustrated an enhanced affinity between the drug 
and the lactose. In the presence of the FCAs, the budesonide particles preferentially 
adhered to the lactose surface rather than forming individual agglomerates. These 
observations were in great contrast to previous work investigating the formulation 
homogeneities o f binary mixtures o f micronised budesonide and lactose (Chapter 4). 
In the absence of a force control agent, the presence o f dense agglomerates o f drug 
particles located on the lactose surfaces suggested an inhomogeneous blend.
Dose content uniformity analysis revealed a dramatic variation in the homogeneity of 
the budesonide formulation upon the introduction o f FCAs (Table 6.3). While the 
content uniformity o f a budesonide-lactosesystem showed an RSD of 9.54%, 
formulations containing pre-conditioned drug exhibited significantly lower content 
uniformities of 3.57, 3.53 and 2.37 for budesonide-leucine, budesonide-lecithin, and 
budesonide-MgST, respectively. These results were in good accordance with the 
corresponding intermixing coefficients calculated from the CAB-graphs for each o f the 
ternary samples, suggesting that powder homogeneity increases as a function o f A12. 
These changes in formulation behaviour may hopefully contribute to enhance the 







Mechanofusion, 10 min @ 5200 rpm Turbula, 30 min @ 46 rpm (% RSD)
Budesonide (non conditioned) Sorbalac 400 0.33 9.54
Budesonide + Leucine Sorbalac 400 1.33 3.57
Budesonide + Lecithin Sorbalac 400 1.43 3.52
Budesonide + MgST Sorbalac 400 1.96 2.37
Table 6- 3: Mixing sequences o f budesonide carrier-based formulations with 
conditioned budesonide and reduced intermixing coefficients and content uniformities.
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Figure 6- 5: Representative scanning electron micrographs o f ternary mixtures of 
lactose and budesonide pre-conditioned with leucine (A), lecithin (B) and MgST (C).
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The aerosol delivery properties of the budesonide carrier-based formulations are 
shown in figure 6.6. In vitro tests performed with micronised budesonide revealed high 
device retention (35%), a significant amount of drug in the throat (15%) and a 
considerable percentage evenly recovered from the 2nd to the 5th stage (~40%). No 
more than 5% of active ingredient was recovered in the lower stages. Mechanofusing 
the budesonide with leucine contributed to a small but significant decrease in the 
amount o f drug recovered from both the device and the throat (28% and 12.5%, 
respectively). This reduction in the upper stages subsequently transferred to increase 
deposition in the lower stages o f the N G I and more especially the 3rd and 4th stage 
(12.9% and 16.3%).
Conditioning the drug with lecithin resulted in a significant improvement in drug 
emission from the device (23.32%) as well as the throat (9.59%). These results 
suggested that the budesonide particles were successfully de-agglomerated and were 
interacting with the lactose to form a more stable powder blend. The amount o f drug 
recovered in the 2nd stage o f the N G I was significantly lower than without FCA 
(6.82%). This led to a concomitant increase in drug deposition in stage 3 (12.76%) and 
stage 4, 5 and 8 (19.96%, 11.69% and 4.66%, respectively). These results suggested that 
the drug was more effectively detached from the carrier and that the magnitude o f the 
conditioned drug cohesive forces allowed sufficient de-agglomeration to reach the 
lower stages o f the impactor.
The addition o f MgST provided the best performances, with a device retention o f just 
22%. The low amount o f drug recovered in the throat and especially the first and 
second stage (11.63% and 4.3%, respectively) suggested efficient drug detachment 
from the carrier. Little was recovered in stage 3 (11.52%) and stage 4 (17.24%) when 
compared to drug coated with lecithin, but was significantly higher than non-treated 
budesonide (9.96% and 12.17%, respectively). The differences in the de-aggregation 
and dispersion behaviour o f conditioned drug particles directly relate to high drug 
fractions in the lowest stages (stages 5, 6, 7 and 8), suggesting a very efficient drug 
dispersion.
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p<0.05, ** p<0.01, *** p<0.001: significant difference compared to without force control agent by ANOVA one-way.
Figure 6- 6: In-vitro deposition o f budesonide carrier-based formulations with 
conditioned budesonide (mean ± S.D., n=3).
6.3.2. M odel Form ulations w ith C onditioned Lactose
Pre-conditioning the lactose particles with a FCA should in theory only affect the 
budesonide-lactose adhesive bonds and the lactose cohesive bonds. Given the nature 
o f the initial interactions occurring in a budesonide-lactose binary system, no 
improvements in formulation performances would be expected as the overall powder 
behaviour would still be dictated by the high cohesive drug-drug interactions. 
Nonetheless, experiments were repeated with the lactose pre-conditioned with a 
ternary agent in order to highlight the specific effects o f the use o f  a selective mixing 
procedure.
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The whole matrix o f interactions between budesonide and lactose mechanofused with 
force control agents was first assessed by atomic force microscopy. The resulting CAB- 
graphs with leucine, lecithin and MgST as force control agents are shown in Figure 6.7, 
6.8 and 6.9, respectively. As expected, the addition o f the ternary agents further 
reinforced the cohesively led systems. The initial reduced intermixing coefficient of 
0.33 between micronised budesonide and lactose further decreased to 0.26, 0.25 and 
0.27 upon mechanofusing the lactose with leucine, lecithin and MgST, respectively 
(Table 6-4).
Surface energy properties o f lactose particles mechanofused with leucine, lecithin and 
MgST have already been investigated in Chapter 5. It was found that, predictably, the 
inclusion o f FCAs with the lactose greatly decreased the surface energy contributions 
o f the coated particles in comparison to the as supplied Sorbalac 400 (Chapter 2). It 
was therefore anticipated from both surface energy data and CAB graph analyses that 
decreasing the lactose-lactose and lactose-budesonide interactions particles with the 




Mechanofusion, 10 min @  5200 rpm Turbula, 30 min @ 46 rpm coefficient (A12) (% RSD)
Sorbalac 400 (non conditioned) Budesonide 0.33 9.54
Sorbalac 400 + Leucine Budesonide 0.26 7.27
Sorbalac 400 + Lecithin Budesonide 0.25 7.37
Sorbalac 400 + MgST Budesonide 0.27 9.65
Table 6- 4: Mixing sequences o f budesonide carrier-based formulations with 
conditioned lactose and reduced intermixing coefficients and content uniformities.
6 The Use of Force Control Agents in Model Budesonide DPI Formulations_________________ 158
Budesonide tips 




( 250  
150 — — '
: y = 3.87x |

















Figure 6- 7: Influence of the coating of lactose with leucine on the cohesive-adhesive
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Figure 6- 8: Influence of the coating of lactose with lecithin on the cohesive-adhesive
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Figure 6- 9: Influence of the coating of lactose with magnesium stearate on the
cohesive-adhesive balances of a budesonide-lactose system.
(fvTu) uo^
3.
6 The Use of Force Control Agents in Model Budesonide DPI Formulations_________________ 161
Representative scanning electron micrographs o f formulations o f budesonide blended 
with mechanofused lactose-leucine, lactose-lecithin, and lactose-MgST are shown in 
Figure 6.10A, 6.1 OB and 6.IOC, respectively. In contrast to mechanofused drug 
formulations, scanning electron micrographs o f mechanofused lactose formulations 
showed extremely segregated systems. The pre-treated lactose particle surfaces virtually 
precluded any drug adhesion. Moreover, large agglomerates o f budesonide o f more 
than 30pm in si2e were visible. Corresponding content uniformities, shown in Table 
6.4, were unsurprisingly high, synonymous o f inhomogeneous formulations, with a 
relative standard deviation o f 7.27%, 7.37% and 9.65% for the formulations o f 
budesonide and lactose mechanofused with leucine, lecithin and MgST, respectively.
The aerosol delivery properties o f the various formulations o f  budesonide and 
mechanofused lactose-FCA formulations are shown in figure 6.11. The drug 
distribution patterns o f pure lactose, and lactose mechanofused with leucine, lecithin 
and magnesium stearate were generally statistically analogous. This indicated the 
relative invariance in the relative cohesive-adhesive balances o f the ternary 
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p<0.05, ** p<0.01, *** p<0.001: significant difference compared to without force control agent by ANOVA one-way.
Figure 6- 10: In-vitro deposition o f budesonide carrier-based formulations with 
conditioned lactose (mean ± S.D., n=3).
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Figure 6-11: Representative scanning electron micrographs o f ternary mixtures o f 
budesonide and lactose pre-conditioned with leucine (A), lecithin (B) and magnesium
stearate (C).
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A summary of the device retention, fine particle fraction (% respirable particle from 
emitted dose) and total fine particle fraction (% respirable particle from initial dose) of 
the various budesonide carrier-based formulations is illustrated in Figure 6.12. An 
unambiguous distinction in formulation behaviour was observable, indicative o f a 
selective mixing. Combining the carrier with a FCA did not contribute to significant 
variations when compared to untreated lactose in device retention, %FPF or %TFP as 
was expected from CAB-graphs predictions. Since altering the lactose physico­
chemical properties predominantly affected the already mediocre carrier-drug 
interactions, the formulations generally behaved as a function of their unchanged 
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p<0.05, ** p<0.01, *** p<0.001: significant difference compared to budesonide 
without force control agent by ANOVA one-way.
Figure 6- 12: Fine particle fraction and emission efficiency of budesonide carrier-based
formulations (mean ± S.D., n=3).
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The inclusion o f a FCA with the budesonide and subsequent modification o f the drug 
cohesiveness resulted in major formulation improvements when compared to a binary 
system o f micronised budesonide and lactose. Mechanofusing budesonide with leucine 
decreased the drug device retention o f the formulation by 17.64% while increasing the 
%FPF by 16.5%. Conditioning the drug with lecithin resulted in a notable decrease in 
device retention by 33.2% and a resulting %FPF increase by 38.6%. The most effective 
FCA was MgST, which led to a 36.29% reduction in device retention and 
corresponding increase in %FPF by 36% with respect to the budesonide-lactose binary 
formulation. As the fine particle fraction only indicates the efficiency o f delivery o f the 
respirable particles which are emitted from the device, it does not reflect any changes 
in actual respirable fraction from the loaded dose. Since a significant increase in drug 
emission was observed with the various conditioned-drug formulations, the effects of 
FCAs were even more noticeable by comparing the total fine particle fractions. This 
showed overall improvement o f 26.8%, 64.26% and 59.1%, for budesonide 
mechanofused with leucine, lecithin and MgST, respectively with respect to pure 
micronised drug.
6.4. Conclusions
The influence o f modifying the interfacial properties o f a highly cohesive drug 
(budesonide) in a model carrier based formulation was studied. Drugs surface 
energetics was lowered using a ternary agent to facilitate interactions with the carrier. 
This was achieved by first coating the drug with a force control agent using a high 
energetic process (Mechanofusion) followed with a low energetic process (Turbula) to 
mix the conditioned drug with the carrier. Controlling the interaction forces led to 
dramatic changes both on a microscopic level (van der Waals forces) and on a 
macroscopic level (formulation homogeneity). A distinct improvement in the 
budesonide formulation performances was subsequendy obtained upon conditioning 
the drug particles. The specific role o f targeting the interfacial interactions on 
formulation behaviour was further exemplified by investigating the influence of 
modifying adhesive interactions by conditioning the surfaces o f the excipient particles.
Chapter 7 
Optimisation of the Fluidisation and 
Aerosolisation of Drug Only Formulations
7.1. Introduction
The majority o f dry powder inhaler (DPI) formulations are developed as carrier-based 
mixtures. Among the various excipient candidates, suitable for these solid dosage 
forms, a-lactose monohydrate is industrially preferred because o f it is generally 
regarded as a safe excipient [1, 2]. However, specific conditions relating to formulation 
incompatibilities or patient pathologies may preclude the use o f lactose as a carrier. For 
instance, various compounds including formoterol, several corticosteroids, peptides or 
proteins, may interact with the reducing sugar function o f the lactose, inducing 
undesired chemical reaction [3]. In this reaction, known as the Maillard reaction, the 
reactive carbonyl group of the sugar interact with the nucleophilic amino group [4]. In 
addition, patients suffering from lactase-deficiency or exhibiting allergenicity to protein 
contaminants (often found as sub-products o f lactose) have developed various degree 
o f lactose intolerance [5]. In such circumstances, alternative DPI formulation 
preparations will be required. These may involve the use o f alternative non-reducing 
carbohydrates or the possible development o f a drug only formulation.
The continued development o f carrier-free formulations are o f utmost interest as the 
use o f undiluted drug would yield to a smaller amount o f powder to be dispensed and 
may concomitantly lead to the engineering o f more ergonomic D PI devices. In 
addition, typical issues encountered with carrier-based formulations such as blending
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homogeneity or powder segregation would no longer be relevant. However, respirable 
sized particles are notoriously difficult to fluidise due to their cohesive nature [6]. 
Moreover, the filling  o f small quantities o f highly cohesive materials may be practically 
difficult, eventually compromising the accuracy o f pre-metered and device metered 
formulations. In order to possibly overcome these poor re-dispersion tendencies and 
device filling  issues, drug particles would need to be specifically engineered or 
processed to display suitable flowing characteristics.
A common D PI approach is to spheronize the micronised drug, which may be 
achieved with a little amount o f a suitable solvent to form uniformly sized 
agglomerates. This technique is often referred as pelletization [7]. A study revealed that 
specific pelletized powders o f disodium cromoglycate (DSCG) performed equally if 
not better than corresponding carrier based formulations [5]. In such systems, the 
pellet form confers an adequate size to improve flowability o f the cohesive drug 
particles. However, the various processes used to pelletise micronised particles can lead 
to an increase in particle-particle forces. Consequently, greater energy would be 
required to de-agglomerate and disperse the respirable drug particles for lung 
deposition. The energy requirements are provided by the shear and impaction forces 
generated by the patient inspiratory air flow through the D PI device. To increase the 
de-aggregation efficiencies o f agglomerated based formulations, the resistance o f these 
devices need to be high. The balance between agglomerate strength (filling, handling) 
and re-dispersion efficiency is therefore critical.
A nother approach to improve the flowability and dispersibility o f fine drug particle is 
to reduce their intrinsic cohesiveness. This paradigm however implies the need to 
significantly optimise the physical and chemical properties o f the active ingredient. 
Current techniques used to modify their physico-chemical properties involve the 
manufacture o f more uniform respirable particles by particle engineering technologies, 
hitherto mainly achieved by spray drying or supercritical fluid precipitation techniques 
[8, 9]. However, the metastable nature of amorphous particles produced via spray- 
drying processes often raises stability issues and has precluded their wider use in dry 
powder formulations [10, 11]. Supercritical fluid (SCF) precipitation methods have 
been shown to produce highly crystalline particles, exhibiting lower surface free
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energies and increased stability in comparison to the conventionally micronised 
products [12]. However, particles produced by SCF techniques can exhibit smooth and 
planar crystal faces, which may result in a significant increase in the contact area of 
contiguous surfaces. Previous studies have emphasised the potential influence of 
contact area upon resulting force magnitude between particles [13]. Despite the 
reduction in interfacial surface free energy, the net particle adhesion may therefore be 
increased and reduce powder flowability [9,14].
Recently, the introduction of force control agents (FCA) was considered as a possible 
means o f decreasing inter-particulate interactions o f micron sized drug particles [15]. 
The primary role o f these low surface free energy materials is to modify the interfacial 
chemistry o f the guest particles in reducing their intrinsic cohesion. Effective coating 
o f the active ingredient was obtained using a Mechanofusion system. This approach 
was first developed for inhalation powders by Staniforth et al [16], This highly 
energetic dry coating process is designed to mechanically fuse the FCA onto the drug 
by solid sintering, thereby forming complete nano-structured layers around the guest 
particles [17]. Previous studies have shown that the mechanical fusion o f a force 
control agent significantly reduced the cohesive interactions o f inhalable particles 
(Chapter 5 and 6).
The objectives o f the present study were to examine the variations in drug properties 
and their performance upon the introduction o f a force control agent. Salbutamol 
sulphate and budesonide, two active ingredients frequently administered via the 
inhalation route, were selected for their contrasting hydrophilic and hydrophobic 
properties [18]. Leucine, lecithin and magnesium stearate, recognized for having 
lamellar “surface-active” properties, were employed as force control agents. Their 
anticipated anti-adherent and /or anti-friction properties were intended to contribute to 
improve the flow and dispersion properties to the fine drug particles.
7.2. Methods
General methods of each technique or apparatus used in this study are described in 
detail in Chapter 2.
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• Preparation of powder formulations
Blends o f the drugs and force control agents (5% w/w) were prepared using a 
Mechanofusion system (Hosokawa-Alpine, Augsburg, Germany). Powders to be 
processed were sealed into the Mechanofusion system core. A cold-water 
circulation assured the regulation o f the internal vessel temperature using an 
incorporated water jacket. Samples were blended for 10 minutes to mechanically 
fuse the FCA to the micronised drug.
• Laser diffraction analyses
Experiments were performed using a laser diffraction particle sizer (Spraytech, 
Malvern Instruments, Malvern, UK) at three different flow rates o f 30, 60 and 
OOL.min1. Approximately 10 mg o f each sample was accurately weighted and 
delivered via a Monohaler® directly into the Spraytech inhalation cell. Test duration 
was set at 5000ms with an acquisition frequency o f 2500Hz. Each experiment was 
performed in triplicates. After each shot, device and capsule were washed in the 
appropriate mobile phase, and the solutions were analysed by UV spectrometry to 
quantify the related emitted dose.
• In  v itro  aerosol deposition studies
Approximately 10 mg o f the formulations was accurately weighed into a gelatine 
capsule to be loaded into a Monohaler® device (Miat SpA, Milan, Italy). In-vitro 
deposition investigations were performed using a next generation impactor (NGI) 
(Copley Scientific, Nottingham, UK).The loaded device was connected to the 
throat o f the N G I via a moulded mouthpiece. In-vitro analysis was performed after 
each actuation o f the device. Each experiment (n=3) was performed at 60L.min1 
flow rate with a 5 second exposure. Each N G I plate was rinsed with mobile phase 
and the subsequent solution was collected in a 50ml volumetric flask. Statistical 
analysis o f the data was performed using one-way ANOVA. The levels o f 
significance are indicated in the legend o f the respective graphs.
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7.3. Results
The inter-particulate forces o f micron-sized drug are o f crucial importance in the de­
agglomeration and dispersion properties of active pharmaceutical ingredients. In order 
to influence these cohesive bonds, force control agents (FCA) were blended in small 
quantities (5% w/w) with two different drugs, salbutamol sulphate and budesonide. To 
proficiently assess the influence o f the FCAs on the drug cohesive forces and their 
subsequent variability in formulation performances, the general appearance o f the 
powders were inspected by scanning electron microscopy. Aerosol deposition studies 
were characterised by in-vitro measurements and laser diffraction measurements, with 
the objective o f obtaining a greater fundamental understanding o f the complex 
mechanisms o f powder aerosolisation and de-agglomeration.
7.3.1. General Powder Morphology
Representative scanning electron micrographs o f salbutamol formulations (Figure 
7.1A-D) and budesonide formulations (Figure 7.2A-D) provided a useful insight into 
the influence o f the various FCA over the degree of drug particle agglomeration. While 
SEM picture o f micronised salbutamol sulphate suggested the presence o f loose 
agglomerates, the inclusion o f either leucine or lecithin appeared to be responsible for 
a slight increase in agglomerate number and size. In contrast, salbutamol particles 
coated with magnesium stearate appeared well dispersed as individual particles. 
Although powders were inspected over a wide area, reliability and consistency o f such 
subjective examination should be treated with caution. It is suggested that the slight 
increase in agglomerate size and frequency may result from the competing granulation 
influences in the process against cohesive reduction resulting from the FCA coating. In 
comparison, budesonide, which is reputed to be a more cohesive material [18, 19], was 
unsurprisingly present in large and dense agglomerates as illustrated in Figure 2A. The 
mechanofusion o f budesonide with leucine did not seem to improve the system as 
shown in Figure 2B, which suggested a considerably aggregated powder composition. 
Similar explanations to those indicated above are proposed. SEM micrographs of 
budesonide mechanofused with lecithin and magnesium stearate both indicated that 
the majority of particles were completely dispersed, with very few agglomerates.
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Figure 7- 1: Scanning electron micrographs o f unprocessed salbutamol sulphate (A) 
and salbutamol sulphate mechanofused with leucine (B), lecithin (C) and MgST (D).
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Figure 7-2: Scanning electron micrographs o f unprocessed budesonide (A) and 
budesonide mechanofused with leucine (B), lecithin (C) and MgST (D).
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7.3.2. In  V itro  Aerosol D ep osition  Studies
In vitro deposition studies o f micronised salbutamol sulphate and blends o f  the 
drug mechanofused with leucine, lecithin and MgST are shown in Figure 7.3. 
Micronised salbutamol sulphate powder bed re-suspended well, with the lowest relative 
device retention o f  17%. However, a large amount o f material was found in the first 
stage o f the N G I (46.79 %) and little was collected past the 4th stage. The inclusion o f 
leucine or lecithin with salbutamol sulphate contributed to a significant increase in drug 
device retention (26.75% and 25.28%, respectively). N o significant variations were 
however observed for magnesium stearate (19.4%). A very substantial drop in the 
amount o f drug collected in stage 1 was however observed for all o f  the three FCAs, 
with a subsequent statistical increase in drug deposition in the lower stages. The 
addition o f lecithin significantly improved the drug performances, although more than 
10% was recovered in the first stage o f  the N G I. Drug conditioned with magnesium 
stearate was predominately recovered from the 3rd and 4th stages (~ 50% between the 
two stages), in addition to a reasonable amount collected between stage 5 and 7.
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* p<0.05, ** p<0.01, *** p<0.001: significant difference compared to without force control agent by ANOVA one-way.
Figure 7-3: In-vitro deposition o f micronised salbutamol sulphate and FCAs 
formulations (mean ± S.D., n=3).
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In vitro deposition studies of micronised budesonide and drug mechanofused with 
FCAs are shown in Figure 7.4. Micronised budesonide exhibited significantly high 
device retention (43.2%), while the emitted drug deposited relatively evenly from the 
throat to the 5th stage. Little was recovered in the NGI lower stages. The processing of 
budesonide with leucine resulted in similar drug deposition patterns to micronised 
budesonide, despite a slight reduction in device retention (36.15%) and an increase in 
drug recovery in stage 1 (12.96%). Significant reductions in device drug recovery 
(27.47%) and drug deposition in the first stage of the NGI were however observed 
when the budesonide particles were coated with lecithin compared to micronised drug. 
An improvement in powder dispersion was nonetheless discernable, with a higher 
amount of drug recovered in the 4th and 5th stages (16.72% and 8.89%, respectively). 
Formulation containing MgST exhibited remarkable fluidisation and dispersion 
aptitudes. A significant reduction in device retention (26.46%) was observed. However, 
the amount of drug recovered in the first stage (5.68%) was similar to the micronised 
budesonide sample (5.95%), yielding to a large increase in drug deposition in stage 4 
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p<0.05, ** p<0.01, *** p<0.001: significant difference compared to without force control agent by A NO VA one-way.
Figure 7- 4: In-vitro deposition of micronised budesonide and FCAs formulations
(mean ± S.D., n=3).
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7.3.3. Laser Diffraction Analyses
The Spraytech apparatus can provide a complete particle distribution of an aerosol 
cloud passing through a laser beam every 2ms for the 5000ms o f device actuation. It 
was felt to be irrelevant and unrepresentative for this study to present a particle 
distribution summary over the duration o f the aerosolisation process since each data 
report to the powder state at a specific time segment. The Spraytech method was 
instead used to characterise the rate o f particle emission and to generate a general 
distribution pattern o f each formulation upon activation. Moreover, experiments were 
performed at three different flow rates in order to compare the effects o f changing 
shear forces and impaction energy on the aerosolisation and re-dispersion properties of 
each formulation. Volume concentrations o f the emitted dose, corresponding to 
particle count, which was recorded every 2ms, and was plotted cumulatively for each 
sample.
Resulting cumulative distributions o f salbutamol sulphate-based formulations delivered 
via a Monohaler® D PI device at 30, 60 and QOL.min1 are shown in Figure 7.5A, 7.5B 
and 7.5C, respectively. At low flow rate pOL.min'1), the emission o f the micronised 
salbutamol sulphate particles seemed continuous and regular throughout the whole 
actuation time. N o significant variations in emission patterns were visible between 
micronised and conditioned salbutamol sulphate with the exception o f the MgST- 
coated drug, which appeared to be emitted slightly faster. Increasing the shear forces 
by raising the flow rate to 60L.min1 unsurprisingly decreased the total emission time o f 
micronised salbutamol sulphate. The conditioning o f the drug with leucine did not 
contribute to significant changes. The addition o f either lecithin or MgST, in contrast, 
resulted in a shorter emission time, suggesting that the conditioned particles were 
fluidised more effectively, subsequently passing through the inhalation cell more 
rapidly. Raising the flow rate to 90L.min1 further increased the discrepancies observed. 
At this flow rate, a clear gradient in emission rate was observable from micronised 
salbutamol sulphate, to leucine-mechanofused, lecithin-mechanofused and finally 
MgST-mechanofused, which again emitted the fastest from the device.
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Figure 7 -5  Cumulative salbutamol sulphate formulation emissions as a function o f 
actuation time at a flow rate o f 30L.min 1 (A), 60L.min 1 (B), and 90L.min 1 (C).
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Figure 7-6: Cumulative budesonide formulation emissions as a function o f actuation 
time at a flow rate o f 30L.min 1 (A), 60L.min 1 (B), and 90L.min 1 (C).
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The cumulative distributions o f budesonide-based formulations delivered via a 
Monohaler® D PI device at 30, 60 and OOL.min'1 are shown in Figures 7.6A, 7.6B and 
7.6C, respectively. Similar patterns were observable between micronised budesonide 
and drug mechanofused with leucine, lecithin or MgST. However, these patterns were 
more pronounced. While the processing of leucine with budesonide resulted in a 
similar emission pattern to the pure drug for all three flow rates, the addition of 
lecithin and MgST contributed to a considerable change in drug emission rate even at 
30L.m iri\ By increasing the shear forces (60L.min 1 and OOL.miri1), the pharmaceutical 
compositions containing either lecithin or magnesium stearate were more rapidly 
discharged from the device. In fact the entire emitted drug passed through the 
Spraytech inhalation cell in the first second o f the device actuation, in contrast to 2-3 
seconds observed for the other cases. These observations again suggested a very 
effective fluidisation o f the powder bed and consequent rapid aerosolisation process.
Concurrent measurements o f the device and capsule retention allowed the location o f 
the non emitted drug. These data are shown in table 7.1. With the exception of 
magnesium stearate, the processing o f salbutamol sulphate with lecithin and leucine 
yielded an increase in device retention, whether at low or high flow rate. Conversely, a 
reduction in device retention was observed when the budesonide particles were treated 
with the FCAs. The results obtained at 60L.min1 were in good accordance with in- 
vitro drug deposition tests performed at an identical flow rate.
While device retention o f the micronised salbutamol only slightly decreased upon 
increasing the flow rate, a more noticeable drop was observed for the conditioned 
materials. Interestingly, the amount o f drug recovered in the capsules remained 
analogous for each mechanofused sample while the amount o f drug recovered in the 
device significantly decreased. These results suggested that the energy delivered to the 
bulk powder beds at low flow rate was sufficient to fluidise and remove the drug 
particles from the capsule. Under such flow conditions, however, the shear forces 
within the device may be unable to efficiently de-aggregate the cohesive particles, 
which may consequently lead to increased impaction and sedimentation o f drug within 
the device, and, thus higher device retention. At higher flow rates, however, the air 
stream characteristics seemed sufficient to entrain and disperse the particles.
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30 L.min-1
Recovered dose Device retention
in device (pg) in capsule (pg) (%)
Salbutamol sulphate 6.27 ±  2.7 15.76 ±  3.33 22.03 ± 4.21
Salbutamol leucine 24.16 ±  3.2.18 16.91 ±  0.85 41.06 ± 2.35
Salbutamol lecithin 24.97 ±  2.06 13.25 ±  6.89 38.22 ±  7.18
Salbutamol MgST 33.10 ±  5.46 7.02 ±  0.70 40.12 ± 5.75
Budesonide 33.14 ± 3.76 12.59± 3.01 45.73 ±  5.17
Budesonide leucine 30.17 ± 1.49 8.27 ±  0.83 38.44 ±  1.71
Budesonide lecithin 24.01 ±  1.17 9.17 ±  0.86 33.17 ±  2.02
Budesonide MgST 19.3 ±  2.67 8.99 ± 1.15 38.30 ±  3.41
60 L.min-1
Recovered dose Device retention
in device (jig) in capsule (pg) (%)
Salbutamol sulphate 10.62 ±  2.00 8.79 ±  2.36 19.40 ± 0.93
Salbutamol leucine 11.85 ± 2.99 16.26 ±  2.55 28.11 ±  1.13
Salbutamol lecithin 15.24 ± 2.81 9.63 ±  2.5 24.86 ± 0.66
Salbutamol MgST 12.82 ±  0.39 5.93 ±  0.78 18.75 ±  1.14
Budesonide 25.93 ±  5.56 13.11 ± 2.37 39.05 ±  5.45
Budesonide leucine 24.38 ±  2.00 9.09 ±  1.79 33.46 ±  3.65
Budesonide lecithin 20.69 ±  0.20 8.99 ±  2.23 29.68 ±  2.03
Budesonide MgST 14.10 ±  0.62 7.73 ±  .95 21.83 ±  1.55
90 L.min-1
Recovered dose Device retention
in device (pg) in capsule (pg) (%)
Salbutamol sulphate 9.17 ±  1.59 4.63 ±  0.91 13.80 ±  2.49
Salbutamol leucine 6.88 ±  1.36 10.24 ±  1.19 17.12 ±  1.79
Salbutamol lecithin 7.93 ±  0.63 8.30 ±  2.76 16.23 ±  3.03
Salbutamol MgST 6.25 ±  0.34 3.90 ±  0.22 10.14 ±  0.51
Budesonide 15.73 ±  2.05 7.80 ±  1.00 23.53 ±  2.74
Budesonide leucine 18.91 ±  0.91 9.11 ± 0 .5 9 28.02 ±  0.60
Budesonide lecithin 18.01 ±  1.74 8.00 ±  1.34 26.01 ±  2.27
Budesonide MgST 13.63 ±  2.24 6.77 ±  0.32 20.40 ±  1.98
Table 7- 1: Summary o f recovered dose in device and capsule, and subsequent device 
retention for salbutamol and budesonide formulations at 30, 60 and 90L.min'1.
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The inclusion o f FCAs with budesonide contributed to a decrease in device retention 
when compared to the micronised active ingredient. Moreover, the reduction in device 
retention observed with increasing the flow rate was related to a decrease in wall 
deposition within the device. This suggested that the conditioned powder was more 
effectively entrained in the air stream. O f particular interest was the improvement in 
the emission o f micronised budesonide particles at bOL.min1 and 90L.min'1. The 
increase in flow rate led to a two-fold decrease in device retention. The emission o f the 
sample o f budesonide mechanofused with MgST, on the other hand, remained 
independent o f the flow rate at 60L.min1 and 90L.min‘1. A two fold decrease in device 
retention drop was however observed between 30L.min1 and 60L.min \  This strongly 
suggested that the high cohesion between the budesonide particles had effectively been 
lowered through the conditioning process with magnesium stearate.
7.4. D is c u s s io n
The fluidisation and dispersion properties o f pure salbutamol sulphate and budesonide 
have been investigated in a previous study [19]. The results showed differing patterns 
depending on the intrinsic cohesiveness o f the drug particles. It was suggested that de- 
aggregation efficiency o f a D PI formulation critically relies on the balance between the 
internal strength o f the agglomerated particles and the aerodynamic diameter (size) o f 
fluidised agglomerates. It was shown that low cohesive materials (e.g. salbutamol 
sulphate) tend to form small agglomerates, which are difficult to efficiently de- 
aggregate with the drag forces and kinetic energies generated via passive DPI device. In 
contrast, highly cohesive materials (e.g. budesonide) tend to form larger airborne 
agglomerates, which are consequently subjected to greater kinetic energy and drag 
forces within a D PI device. This was shown to contribute to a more efficient de­
agglomeration process than the low cohesive material. However, the strong cohesive 
forces may form a stable powder bed, which may prevent efficient entrainment upon 
actuation. In order to assess these mechanistic processes, a particle sizing apparatus 
operating on airborne powders was used to provide information into the fluidisation, 
de-aggregation and dispersion properties o f particles with modified cohesive 
behaviour.
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Using the Spraytech analyses, a dynamic study o f the particle cloud profiles was 
performed for each formulation sample at 30, 60 and 90L.min The plume duration 
for the various samples were assessed from the cumulative undersize distributions by 
identifying the time at which 10% (t10), 50% (t50) and 90% (t90) o f the sample dose has 
passed through the Spraytech inhalation cell. In addition, the effective emitted dose of 
each formulation was calculated from the measurement o f the weighted dose and the 
recovered drug after each Spraytech experiment. These values were associated to the t90 
to describe the actual density o f the airborne particle clouds. Resulting emission time 
span and plume density o f  salbutamol sulphate and budesonide formulations are 
illustrated in Figure 7.7 and 7.8, respectively.
A t 30L .m in ', the discharge o f micronised salbutamol sulphate and co-processed 
salbutamol formulations were similar, as 90% o f the samples were emitted between 
2.6s and 3s. The long window o f particle emission resulted in low cloud densities 
around 2000(ig.s An incremental increase in the flow rate from 30 to 90L.min 1 
gradually reduced the plume duration for each o f the four salbutamol samples. Since 
the emitted dose increased as a function o f flow rate (Table 1), the subsequent cloud 
density progressively increased from 5000pg.s 1 for micronised salbutamol sulphate to 
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Figure 7-7: Plume duration and density o f salbutamol sulphate formulations.
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Figure 7- 8: Plume duration and density o f budesonide formulations.
At identical flow rates, the budesonide formulations generally passed through the 
Spraytech cell faster than the salbutamol formulations. A t 30L.min ’, the 50th percentile 
o f emission time was attained in about Is for micronised budesonide, with a decreasing 
gradient from leucine-mechanofused, lecithin-mechanofused to MgST-mechanofused. 
Surprisingly, budesonide fused with MgST fully emitted in approximately 2.5s when it 
was anticipated that this sample would re-suspend the fastest. At this stage, it is not 
clear why such incongruity was observed other than a potential experimental variability 
occurring at low flow rate. At higher flow rate, however, the choice o f force control 
agent dramatically affected the rate o f particle emission. The t50 o f micronised 
budesonide and budesonide-leucine was reached after 0.6 seconds o f device actuation 
at 60L.min for an overall cloud density o f 2900[ig.s ’. In the meantime, the whole 
emitted dose o f the budesonide samples treated with either lecithin or MgST was 
released in 0.5s. Due to this very short time o f  emission, cloud densities greatly 
increased from an average 2900pg.s 1 for the untreated material to 12,000pg.s 1 and 
18,000[jLg.s 1 for the lecithin and MgST coated materials, respectively. Increasing the 
flow rate to 90L.min 1 further accentuated this discrepancy. As the budesonide samples 
were discharged faster and in greater quantity, the measured cloud densities o f lecithin
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and MgST-based compositions reached very high concentrations o f lSjOOOpg.s1 and 
26,000pg.s \  respectively. In fact, lecithin and magnesium stearate had a similar effect 
on the plume duration for both drugs, although to different extents. Their anti­
adherent or anti-friction aptitudes seemed to generate a greater degree o f flowability. 
This resulted in more efficient fluidisation and entrainment from the capsule and 
device. Such characteristics would undoubtedly have serious implications on the re­
dispersion behaviour o f the materials and resulting lung delivery efficiency.
Inter-particulate forces of ternary blends composed o f a drug, a force control agent 
(leucine, lecithin and MgST) and fine lactose were investigated previously for 
salbutamol sulphate (Chapter 5) and budesonide (Chapter 6) using the colloid probe 
AFM technique together with the novel cohesive-adhesive balance (CAB) analysis 
procedure. From these data, it was possible to deduce the variations in drug cohesion 
upon the introduction o f the FCAs. It is important to stress, however, that 
experiments were performed with compacted tablet substrates, leading to notable 
variation in surface roughness and consequent higher variability in interaction force 
measurements. A summary o f the inferred ratios o f cohesion for salbutamol sulphate 
and budesonide formulations is shown in Table 2.
% Ratio o f  cohesion







78.23 ±  3.55 
94.67 ±  2.08 
75.95 ±  2.57
100 
16.14 ±  2.87 
19.54 ±  1.75 
11.45 ±  1.84
Table 7-2: Variations in drug cohesiveness by co-processing drug and force control
agent by mechanofusion.
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Results suggested that conditioning salbutamol sulphate with leucine or MgST caused a 
decrease in interaction forces o f 21.77% and 24.05%, respectively. The influence o f the 
conditioning o f the salbutamol sulphate particles with lecithin was not so evident, with 
a slight decrease o f 5.63%. The affect o f  conditioning more cohesive material such as 
budesonide with the force control agents were more apparent with a dramatic drop of 
more than 80% in particle interaction forces. However, these percentages should be 
interpreted carefully as they are calculated relatively to the initial cohesive force 
measurements o f the micronised drugs. According to these data, binding strengths o f 
both micronised salbutamol sulphate and budesonide significantly decreased when 
coated with a force control agent via mechanofusion.
In order to relate the reduction in blend cohesiveness to aerosol performances, a 
summary o f the device retention, fine particle fraction (% respirable particle o f the 
emitted dose) and total fine particle fraction (% respirable particle from total recovered 
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Figure 7- 9: Fine particle fraction and emission efficiency o f salbutamol sulphate 
formulations (mean ± S.D., n=3).
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Figure 7-10: Fine particle fraction and emission efficiency o f budesonide formulations
(mean ± S.D., n=3).
A clear change in the salbutamol sulphate delivery performance was observed as a 
result o f  the drug conditioning with FCAs and the subsequent reduction in particle 
cohesiveness. The device retention slightly increased for the salbutamol sulphate 
mechanofused with leucine lecithin or MgST (26.75%, 25.28% and 19.40%, 
respectively) when compared to pure salbutamol sulphate (16.91%). These results were 
analogous to the results obtained in Table 1 for the Spraytech analyses. It is suggested 
that the loss in kinetic energy for an individual particle compared to an agglomerated 
system may explain the slight reduction in the percentage o f emission. More striking, 
however, was the increase in % FPF by mechanofusing the salbutamol sulphate with 
the FCAs. The fine particle fraction increased from 29.18% to 78.03% for the 
conditioning o f salbutamol sulphate with leucine, 70.79% for salbutamol sulphate- 
lecithin and 79.42% for salbutamol sulphate-MgST. It is suggested that for these 
conditioned particles, the salbutamol bonds weaken to such an extent that the powder 
bed was more effectively fluidised and dispersed upon actuation, therefore 
contributing to this convincing increase in aerosol performances. Consequently, the
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respirable fraction o f the total dose increased from 24.26% to 57.19% for the 
conditioning o f salbutamol sulphate with leucine, 52.94% for salbutamol sulphate- 
lecithin and 64.03% for salbutamol sulphate-MgST.
Noticeable variations in aerosol performances were also discerned for the conditioned 
budesonide blends (Figure 9B). The device retention decreased from 43.18% to 
36.25% for the conditioning o f budesonide with leucine, 28.25% for budesonide- 
lecithin and 26.46% for budesonide-MgST. These results were again in good 
accordance with the Spraytech analyses at 60Lmin. This enhanced particle emission 
was expected from the ratios o f cohesion previously mentioned since the FCAs 
contributed to reduce the drug particle cohesiveness. As the powder bed strength 
weakened, the conditioned drug particles became more sensitive to the drag forces 
generated upon patient actuation ensuring more effective fluidisation and re­
dispersion. The highest %FPF of the emitted dose was obtained for formulations 
budesonide particles coated with MgST (74.80%). The addition o f either leucine or 
lecithin did not contribute to improve the %FPF and led to similar values than for 
pure budesonide (~60%). This was corroborated with SEM micrographs o f the 
conditioned budesonide particles with leucine and lecithin, which suggested that the 
processed particles formed agglomerates.
It should be noted that as the ratio o f cohesion decreases as a result o f conditioning 
the drug particles, so does the size o f the airborne agglomerates. This raises the issue 
o f the conflicting mechanisms o f reduction in drag forces and impaction energy acting 
on the agglomerates concomitant to the reduction in agglomerate binding strength. 
This may explain that no major increase in %FPF such as observed with the 
conditioned salbutamol sulphate blends occurred with the conditioned budesonide 
blends. Nevertheless, due to an increase in percentage in particle emission, the 
conditioning o f budesonide with either lecithin or MgST contributed to significantly 
improve the total fine particle fraction (38.74% and 55.01%, respectively).
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7.5. Conclusions
Force control agents (leucine, lecithin and magnesium stearate) were used to modify 
the physico-chemical properties of two model respirable drugs (salbutamol sulphate 
and budesonide). Powders were co-processed using a Mechanofusion system whereby 
high shear forces ensured a nanometre thick coating o f the specific components o f the 
formulation.
Particle size analyses performed on the airborne powders using a Spraytech system 
revealed dramatic variations in rate o f particle emission, upon device actuation, 
between treated and untreated drug particles. The anti-adherent or anti-friction 
aptitudes o f the FCAs seemed to generate increased flowability of the pharmaceutical 
materials, especially with the addition o f lecithin or MgST. A considerable time 
reduction in powder bed fluidisation and increased entrainment efficiency was 
observed.
In-vitro measurements performed on both treated and untreated salbutamol sulphate 
revealed striking improvements in aerosol deposition by mechanofusing an FCA with 
the drug particles. By physically disrupting the drug interparticulate interactions, the 
formulatory procedure led to a critical state in drug cohesiveness that allowed more 
effective de-agglomeration. For budesonide, although no variation was observed in 
%FPF, a net decrease in device retention due to a reduction in powder bed strength 
contributed to significantly increase the drug respirable fraction.
In summary, an improved de-agglomeration and entrainment o f both drugs was 
achieved by selecting a force control agent in conjunction with a mixing procedure 
capable o f producing effective nano-layer coating.
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The development o f efficient powder aerosols for inhalation therapy demands the 
formulation o f drug as a simple or compound powder which disaggregates into an 
aerosol containing a large fraction o f respirable particles to reach the deep lung. The 
efficiency o f particle aerosolisation and de-agglomeration rests on a critical balance o f 
two competing physical mechanisms. The intrinsic short-ranged forces acting between 
the solid particles contribute to the metastable agglomeration o f the powder 
formulation and its stability during storing and handling. Conversely, the aerodynamic 
forces generated by the patient’s inspiration through the device provide the necessary 
energy required to yield effective de-agglomeration and produce respirable particles. 
The prediction and control o f the interparticulate forces in dry powder inhaler (DPI) 
formulations for inhalation are therefore o f uppermost importance in the 
improvement o f drug delivery performances.
The first aim o f this study was to develop a novel technique capable o f quantifying the 
degree o f interaction between the various components o f a given dry powder 
formulation. From this knowledge, model formulations were tested in terms o f their 
flowability, dispersibility and aerosolisation with the purpose o f relating the 
formulation behaviour to its inherent balance o f interactive forces. Finally, the selective 
introduction o f force control agents (FCA) to reduce specific inter-particulate 
interactions within a DPI formulation was investigated as a possible means of 
improving drug delivery to the lung.
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8.2. S um m ary
The inter-particulate forces between two drugs, salbutamol sulphate and budesonide, 
and lactose were assessed by colloid probe AFM technique. The tailoring o f well- 
defined substrate surfaces by crystallisation minimised intra-variations in the contact 
area o f a colloid probe. This enabled direct quantification o f the relative adhesive- 
cohesive contributions within a model dry powder inhaler formulation. From this 
knowledge, a novel cohesive-adhesive balance (CAB) analysis procedure was 
developed in order to predict formulation characteristics and behaviour from its 
relative interactive force ratios. A clear hierarchy in interaction forces observed 
between various materials. The CAB graph analyses anticipated that the formulation o f 
budesonide with a lactose carrier would largely be governed by the relatively strong 
cohesiveness o f the drug whilst the formulation o f salbutamol with lactose would 
principally hinge on the adhesive forces between the two compounds.
Aerodynamic particle analyses together with aerosol deposition studies performed on 
pure micronised salbutamol sulphate and micronised budesonide provided a plausible 
explanation in the fluidisation and aerosolisation properties between low and high 
cohesive particles, modelled on the relationship between cohesion, metastable 
agglomerate size and the resulting aerodynamic mechanisms acting on the fluidised 
agglomerates such as drag forces and impaction/collisions. It is suggested that during 
the de-aggregation and dispersion process, the internal binding forces o f the 
agglomerate and the drag forces generated within the device reach equilibrium. This 
subsequently would lead to the suspension o f the elutriation process. The characteristic 
properties o f the metastable aggregates would be direcdy dependant on the airflow 
characteristics via the inhaler device and the cohesive properties o f the agglomerated 
particles.
The formulation o f these drugs with a fine particle lactose carrier generally contributed 
to a better emission from the device, principally due to the aerodynamic properties o f 
the carrier particles. However, the relative strong adhesion between salbutamol 
sulphate and lactose measured from the CAB graph analyses precluded an effective 
drug particle detachment. Therefore, notwithstanding exemplary low device retention,
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the overall performances o f the carrier-based formulation were disappointing since 
most o f the drug particles remained attached to the carrier and did not reach a 
respirable size. In contrast, the highly cohesive nature o f budesonide resulted in an 
unstable carrier based formulation. The mediocre affinity between drug and carrier 
resulted in the rapid separation o f the budesonide agglomerates from the lactose 
surface, introducing a similar dispersion mechanism as for the cohesive drug only 
formulation.
In order to improve dry powder formulation delivery characteristics, the influence of 
force control agents (FCAs) on the properties and performances o f model carrier- 
based formulations was investigated. Three FCAs were chosen for their low surface 
energetic properties: leucine, lecithin and magnesium stearate. The cohesive and 
adhesive dependencies were controlled by conditioning either the drug or the carrier 
with an FCA before mixing in order to create selective modifications o f the inter­
particulate interactions within the dry powder formulation. This was achieved by first 
using a high energetic process (Mechanofusion) following a low energetic process 
(Turbula blending). Controlling the interaction forces led to dramatic changes both on 
a microscopic level (van der Waals forces) and on a macroscopic level (formulation 
homogeneity and aerosolisation patterns). Radical modifications in the behaviour of 
the formulation were dependant on whether the FCAs were first conditioned with the 
drug or the lactose. This influence was predicted by the CAB-graph analyses and 
confirmed experimentally via in-vitro deposition studies. A distinct improvement in the 
salbutamol sulphate and budesonide formulation performances (emission and 
aerosolisation) was obtained when a weak adhesive system was obtained.
Alternatively, the same conditioning procedure was performed on pure micronised 
salbutamol sulphate and budesonide to investigate the effect o f modifying the physico­
chemical properties o f the drugs on their flowability, dispersibility and aerosolisation 
characteristics. Results indicated that the introduction o f FCAs dramatically reduced 
particle emission time, suggesting a very effective fluidisation of the powder bed and 
consequent rapid aerosolisation. Accordingly, in vitro studies revealed net 
improvements in aerosol deposition patterns by mechanofusing an FCA with the drug 
particles.
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8.3. F u tu re W ork
It has been shown that controlled crystallisation o f model substrates for AFM studies 
provided the opportunity to direcdy quantify the interaction forces between a single 
particle and the crystal substrate. However, the 3-D arrangement o f the molecules in 
the crystal lattice resulted in specific chemical groups being exposed at the surface of 
the crystal faces. Further investigations into the potential discrepancies in interactions 
between two materials upon the choice o f crystal face for AFM analyses are required.
Notwithstanding, only a-lactose monohydrate was considered as a carrier in this study. 
Further CAB graph and complementary in vitro analyses should focus on the use of 
alternative excipients as a choice of carrier to help in determining the best suitable 
candidate for a specific active agent.
Additionally, a more complex matrix o f active agent, carrier and fines should be 
investigated from both a microscopic (CAB assessment) and macroscopic approach 
(fluidisation and aerosolisation properties). The concomitant use o f carrier and fines 
differing in their chemical nature could provide a desirable synergetic effect in 
producing effective dry powder formulations for inhalation.
